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Combination antiretroviral therapy for HIV-1 suppresses viral replication, but is not curative. 
HIV-1 remains detectable in those on suppressive therapy as cellular proviral DNA and cellular 
HIV-1 RNA in peripheral blood mononuclear cells (PBMC), and as low-level plasma viremia. A 
long-lived reservoir of intact proviruses is also retained in the resting CD4+ T cell population. 
This population of long-lived, latently infected cells is believed to cause life-long persistence of 
HIV-1. To deplete latently infected cells, a “kick and kill” strategy has been proposed, in which 
HIV-1 is “kicked” out of proviral latency by small molecule latency reversing agents, leading to 
the “kill” from viral cytopathic effects or immune mediated clearance. Recent ex vivo and in vivo 
studies have concluded that histone deacetylase inhibitors, protein kinase C agonists and Brd4 
inhibitors can effect HIV-1 latency reversal. We evaluated this proposed strategy at the level of 
individual proviruses using a limiting dilution assay, and found that currently used latency 
reversal agents are not potent activators of HIV-1 latency compared with T cell activation. These 
latency reversal agents also do not lead to significant depletions of the HIV-1 reservoir in resting 
CD4+ T cells. We also sought to better understand relationships between molecular biomarkers 
of HIV-1 persistence and the size of the inducible reservoir. We found that as the frequency of 
infected cells and their transcriptional activity in PBMC increases, the size of the inducible 
reservoir also increases. Spontaneous virion production from resting CD4+ T cells and PBMC 
was also associated with low-level viremia. We also found that the magnitude of the inducible 
reservoir, and the levels of infectious virus, were higher in total CD4+ T cells compared with 
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resting CD4+ T cells. Finally, we also found that the size of the inducible reservoir was 
significantly correlated with the magnitude of viral outgrowth from total and resting CD4+ T 
cells. Overall, these findings demonstrate that more potent latency reversing agents will be 
required to reduce the size of the latent reservoir, and suggest that measures of the infectious and 
inducible reservoirs in those on long-term antiretroviral therapy can be greatly simplified. 
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1.0  INTRODUCTION 
The Acquired Immunodeficiency Syndrome (AIDS) epidemic was first brought to the attention 
of the world by isolated case reports of Pneumocystis carinii pneumonia and Kaposi’s sarcoma 
in previously healthy homosexual men without an underlying cause of immunodeficiency1-3. 
Even in these initial reports, there was speculation that a new disease transmitted by sexual 
contact was responsible for the severe immunodeficiency evident in these index cases. Following 
the discovery of a severe communicable disease among individuals who had been healthy, the 
race was on to find the underlying etiologic agent responsible for this disease. 
The first report describing a retrovirus associated with AIDS from Barre-Sinousi et al. at 
the Pasteur Institute was published in 1983 in Science4. This report was followed in 1984 by four 
manuscripts from Robert Gallo’s laboratory at the National Cancer Institute, also published in 
Science, describing a retrovirus related to human T cell leukemia virus as the causative agent of 
AIDS, and describing antibodies elicited by this retrovirus in the sera of patients5-8. The two 
groups independently named the virus, with the French group settling on lymphadenopathy 
associated virus (LAV), and the group from the United States choosing human T cell 
lymphotropic virus (HTLV-III). These groups and others eventually came to a consensus, calling 
the etiologic agent of AIDS the Human Immunodeficiency Virus (HIV; this dissertation will 
focus on HIV type 1, and will therefore refer to HIV as HIV-1 throughout). 
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1.1 STATE OF ART: A BRIEF HISTORY OF ANTIRETROVIRAL THERAPY 
1.1.1 Importance of the development of azidothymidine 
After the discovery of a human retrovirus as the causative agent of AIDS, the development of 
effective therapy to prevent disease progression became a top priority. With retroviruses now 
garnering the attention of the biomedical research community, groups began to apply extant 
knowledge of the retroviral lifecycle9 to investigate viral drug targets. The discovery of an RNA-
dependent RNA-polymerase in Rous sarcoma virus by Temin and Mizutani10 and in murine 
leukemia virus by Baltimore11, both in 1970, paved the way for development of antiretroviral 
therapy against a human retrovirus more than 13 years before HIV-1 was discovered. This 
example demonstrates the importance of basic research; without an understanding of the 
retroviral lifecycle, it would not have been possible to detect and identify a retrovirus as the 
causative agents of AIDS, or to develop antiretroviral drugs. Without the foundation of basic 
research, many more lives would have been lost to HIV/AIDS. 
The development of the first antiretroviral drug, azidothymidine (AZT), a thymidine 
nucleoside analog was a turning point in the treatment of HIV-1 infection. Like most 
revolutionary breakthroughs, the discovery that AZT could inhibit viral replication is a rich 
story, rife with conflict as to who truly made the pivotal discovery. AZT was first synthesized in 
196412-14 to be tested for the treatment of cancer. However, it was not until years later that AZT 
was resurrected for investigation as a potential antiretroviral. This resurrection was the result of a 
number of key players in the pharmaceutical industry and government research positions. 
Scientists at Burroughs-Wellcome had evidence that one of their drug candidates (AZT) 
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inhibited replication of MLV in vitro, but they lacked an in vitro model of HIV-1 infection to test 
AZT15. However, Burroughs-Wellcome was aware that the NCI had recently established an in 
vitro model of HIV-1 replication in the laboratory of Samuel Broder16,17. Burroughs-Wellcome 
then approached scientists at the NCI about testing their potentially promising drug candidate 
AZT in their in vitro system. The results of this collaboration was that in 1985, Mitsuya et al. 
from Samuel Broder’s lab published a seminal manuscript describing the in vitro efficacy of 
AZT in preventing viral replication18. These results were followed up with in vitro and ex vivo 
confirmatory studies in subsequent years19,20, demonstrating a surprising efficacy and therapeutic 
index, considering many at the time did not believe that any therapy would be safe and effective. 
However, debate would go on for years as to whether the NCI or Burroughs-Wellcome actually 
discovered the efficacy of AZT and who deserved the patent rights21. 
In parallel with the further investigation of AZT in vitro, researchers at the NCI began to 
take steps into evaluating the clinical efficacy of AZT in patients with advanced AIDS. These 
pioneering researchers were following the lead of their oncology counterparts at the NCI, and 
were going from laboratory benches to patient bedsides to investigate whether the findings from 
the laboratory were clinically relevant. In less than a year after the first publication of AZT as an 
inhibitor of HIV-1 replication in vitro, exploratory clinical results were published, demonstrating 
that AZT lead to increases in CD4+ T cell counts and restoration of hypersensitivity reactions 
mediated by CD4+ T cells22, providing evidence of clinical benefits. Follow-up trials came 
quickly, and expanded into other potential nucleoside drug candidates, with promising clinical 
responses at several institutions23-26. 
  These first trials laid the framework for phase II placebo controlled trials to evaluate the 
true efficacy and toxicity of AZT in HIV-infected people. Burroughs-Wellcome sponsored the 
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multicenter phase II, double-blind placebo controlled trial of AZT in 248 people, which was the 
first study of its kind. The data safety monitoring board for this trial decided to end the trial 
early, after clear clinical benefit was observed in the AZT treated arm of the trial12,27. This first 
placebo controlled trial was a major milestone in treatment of HIV-1 infection, as it showed 
conclusively using clinical endpoints that AZT treatment conferred a significant survival 
advantage. In one month following the early cessation of the phase II AZT trial for efficacy, a 
treatment investigational new drug designation was granted for AZT, allowing physicians to 
prescribed AZT to patients. Finally, in March 1987, the Food and Drug Administration (FDA) 
granted approval for a New Drug Application (NDA) for AZT.  This approval from the FDA led 
to a federally sanctioned drug to inhibit HIV-1 replication in approximately 2 years from the first 
publication describing its activity12.  
The placebo-controlled design provided the groundwork for future trials investigating 
new compounds to suppress viral replication. Other pharmaceutical sponsors of new clinical 
candidates to suppress replication of HIV-1 were not required to have placebo controls in their 
early-phase proof of concept trials, due in part to the leadership and forward-thinking of 
Burroughs-Wellcome. Didanosine (ddI) and dideoxycytidine (ddC) were the next drugs to be 
approved in October of 1991 and June of 1992, respectively12. Thus, the path used to develop 
AZT as a clinical drug involved collaboration between government agencies and pharmaceutical 
companies, and the use of a rapid bench to bedside model adopted from oncology trials at the 
NCI. The FDA also demonstrated leadership by working diligently to translate the clinical 
findings from Burroughs-Wellcome and the NCI to patients in need of treatment. This eventually 
led to the new Treatment Investigational New Drug category of regulation in the FDA, wherein 
drugs can be prescribed by physicians prior to full approval in cases of advanced disease and 
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where no other treatment options are available28. The development of AZT from an effective 
drug candidate in vitro to an FDA-approved drug was a testament to the clear thinking at all 
stages of scientific development, and a willingness of groups with sometimes divisive interests to 
work together to achieve something that none could achieve alone. The model for the 
development of AZT illuminated a pathway forward further drug candidates for the treatment of 
HIV-1, and it is clear that we would not have the suppressive antiretroviral therapy regimens we 
have today without the development of AZT. 
1.1.2 Development of combination antiretroviral therapy 
The development of AZT as the first treatment for HIV-1 infection was pivotal in the HIV/AIDS 
epidemic, but early enthusiasm from the clinical benefit was quickly dashed. In the first placebo-
controlled study of AZT, it was already clear that the clinical benefit was dwindling towards the 
end of the 24-week trial. The increases in CD4+ T cell counts and recovery of responsiveness to 
hypersensitivity tests that were associated with the clinical benefit had already begun to reverse 
in some study participants by the end of the relatively short trial27. Indeed, this was an early 
harbinger of things to come. 
 Soon after AZT was used broadly to treat HIV-1, it became clear that the responsiveness 
to therapy waned over time, with AZT only providing approximately three additional years of 
life after diagnosis of AIDS29-31. It was also becoming clear that AZT was associated with 
significant toxicity32, and that the virus could evolve resistance to AZT over time33,34. Careful 
analysis demonstrated that the resistance of HIV-1 to AZT therapy was the direct result of 
specific mutations in the reverse-transcriptase portion of the HIV-1 genome35,36. These findings 
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would have major repercussions, as the study of drug resistance to HIV-1 would come to 
dominate HIV research for the next two decades. 
 Appreciation of the limited ability of AZT to suppress viral replication due to the 
emergence of drug resistance enhanced the race to find new and more potent suppressors of 
HIV-1 replication. The development of new nucleoside reverse-transcriptase inhibitors (NRTIs) 
such as ddI37,38, d4T39, and ddC40 were additional tools for the treatment of HIV-1. Combinations 
of AZT and these newer NRTIs were compared in clinical trials, with combinations performing 
slightly better than AZT alone41,42. A subsequent large trial involving 2,467 participants showed 
that monotherapy with AZT was inferior to ddI alone, to AZT and ddI, and to AZT and 
zalcitabine43. In the most successful arm of this trial (AZT and ddI), 20% of the participant 
reached a 50% decline in CD4+ T cell counts, AIDS or death on therapy, with 31 of 613 
participants in this arm dying during the 160 weeks of the trial. It was clear that additional 
classes of compounds would be needed to prolong the suppression of viral replication.  
The sobering results of the large-scale clinical trial investigating combinations of other 
NRTIs with AZT drove the point home that combination therapy with new drugs classes and 
NRTIs would be required to achieve prolonger viral suppression. Two years after the approval of 
AZT as the first therapy against HIV-1, the structure of HIV-1 protease44 was solved, and 
rational design of inhibitors of HIV-1 protease had begun45. Subsequent medicinal chemistry 
yielded the protease inhibitors Ro-31-895946, L-735,52447 and ABT-35848, demonstrating sub-
micromolar potency for inhibition of HIV-1 protease and favorable therapeutic indices (>1000-
fold difference between effective dose and toxic dose46) in vitro, and minimal toxicity in animals 
models48. In a small scale studies of 49 patients49, Ro-31-8959 (saquinavir) alone was found to 
transiently reduce viral load by 80% after eight weeks of therapy, and to transiently increase 
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CD4+ T cell counts by 60 cells/mm3 after four weeks. The FDA considered these preliminary 
results by Kitchen et al.49 to be sufficient evidence for rapid licensure. During this same time 
period, both L-735,524/MK-639 (indinavir) and ABT-358 (ritonavir) were undergoing small-
scale trials for safety and efficacy, and both were also found to transiently restore CD4+ T cell 
counts and reduce viral load50-52. However, the point that therapies needed to be combined was 
once again driven home by the emergence of well-defined genetic mutations in the protease 
region of the HIV-1 genome conferring resistance to protease inhibitors53-55.  
 In parallel to the development of protease inhibitors and soon after the development of 
d4T, came another NRTI known as 3TC with highly potent in vitro activity against a range of 
isolates of HIV-156-58. Although the mutation M184V was shown to be selected by 3TC early on, 
viruses with this mutation remained susceptible to AZT therapy, and conversely viruses with 
AZT resistance remained sensitive to 3TC59-61. Based on this preliminary in vitro data and two 
early phase clinical studies demonstrating safety and bioavailablity62,63, it seemed that the 
combination of AZT and 3TC could potently inhibit HIV-1 replication in vivo. Two seminal 
studies published in 1995 and 1996 showed that this was indeed the case, as participants who 
received AZT and 3TC did profoundly better than those that received AZT or 3TC alone64,65. 
Importantly, these positive results persisted after 52 weeks of therapy, with CD4+ T cell counts a 
mean of 60 cell/mm3 above baseline and mean viral loads a log lower compared with baseline65. 
It seemed that the combination of AZT and 3TC was indicating that researchers and physicians 
were on the right path to finding a regimen that fully suppressed HIV-1 replication. 
 The first true test of combination of therapies targeting different aspects of viral 
replication came from a trial investigating the combination of AZT, ddC, and saquinavir, likely 
due the fact that these drugs were available prior to the FDA’s approval of 3TC and indinavir. It 
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was unknown at the time that the clinical efficacy of AZT and 3TC would be much superior to 
AZT and ddC, and in vitro studies suggested that the three drug combination of AZT, ddC and 
saquinavir would be highly synergistic against HIV-1 replication66-68. Unfortunately, the 
encouraging in vitro results did not translate to the clinic. Results from the trial of this three drug 
combination showed that HIV-1 viral loads dropped nearly a log10 after four weeks of therapy, 
but quickly rebounded to approximately a 0.5 log10 decrease after 16-24 weeks of therapy and 
remained stably there69. CD4+ T cell counts mirrored plasma HIV-1 RNA levels, and by 24 
weeks had dropped to only a 10% increase; by week 48, CD4+ T cell count had returned to 
baseline69. 
 About one year following the publication of the results from the combination of AZT, 
ddC, and saquinavir, results from two trials that combined AZT, 3TC and the newer protease 
inhibitor indinavir were published70,71. The results of these trial were much more positive. In the 
study by Gulick et al., combination therapy of AZT, 3TC and indinavir dropped viral load by 
two log10 within eight weeks, and led to a 100 cell/mm
3 increase in CD4+ T cell counts in the 
same time period71. Strikingly, plasma viremia stayed suppressed, with over 80% of study 
participants on the triple combination having viral loads <500 copies per milliliter of plasma by 
24 weeks71. Even more amazingly, after 52 weeks of therapy 100% of study participants on the 
triple drug combination had viral loads <500 copies per milliliter, and 80% had viral loads <50 
copies per milliliter. CD4+ T cell counts also continued to rise during this period, reaching a 
mean increase of 200 cell/mm3 after 52 weeks of therapy71. The trial by Hammer et al. was 
focused more on clinical outcomes (i.e. AIDS or death), as the cohort studied in this trial were 
participants with CD4+ T counts <200 cells/mm3. Focusing on clinical endpoints, this study also 
had positive results, in that participants were much less likely to have disease progression when 
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treated with the three drug regimen versus two NRTIs. The results of these two trials clearly 
demonstrate that combinations of antiretroviral drugs specific to more than one viral target led to 
the prolonged suppression of plasma viremia, increases in CD4+ T cell counts, and profound 
clinical benefit. 
 The development of triple drug combination antiretroviral therapy regimens was a 
triumph of modern science. Within a little over a decade after the initial discovery of a 
compound that could inhibit HIV-1 replication in vitro, multiple classes of drug compounds 
targeting reverse transcriptase and protease had gone through inception to testing for efficacy in 
clinical trials. The ultimate outcome was that HIV-1 went from being an untreatable (and some 
thought impossible to safely treat) disease, to one in which there was hope for long term viral 
suppression. It was undoubtedly the combination of a strong foundation of the basic science 
necessary to understand reverse transcriptase, protease, and viral replication in conjunction with 
close work between different groups that facilitated the rapid progress in the treatment of HIV-1. 
The HIV/AIDS epidemic brought together government clinicians working at the NCI with a 
mind towards bench to bedside approaches to treatment, pharmaceutical companies who had 
promising drug candidates, the FDA, and patient advocacy groups. The cooperation of these 
groups at an early stage contributed substantially towards the rapid progress that was achieved. It 
is prudent to bear this model in mind when working towards breakthrough therapeutics.  
1.1.3 Modern ART Regimens and the Status of the War on HIV/AIDS 
At the time when the results of the first triple drug combination therapies were being published, 
much work was concurrently being done on the development of new classes of reverse 
10 
 
transcriptase inhibitors, the non-nucleoside reverse transcriptase inhibitors (NNRTIs). The first 
NNRTI to be developed was nevirapine72-75, which was less effective alone or in combination 
with AZT or AZT and ddI in maintaining suppression of viral replication than three drug 
regimens with indinavir, 3TC and AZT70,71. The next NNRTI developed was efavirenz, which 
showed improved ability to suppress plasma HIV-1 RNA when paired with AZT and 3TC 
compared with indinavir, AZT and 3TC, plus was associated with fewer side effects76. Efavirenz 
was also shown to be superior to triple therapy with NRTIs alone77. Correspondingly, efavirenz 
is still a backbone of many regimens used today, and is typically prescribed with the NRTIs 
tenofovir disoproxil fumarate and 2’,3’-dideoxy-5-fluoro-3’-thiacytidine (FTC)78. Indeed, 
efavirenz, tenofovir and FTC are currently available in a one pill, once a day dosing option 
(known as Atripla®) that was superior to other cornerstone options including boosted protease 
inhibitors and protease inhibitors plus efavirenz79. 
Other classes of drugs, such as entry inhibitors80 and integrase inhibitors81,82 are also 
constituents of modern ART regimens. Although newer drugs are becoming available, it is worth 
noting that no combination of drugs has been shown to be virologically superior to efavirenz, 
tenofovir and emtricitabine. However, the Department of Health and Human Services has moved 
towards 5 basic regimens, 4 of which include integrase inhibitors plus NRTIs and one of which 
includes a boosted protease inhibitor plus NRTIs83. This movement away from NNRTI based 
regimens has principally been due to the side effects from efavirenz-based regimens, notably 
psychological side effects84. It is worth noting that efavirenz containing regimens are still 
recommended as alternative regimens, and that the World Health Organization still recommends 
efavirenz plus NRTIs as first-line therapy85. 
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Despite the overwhelming success that has been achieved and the lives that have been 
saved by combination antiretroviral therapy, HIV-1 still remains a public health problem in the 
United States and worldwide. There are still major barriers to overcome to win the battle against 
HIV-1. Low frequency resistance mutations can lead to subsequent virologic failure on ART86, 
demonstrating that resistance still remains a major barrier to long term viral suppression. Modern 
ART regimens have downsides, including significant long-term toxicity87-92. Although many 
people receiving ART suppress their viral loads, the immune system fails to reconstitute in some 
individuals93,94, leading to persistently low CD4+ T cell counts. Though highly effective, ART 
regimens remain costly in practice; a survey of generic prices reveals that the annual cost of 
Atripla® is approximately $31,000 based on wholesale prices in the United States, which is 
obviously cost prohibitive in many contexts83. Regardless of these shortcomings, antiretroviral 
therapy has been responsible for saving over three millon life-years in the United States alone 
from 1989 to 200695. 
It is important to remember that as of 2013, nearly 78 million people have acquired HIV-
1 since the beginning of the epidemic, and 39 million people have died from AIDS96. As of 2014, 
the World Health Organization estimates that there are nearly 37 million people living with HIV-
1 today, with 2 million new HIV-1 infections in 2014 and 1.2 million AIDS deaths97. The 
HIV/AIDS epidemic is far from over, and the most expedient path towards an end to the 
epidemic has two components: one component in which HIV-1 transmission is prevented by 
either vaccination, pre-exposure prophylaxis or ART of infected individuals, and another in 
which those living with HIV-1 infection are cured. 
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1.2 PERSISTENCE OF HIV-1 AFTER LONG TERM SUPPRESSIVE ART 
Combination antiretroviral therapy (ART) has progressed to the point where those who are 
adherent and do not have resistance mutations, have undetectable levels of HIV-1 RNA in 
plasma and high CD4+ T cell counts. As long as these individuals continue to take suppressive 
ART regimens, the virus and the body are in a status quo. The virus cannot replicate any further, 
and the host cannot further reduce the number of latently infected cells in the body. The 
apparently peaceful status quo observed when ART is regularly taken belies the true state of 
viral persistence. 
1.2.1 Viral load: measure of effective therapy becomes measure of persistence 
The first assays capable of assessing whether HIV-1 was present in the body came soon after the 
discovery of HIV-1 as the etiological agent of AIDS. These ELISA-based tested were developed 
by Robert Gallo’s group, and were the first serologic tests capable of identifying those with HIV-
15,6. Additional tests were soon available, as well as measures of p24 antigenemia in the plasma 
as a quantitative marker of virus levels98,99. Another early measure of disease progression prior to 
the development of ART was measures of cellular HIV-1 RNA in peripheral blood mononuclear 
cells100, which had moderate predictive power to determine those at risk for early disease 
progression. One measure that was readily performed, and that was assumed to be the best 
possible predictor of disease progression, was the quantification of the number and percent of 
CD4+ T cells in blood101. 
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Although the polymerase chain reaction was first described in the mid-1980s102,103, it had 
not yet come to the forefront of molecular diagnostics. Manuscripts published back to back in 
Nature in 1995 by Ho et al.104 and Wei et al.105 utilized PCR to achieve two distinctly novel 
results. The first novel finding was that although patients were in a state of clinical latency, it 
became clear that there was actually a highly dynamic process of viral infection and turnover of 
infected cells occurring. The second novel result that was achieved by using PCR was the 
detection of viral variants at the nucleotide level by sequence analysis. Longitudinal sequence 
analysis showed that nearly complete turnover of viral species occurred in 14 days. Taken 
together, these two manuscripts shed significant light on the viral dynamics of HIV-1 infection 
using PCR. These results led to a subsequent manuscript by Perelson et al., where viral dynamics 
were inferred from the clearance rates observed after administration of ritonavir, and led to the 
finding that the lifespan of the infected cell is on average 1.2 days, with a generation time of 
virion infecting one cell, to new virions infecting a second cells of 2.6 days106.  
These results contributed to the time being ripe for the development of a new prognostic 
marker of progression to AIDS. Recent advances in PCR, coupled with new knowledge about the 
highly dynamic nature of HIV-1 infection during clinical latency, led to the hypothesis that the 
number of infected cells in the body would be reflected by the amount of virus in plasma. A 
small preliminary study had suggested that lower levels of viral RNA in serum was associated 
with a longer time to disease progression107. The hypothesis that HIV-1 RNA levels in plasma 
could predict the time to disease progression was then tested in two clinical studies. These 
studies demonstrated that plasma HIV-1 RNA levels were weakly correlated with the CD4+ T 
cell counts, and that HIV-1 RNA in plasma was a much better predictor of the time to AIDS or 
death108,109. The finding that measures of cell-free viral RNA in plasma were strongly related to 
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the time to disease progression was striking, with numerous immediate clinical applications. The 
clearest and most profound clinical application was the in vivo evaluation of the efficacy of any 
given therapy at reducing plasma viral load. Instead of waiting for clinical endpoints such as 
progression to AIDS or death, investigators could instead rely on plasma viral loads as indicative 
of the efficacy of a given therapy. The well-documented power and relative ease of viral load 
testing cemented its status as a predictor of clinical efficacy, and as such it is widely used today 
to monitor therapy. 
After the discovery of fully suppressive ART regimens, plasma viremia was also used to 
infer the lifespans of infected cell populations. The rationale was that following initiation of fully 
suppressive ART, all virion production had to be derived from cellular sources that were already 
infected. Falling levels of virus in the plasma, therefore, would represent the death of the virus 
producing cells. Using this logic, Perelson et al. found that there were two phases of viral decay, 
one that was extremely rapid, and a second, longer and slower decay phase110. The authors then 
speculated that extrapolation of this decay would lead to the complete clearance of virus in as 
few as 3 years. This inference, based on extrapolated data from 1997, is obviously incorrect 
based on today’s knowledge of the latent reservoir, as described below. 
One thing that was clear from the initial study of the decay of plasma viremia was that 
patients on therapy were reaching the limit of detection of clinically available assays, usually 
within 6 to 12 months. In order to more faithfully assess the decay kinetics of plasma viremia, it 
would be necessary to develop a new, much more highly sensitive assay. Preliminary attempts 
were made to lower the limit of detection of viral load assays111, but a research group at the 
National Cancer Institute would ultimately develop and validate what would come to be known 
as the single copy assay (SCA)112. The first SCA assay was capable of detecting virus down to 
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one copy per milliliter of plasma by incorporating ultracentrifugation of up to 7 milliliters of 
plasma. This assay could indeed readily detect plasma viremia at low levels, and was extensively 
validated with panels of control samples with known quantities of plasma virus. 
SCA was first used to assess whether there were differences in the low-level viremia 
setpoint after years on different ART regimens. This study revealed that there was no difference 
between classes of fully suppressive ART regimens and the amount of virus in plasma after long-
term suppressive therapy113. These findings suggested that, regardless of ART regimen, all 
people on fully suppressive regimens have approximately the same magnitude of viral 
persistence in plasma. These findings were followed up shortly thereafter with evidence that low-
level viremia in plasma hits a viral set point of approximately 3 copies per milliliter of plasma, 
and stays there for at least 7 years114. This study also found that there were three quantifiable 
phases of viral decay, with a 4th phase with an infinite half-life. This was largely accepted as 
evidence that there was no appreciable decay in amount of virus in plasma over time, until a 
recently published manuscript. Riddler et al. recently found, in a longitudinal cohort of 64 
participants, that plasma HIV-1 RNA levels continue to decline with an average rate of loss of 
6% and an estimated half-life of 11.5 years115. Notably, this study evaluated participants in years 
4-12 of suppressive therapy, and therefore had a longer period of time to assess decay than the 
previous study by Palmer et al.  
 In summary, studies of plasma viremia in people on long-term suppressive ART have 
consistently shown several phases of viral decay, followed by a period in which the virus in 
plasma decays extremely slowly. These studies suggested that the virus produced in plasma 
during long-term suppressive therapy is likely from cells that were infected prior to the initiation 
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of therapy, and are either long-lived or are periodically exiting from a latent reservoir and 
producing virus and dying, or perhaps both.  
 What is abundantly clear is that once suppressive ART is stopped, plasma HIV-1 RNA 
levels quickly rebound within days to weeks to levels at or near pre-therapy viral loads, leading 
to depletion of CD4+ T cells and increased risk of transmission of HIV-1 to others116-121. The 
results from these treatment interruption studies begins to bring to light the fact that, although 
plasma HIV-1 RNA is suppressed to levels that require large volumes of plasma and highly 
specialized assays to quantify this low-level viral load, there is still a large reservoir looming 
under the surface.  
 Viral load measures for HIV-1 have been useful since PCR technology was brought into 
the realm of diagnostic molecular biology. At the beginning of the epidemic, viral load was used 
to assess the rapid turnover of infected cells during clinical latency. Viral load measures guided 
the assessment of the clinical efficacy of antiretroviral therapy at the turning point of the 
epidemic, and viral load measures are still being used to assess the amount of virus in patients on 
long term suppressive ART as well as the time to viral rebound following cessation of ART. 
Doubtlessly, measures of HIV-1 RNA will remain useful as long as the HIV-1 epidemic 
continues. 
 
1.2.2 A reservoir of HIV in resting CD4+ T cells 
Clinical evidence of persistent low-level viremia in HIV-positive persons on long-term 
suppressive ART, in conjunction with rapid viral rebound following cessation of ART, is 
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consistent with the idea of a latent reservoir of HIV-1. While clinical development was correctly 
focused on identifying markers of viral replication in plasma to develop drugs to extend the 
lifespans of those living with HIV-1, others were working on elucidating further biological 
details about the latent nature HIV-1 infection. The outright focus on development of suppressive 
ART was more immediately important to prolong the lives of those infected with HIV-1, 
especially given the rapid turnover of infected cells and virions in plasma, compared with 
elucidating whether there was a latent reservoir of infected cells. 
Nevertheless, groups in the mid-1990s were seeking ways to quantify the amount of 
infectious virus within CD4+ T cells. Investigation of the levels of infectious virus in plasma and 
cells from people living with HIV-1 has roots in a 1989 manuscript by Ho et al.99, in which a 
limiting dilution culture assay with activated cells from HIV-negative donors were cultured with 
PBMC from HIV-positive people either not receiving therapy or receiving AZT monotherapy. 
The endpoint of the assay was assessment of p24 by ELISA in cell culture supernatants with 
twice weekly sampling over a 28-day culture, and inferring the amount of infectious virus 
present by endpoint assessments. This crude version of a viral outgrowth assay indicated that at 
least 1 in 400 mononuclear cells were infected with HIV-1 in the periphery, and that the levels of 
infectious virus in plasma decreased 25-fold following 4 weeks of therapy with AZT, but did not 
change in mononuclear cells. This assay format was the forerunner of more complicated assays 
of viral outgrowth to come. 
Prior to the use of a viral outgrowth assay, it was first necessary to identify a population 
of cells that could harbor HIV-1 for the life of the patient. Work by Chun et al. in 1995 isolated 
resting CD4+ T cells from patients, and quantified integrated HIV-1 DNA in this cell population. 
While they found integrated HIV-1 DNA in resting CD4+ T cells, they also found that it did not 
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accumulate over time, drawing the conclusion that the majority of actively infected CD4+ T cells 
do not convert to infected resting memory CD4+ T cells122. This study was the first to identify 
directly the infection of resting CD4+ T cells. 
During the time when Perelson and Ho’s modeling suggested that HIV-1 may be 
eradicated in 3 years with fully suppressive antiretroviral therapy, others were investigating 
whether there was a latent reservoir that could prevent the eradication of virus from patients with 
ART alone. The first study to demonstrate replication competence of virus in resting CD4+ T 
cell was by Chun et al. in 1997, in which they found that overall there was relatively infrequent 
infection of resting CD4+ T cells during infection123. The authors of this study also used samples 
from both blood and tissues to estimate that the size of the total body reservoir was less than 107 
cells containing replication competent integrated proviruses in resting CD4+ T cells. This was 
considered to be a relatively small reservoir, considering the highly dynamic nature of virion 
production in HIV-1 infection, with greater than an estimated 1010 viral particles produced per 
day106. 
Several months later, two separate laboratories expanded on these preliminary findings 
by looking for the presence of latently infected cells from patients on suppressive ART 
regimens124,125. The recent development of suppressive ART regimens with indinavir, AZT and 
3TC allowed these studies to assess whether there was a latent reservoir in those without levels 
of detectable viremia in their peripheral blood. Other newer ART regimens, including ritonavir 
based and d4T based regimens were also available, to name a few. Both Wong et al. and Finzi et 
al. found that there was replication competent HIV-1 in the peripheral blood of HIV-1 patients 
despite prolonged suppression of viremia with newer ART regimens. Importantly, the authors 
also performed sequence analysis to determine if there were drug resistance mutations. Finding 
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no resistance mutations, the authors concluded that there was a stable reservoir in peripheral 
blood, and that ART should not be stopped until this reservoir is further evaluated. The modeling 
data that had been presented earlier in 1997 by Perelson et al. had assumed that there was no 
third phase of viral decay in plasma, and (critically) that there was no latent reservoir. This study 
was quickly followed up by Chun et al., who also found that there was an inducible reservoir in 
CD4+ T cells of those receiving ART126. 
The decision to look at resting CD4+ T cells by Finzi et al. (rather than CD8-depleted 
PBMC by Wong et al. or total CD4+ T cells by Chun et al.) turned out to have important 
implications for future research into HIV-1 reservoirs. The study by Finzi et al. was the first to 
demonstrate that resting CD4+ T cells in patients on suppressive ART harbor replication 
competent virus. At this point, the stage was set for the elucidation of a life-long reservoir of 
HIV-1 in patients on fully suppressive therapy. The groundwork had come early, with a 
rudimentary understanding of the molecular mechanism of HIV-1 proviral latency127, with work 
by Chun et al. demonstrating the presence integrated HIV-1 DNA in resting memory CD4+ T 
cells122,123, and by Wong et al. and Finzi et al.124,125 demonstrating the presence of replication 
competent virus in those on suppressive ART. All that was left to do was to connect the dots, and 
demonstrate that this supposed reservoir in resting CD4+ T cells was highly stable over time.  
The first report of the stability of this reservoir in resting CD4+ T cells came in 1999, 
with the finding that the half-life of this latent reservoir was nearly 44 months by a mixture of 
cross-sectional and longitudinal analysis of 34 patients on long term suppressive ART128. This 
preliminary estimate, combined with an estimated total body load of 106 latently infected cells as 
constituting the latent reservoir, led to the inference that it would require an average of 60 years 
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of uninterrupted therapy for this reservoir to be eradicated, providing evidence of a life-long 
persistent reservoir in resting CD4+ T cells.  
Shortly after the publication of this study, two other manuscripts were published129,130 
suggesting that the decay rate of the latent reservoir in resting CD4+ T cells was substantially 
less than that found by Finzi et al. Zhang et al. sought to evaluate the decay rate of the reservoir 
by evaluating the number of sequences present in resting CD4+ T cells over time, and by fitting 
slopes to sparse longitudinal measures of viral outgrowth data from eight participants129. 
Ramratnam et al., on the other hand, inferred from a negative association between episodes of 
intermittent viremia and the slope of decay of the size of the infectious reservoir through 
longitudinal analysis, that replenishment of the reservoir was occurring from ongoing viral 
replication130. Both studies estimated a half-life of the latent reservoir of approximately 6 
months, assuming fully suppressive therapy; both studies also shared the idea that there was 
ongoing viral replication replenishing the reservoir, and therefore not allowing the reservoir in 
resting CD4+ T cells to decay. These studies also ignored the fact that no HIV-1 DNA bearing 
resistance mutations was found within the reservoir of those on suppressive ART regimens124,125. 
Ultimately, both of these studies suggesting that the decay rate of the reservoir in resting 
CD4+ T cell was much less than 44 months were shown to be incorrect. A follow-up study 
published by Siliciano et al. in 2003 evaluating the longitudinal decay rates of the latent reservoir 
in 62 participants demonstrated that people on stably suppressive therapy for up to 7 years had 
similar decay rates, and that the half-life of the latent reservoir was indeed 44 months131, 
consistent with the previous result by Finzi et al. in 1999128. 
These studies of the decay rate of the latent reservoir highlight an important theme that is 
still occurring in HIV/AIDS research today: the argument as to whether ongoing viral replication 
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is occurring in those on long term suppressive ART. This argument was once again brought to 
the forefront by recent study asserting that the lower concentration of antiretroviral drugs in the 
lymphoid compartment causes replenishment of the viral reservoir, with deep sequencing being 
performed on bulk viral sequence populations cited as evidence of viral evolution132. 
A body of research has demonstrated that intensification of ART regimens does not lead 
to reductions in low-level viremia133-135 or increases in 2-LTR circles136,137, and there is no 
ongoing replication detectable by highly sensitive and properly performed sequence analysis of 
individual viral templates in those on long term suppressive therapy138-140. Although increases in 
2-LTR circles have been reported in those on stable ART, these have primarily been in patients 
with potentially suboptimal adherence to protease inhibitors141,142. Perhaps the strongest evidence 
for a lack of ongoing replication is that fact that those who are adherent to long term ART 
regimens do not spontaneously fail these regimens. If any substantial viral replication was 
occurring, mutations would eventually develop to ART, leading to virologic failure. Continuous 
replenishment of the reservoir would eventually lead to viral breakthrough. The Centers for 
Disease Control and Prevention data from 2011 showed that more than 81% of those retained in 
care and receiving ART for HIV-1 had suppressed viral loads in the United States143. The fact 
that those who are highly adherent to ART can maintain suppressed viral loads for decades is 
substantial proof that ongoing viral replication does not contribute to replenishment of the viral 
reservoir. 
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1.2.3 Clonal expansion as a new mechanism of viral persistence 
The dogma of the latent reservoir in resting CD4+ T cells as a key driver of persistence has been 
the dominant theme regarding HIV-1 persistence since at least 2003, and probably since 1999. 
While other reservoirs may very well exist in long-lived macrophages and microglia, resting 
CD4+ T cells are currently the only well-described reservoir that can contribute to life-long 
persistence of HIV-1 due to the innate immunologic memory of CD4+ T cells. The latent 
reservoir in resting CD4+ T cells is thought to stochastically reactivate via regular mechanisms 
of CD4+ T cell activation from memory cells, leading to these cells producing viral proteins, 
then quickly dying from viral cytopathic effects. The persistence of HIV-1 is therefore mostly 
attributable to the long lifespan of memory CD4+ T cells144-146. Indeed, human CD4+ T cells 
responses to HCV can be quantified nearly 2 decades after exposure147, and responses to 
Vaccinia virus vaccination can be detected nearly 40 years after vaccination148 in the absence of 
further antigenic stimulation, demonstrating the long life of memory CD4+ T cells. 
There is clearly a persistent long-lived reservoir in resting CD4+ T cells. However, recent 
evidence has pointed towards another mechanism of viral persistence. Maldarelli et al. and 
Wagner et al. in 2014 published evidence that the integration site of HIV-1 proviruses can play 
an important role in the persistence of infected cells over time149,150. Maldarelli et al. showed that 
nearly 40% of the integration sites in one individual were identical, indicating that they were in 
cell clones and suggesting that extrinsic or intrinsic factors could drive this clonal 
expansion149,150. In one case, the sequence of a drug-sensitive virus in plasma was identical to 
one massively expanded clone, suggesting that these clonally expanded proviruses can produce 
virions in the presence of suppressive ART. Some have claimed that these clonally expanded 
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proviruses are not likely to be replication competent151, and have been found to be predominantly 
mutated152. However, Simonetti et al. recently reported that the expanded clone that contributed 
substantially to the plasma viremia observed in one study participant was indeed replication 
competent153. It remains to be seen how frequently clonally expanded populations can be found 
in plasma, and how often these clonally expanded populations are infectious. 
1.3 MOTIVATION FOR A CURE: THE BERLIN PATIENT 
1.3.1 Early studies of stem cell transplantation for HIV-1 
In those with AIDS, the risk of developing both hematologic and non-hematologic malignancies 
is much higher due to the compromised state of the immune system and the often-unchecked 
replication of herpes viruses (i.e., Epstein Barr virus and HHV-8) and human papilloma 
viruses154. However, even following the control of viral replication during the era of fully 
suppressive ART, the frequency of cancer in those living with HIV-1 is higher155-162 than those 
living without HIV-1. As such, oncology and HIV-1 have had an ongoing relationship since the 
beginning of the epidemic, especially before the invention of suppressive ART regimens. In the 
time before fully suppressive ART regimens, oncologists attempted to improve the course of 
HIV-1 infection through donor lymphocyte infusions or transplantations (reviewed in 163).  
The first studies of treatments for HIV-1 in the field of oncology were lymphocyte 
transfusions in the early 1980s. These first studies showed that they were essentially completely 
ineffective at treating AIDS, likely due to infection of the transfused donors T cells and the lack 
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of engraftment of the transfused lymphocytes164,165. Another study was undertaken where donor 
lymphocytes from an HIV-uninfected identical twin were serially infused into an HIV-positive 
identical twin, based on the principle that this could lead to engraftment in the absence of 
conditioning chemotherapy166. Surprisingly, this showed some benefit, including an increase in 
CD4+ T cells, but the HIV-positive twin ultimately died 1 year after the serial transfusions 
began167. Together, these initial studies of donor lymphocyte transfusions demonstrated that 
there was no clinical benefit to simply transfusing in more T cells. 
With AZT becoming available in 1987, transplantation oncologists began attempting to 
investigate the effects of transplantation on HIV-1 persistence in patients for whom 
transplantation was indicated based on malignancy. Many studies found no effect on HIV-1 
persistence following transplantation (reviewed in 163). However, results from several studies 
were intriguing. In one study, a man with refractory lymphoma received an allogeneic stem cell 
transplantation in addition to AZT throughout the transplantation period168. Following 
engraftment, PBMC and bone marrow became negative for HIV-1 by PCR, but unfortunately the 
patient died shortly thereafter from tumor relapse. Intriguingly, no HIV-1 was detectable by PCR 
or culture from lymph nodes, bone marrow, tumor or other tissue samples obtained after death. 
The authors concluded that chemotherapy and transplantation may have eradicated HIV-1, and 
AZT protected the graft in this context168. This basic rationale, of wiping out the host immune 
system and replacing it with a new one, while protecting the new immune system from being 
infected with HIV-1, is the same rationale that would lead to the long term remission in the 
Berlin Patient 20 years later. At the time, it was not known that CCR5 was a major co-receptor 
for HIV-1 entry169-173 or that a percentage of the population is homozygous for a deleted version 
of CCR5174, and are therefore resistant to HIV-1 infection from CCR5-tropic viruses175,176.   
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One year later, a study was conducted in which 16 HIV-positive twins received syngeneic 
stem cell transplantation from their identical twins, and were randomized to receive AZT or 
placebo after transplantation177. This study found no clinical benefit other than a small increased 
in CD4+ T cell counts following transplantation, and no differences between the placebo and 
AZT groups. 
Several years later, a woman with AIDS underwent conditioning chemotherapy along 
with AZT, interferon-α, and anti-HIV-specific cytotoxic T lymphocyte clones as treatment for 
HIV-1, followed by allogeneic stem cell transplantation from an HLA-identical donor178. 
Engraftment occurred, and the patient was negative for HIV-1 after 30 days, but immunologic 
reconstitution was poor. The patient ultimately died 10 months after transplantation, and PCR on 
tissues obtained post-mortem was negative for HIV-1. This study, together with the study by 
Holland et al. from 1989168, highlights the potential importance of graft versus host disease in 
eradicating or greatly reducing the frequency of HIV-1 infected cells. Juxtaposing these studies 
with the lack of an observed effect in the study following syngeneic transplantation by Lane et 
al. from 1990177 further illustrates this point. 
 One further case of transplantation prior to the advent of suppressive ART is worth 
reviewing, and it is the case of Jeff Getty, who received a bone marrow transplant from a baboon 
following non-myeloablative conditioning in 1996 as an experimental treatment for advanced 
AIDS179. This study was approved by the FDA after much convincing from the outspoken and 
well-known AIDS activist Jeff Getty due to his rapidly deteriorating condition180,181. Justifiably, 
concerns existed about zoonotic transmission of disease from the donor baboon to the recipient, 
and the possibility of subsequent spread of zoonotic disease from person to person if Mr. Getty 
was infected with a new pathogen182. Fortunately for Mr. Getty, the transplant was relatively 
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innocuous179, but was also unsuccessful in treating his HIV-1, although his condition did 
independently improve. This study raised important concerns about the use of xenogeneic 
sources of blood stem cells, but also xenogeneic sources of whole organs for transplant, leading 
some to call for a moratorium on xenotransplantation research183. While a moratorium ultimately 
did not occur184, more research and an abundance of caution should be used when investigating 
xenotransplantation.  
Overall, stem cell transplantation in the era prior to suppressive ART was largely 
unsuccessful due mostly to the inability to control the replication of HIV-1, and perhaps partially 
due to bone marrow toxicity of AZT and the related failure to efficiently reconstitute the immune 
system following transplantation185. 
1.3.2 Stem cell transplantation in the era of suppressive ART 
In the era of suppressive ART, HIV-1 infected persons with hematologic malignancies requiring 
stem cell transplantation fare remarkably well. The overall quality of health of those living with 
HIV-1 on suppressive ART regimens has permitted the assessment of preparatory conditioning 
regimens186,187, leading to improved outcomes. Reconstitution of the periphery has also been 
much improved in the context of suppressive ART188,189.  
In particular, autologous stem cell transplantation has improved dramatically in the era of 
suppressive ART. At this point, there is essentially no difference in terms of outcomes between 
those with and without HIV-1 when it comes to autologous stem cell transplantation for 
lymphoma190-195. Considering there was a time when having HIV-1 was a contraindication for 
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receiving a stem cell transplantation, the transplant oncology field has progressed substantially in 
parallel to the development of ART.  
This progress in the treatment of HIV-1 related malignancies with transplantation has led 
to the ability to inquire as to the effects the process of transplantation itself may have on HIV-1 
reservoirs in the context of fully suppressive ART. Studies of autologous stem cell 
transplantation had generally focused on outcome (as described in the paragraph above), and not 
directly on whether there was reduced persistence of HIV-1 following autologous stem cell 
transplantation. To date, three studies have evaluated the impact of autologous stem cell 
transplantation on HIV-1 persistence. Resino et al. found no change in cellular HIV-1 DNA 
levels 12 months after transplant in 6 HIV-positive autologous transplant recipients188. Simonelli 
et al. studied 24 HIV-positive patients who underwent autologous stem cell transplantation, 
finding that levels of HIV-1 DNA in PBMC decreased significant at 24 months post-
transplant189. Our group studied 10 patients who underwent autologous stem cell transplantation 
at the City of Hope with minimal interruptions in ART during conditioning and transplantation, 
and found that plasma viremia was detectable with the single copy assay in 9 of 10 patients, and 
that HIV-1 DNA was detectable in all 10 patients following transplantation196. We also found no 
relationship between levels of HIV-1 DNA in PBMC and the length of follow-up, with a follow-
up of >4000 days. Therefore, it seems clear that autologous stem cell transplantation is not 
curative nor does it substantially reduce the size of the reservoir, likely due to the infusion of 
infected cells as a component of the mononuclear cell autograft and incomplete suppression of 
viral replication in the peri-transplant period. Interestingly, another study by our group also 
suggested that moderately intensive chemotherapy for HIV-associated malignancies did not lead 
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to long-term changes in the levels of low-level plasma viremia or cellular HIV-1 DNA in 
PBMC197. 
Leading up to the success story of the Berlin Patient (published in 2009; see below)198, 
many studies of allogeneic stem cell transplantation were attempted in the era of suppressive 
ART. The vast majority of these cases proved to be entirely unsuccessful, as reviewed by Hütter 
and Zaia in 2011163. In Hütter and Zaia’s summary of 20 HIV-positive people who received 
transplants between 2000 and 2010, many either died shortly after transplant or there was no 
major impact on the HIV-1 reservoir. In one study by Avettand-Fenoel et al., an HIV-positive 17 
year old received an allogeneic stem cell transplantation and concomitant suppressive ART, and 
subsequently became HIV-1 DNA negative in PBMC199. Ultimately, this patient experienced a 
rapid viral rebound following cessation of ART. In a study of two patients who underwent 
conditioning and transplantation while receiving ART, one had undetectable levels of HIV-1 
DNA in PBMC shortly after transplant, but unfortunately treatment interruption could not be 
attempted because the patient died soon after200. 
In the era of modern ART regimens, both allogeneic and autologous stem cell 
transplantation for HIV-associated malignancies are a reality and are commonly performed. 
What is also clear is that there is almost no role of transplant alone in reducing or eliminating the 
reservoir of HIV-1 infected cells in patients receiving suppressive ART regimens. Despite 
having come a long way in learning how to perform hematopoietic stem cell transplantations in 
those with HIV-1 infection, we were seemingly no closer to a cure for HIV-1. 
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1.3.3 Timothy Ray Brown and the first cure of HIV 
The “Berlin Patient”, or Timothy Ray Brown, is an American man who was living with HIV-1 
suppressed on ART and working as a translator in Germany, when he was diagnosed with acute 
myeloid leukemia (AML)198. As initial treatment for AML, Mr. Brown received two courses of 
induction and one course of consolidation chemotherapy, but unfortunately developed severe 
hepatic and renal toxicity, leading to the discontinuation of ART and subsequent viral rebound. 
ART was once again started, and viremia was re-suppressed. Despite the initial response of AML 
to chemotherapy, Mr. Brown experienced a relapsed of AML 7 months later. This relapse was an 
indication that myeloablative chemotherapy and stem cell transplantation was required. 
At this juncture, Dr. Gero Hütter, Mr. Brown’s physician at the Chartié 
Universitätsmedizin Berlin, applied some unique insight. The majority of HIV-1 viral strains 
enter CD4+ T cells through CCR5, a chemokine receptor expressed on the cell surface169-173, 
although some utilize CXCR4 to enter the cell201-203. Individuals who are homozygous for the 
CCR5delta32/delta32 mutation in the CCR5 gene are resistant to HIV-1 infection by CCR5-
tropic strains175,176, and those who are heterozygous are also resistant to infection and exhibit 
slower disease progression when infected204,205. Large-scale studies have determined that the 
frequency of the delta32 version of the CCR5 allele is approximately 10% in European 
populations, and at approximately 2-5% across the Middle East and the Indian subcontinent174. 
Importantly, the CCR5delta32 mutation leads to a truncated version of the CCR5 protein that is 
not expressed on the cell surface206. Therefore, those who are homozygous do not express any 
CCR5, and those who are heterozygous express reduced levels of CCR5 on the cell surface.  
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Dr. Hütter used the knowledge that homozygosity for the CCR5delta32 allele conferred 
resistance to HIV-1 infection, and investigated a group of 80 potential stem cell donors from the 
German Bone Marrow Donor Center who were HLA-identical to Mr. Brown198. He found that 
the frequency of the mutated version of the CCR5 allele was 21% in this cohort of 80, and one 
donor was homozygous for the delta32 mutation, consistent with population estimates of the 
frequency of this mutation in European populations174. This donor was selected as the stem cell 
donor for Mr. Brown, and Mr. Brown gave informed consent for the procedure. Mr. Brown was 
heterozygous at the CCR5 allele prior to the transplantation, though it is unknown if this had any 
bearing on the clinical outcome. 
Mr. Brown underwent conditioning chemotherapy and total body irradiation, as well as 
prophylaxis against graft versus host disease with antithymocyte globulin207, all of which 
substantially depleted T cells. ART was administered throughout conditioning until the day 
before transplantation, and engraftment subsequently occurred on day 13. Mr. Brown achieved 
full chimerism, and the wildtype CCR5 allele became undetectable in peripheral blood. Rectal 
biopsy at day 159-post transplantation showed no expression of CCR5, consistent with 100% 
chimerism from a delta32 homozygous donor. However, macrophages isolated from the rectal 
biopsy still expressed wildtype CCR5, likely due to their long lifespan in vivo.  
Unfortunately, AML relapsed approximately 330 days following transplantation, leading 
to another round of conditioning chemotherapy and full body irradiation in preparation for 
another stem cell transplantation from the CCR5delta32/delta32 homozygous donor. Once again, 
100% chimerism was achieved, and AML went into remission. Remarkably, ART was never 
restarted after the first transplant, and Mr. Brown never experienced viral rebound198.  
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In a follow up study by Allers et al. 3.5 years after stem cell transplantation, additional 
evidence was presented for the complete replacement of Mr. Brown’s immune system. Tissue 
samples from the colon, liver, and brain were obtained primarily for the assessment of graft 
versus host disease, and to attempt to identify the cause of leukoencephalopathy associated with 
neurological disorders (likely as a result of the extensive toxic chemotherapy and total body 
irradiation as treatment for AML), and were subsequently assessed for the presence of CCR5 
positive cells for research purposes. No cells expressing CCR5 were present in the brain or liver, 
consistent with replacement of potentially long-lived cells in these compartments with donor-
derived cells208. Initially, and consistent with the report by Hütter et al.198, macrophages 
expressing CCR5 were detectable, but disappeared at later time points. Additionally, antibodies 
to HIV-1 also faded over time. This wealth of evidence led the authors to conclude that the 
Berlin patient was likely cured. 
Interestingly, Mr. Brown’s donor-derived cells expressed CXCR4, and were shown to be 
susceptible to CXCR4-tropic virus208. Initial analyses of the viral species present in Mr. Brown’s 
reservoir suggested that there was ~2% predicted CXCR4-tropic virus198. These viruses could 
theoretically have led to viral rebound by infecting CXCR4 expressing donor cells. Three 
possibilities exist, with one being that the entire reservoir was eliminated when Mr. Brown’s 
cells were killed by chemotherapy- and graft versus host-mediated toxicity. Another possibility 
is that HIV-infected cells containing CXCR4-tropic infectious virus were too infrequent to 
permit viral outgrowth. Finally, it is also possible that there was not any CXCR4-tropic virus in 
Mr. Brown’s reservoir. This last possibility is also supported by the literature, in that the 
predicted CXCR4-tropic virus actually relied upon CCR5 for entry209.  
32 
 
These reports documenting the cure of HIV-1 in one patient were received with great 
enthusiasm and optimism. A commentary published in the journal Blood following the report by 
Allers et al. entitled “The Power of 1 in HIV Therapeutics” captured the sentiment generated by 
these studies, stating: “The cure of HIV now has a face and a name after a 3-decade fight with 
HIV. The quest for more practical options for the remaining 33 million people living with HIV 
worldwide has to continue.”210 
1.3.4 The Boston Patients and subsequent attempts at curative stem cell transplantation 
The cure of Mr. Brown following myeloablation and stem cell transplantation with 
CCR5delta32/delta32 homozygous stem cells as treatment for AML doubtlessly changed the 
field of HIV-1 research forever. Prior to the cure of Mr. Brown, it was unknown if a cure for 
HIV-1 was possible, and if it was possible, what it would look like. Mr. Brown and Gero 
Hütter’s team demonstrated that a cure was indeed possible. However, given the drastic 
measures that had to be taken to cure Mr. Brown (i.e., complete elimination and replacement of 
his immune system with one that was resistant to HIV-1 infection) and the morbidity that is 
associated with such treatment, this case of a cure in N=1 is purely inspirational, and is 
applicable only to a few of the many living with HIV-1 in whom malignancies necessitate stem 
cell transplantations. 
 Stem cell transplantation cannot be performed in those living with HIV-1, unless it is 
done as a last resort for the treatment of a hematologic malignancy, due to the high rates of 
mortality (1 year survival of 69% for unrelated allogeneic transplantation for AML in the first 
remission211, and 59% for chronic myeloid leukemia in the 2nd chronic or accelerated phase 212) 
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associated with allogeneic stem cell transplantation. Although malignances are more common in 
HIV-1 infected patients, they are still very rare. This has not stopped physicians from identifying 
prospective patients with HIV-1 suppressed on therapy and malignancies that necessitate stem 
cell transplantations. Two such patients whose clinical courses were recently reported have 
become known as the “Boston Patients”. Not unlike the Berlin Patient, these two individuals 
developed malignancies while on fully suppressive ART regimens213.  
The first of the Boston patients was a male who was diagnosed with Hodgkin’s 
lymphoma in 2006, and whose lymphoma recurred following initial chemotherapy and recurred 
again following autologous stem cell transplantation, indicating that allogeneic stem cell 
transplantation was required. This patient underwent reduced intensity conditioning, and 
received an allogeneic HLA-C-mismatched (7/8 matched alleles) unrelated stem cell transplant. 
Full donor chimerism was achieved by 216 days after transplantation213.  
The second patient was a male who was initially diagnosed and successfully treated for 
diffuse large B-cell lymphoma in 2003. However, in 2006 he was diagnosed with mixed-
cellularity Hodgkin’s disease. His Hodgkin’s disease was then treated with chemotherapy, but he 
relapsed and then underwent an autologous stem cell transplant. Unfortunately, persistent 
thrombocytopenia and anemia arose, leading to a diagnosis of myelodysplastic syndrome. In 
2010, this patient underwent reduced intensity conditioning and received an HLA-matched 
allogeneic stem cell transplant from a sibling. Full chimerism was achieved by day 220 post-
transplant213. 
In this case report, both patients were CCR5delta32 heterozygous, with one wild type 
CCR5 allele each. Both then received allogeneic stem cell transplantation from CCR5 wild type 
homozygous donors. Both Boston patients had been heavily pre-treated with chemotherapy, and 
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had received autologous stem cell transplantations. In this case, both patients engrafted well and 
achieved full donor chimerism. Some graft versus host disease was reported in each patient, and 
was controlled with prednisone. HIV-1 DNA in PBMC was detectable pre- and immediately 
post-transplant in both patients, as was HIV-1 RNA in plasma. However, HIV-1 DNA in PBMC 
and total CD4+ T cells isolated from both patients were negative for HIV-1 DNA at later time 
points, corresponding with full chimerism and consistent with replacement of the host immune 
systems with that of the donor. Levels of HIV-1 antibodies also decreased in both patients, with a 
five-fold decrease in the first patient 1,266 days post-transplant and a 10-fold decrease in the 
second patient at 652 days post-transplant213. 
After observing that the levels of HIV-1 DNA in PBMC and total CD4+ T cells became 
undetectable, and levels of HIV-specific antibodies declined, the investigators sought to more 
thoroughly evaluate viral persistence in leukapheresis products and rectal biopsies214. The 
authors once again found that no HIV-1 DNA was detectable in PBMC, and that no infectious 
virus was present in >150 million cultured total CD4+ T cells from these two patients. Rectal 
biopsies in the second patient revealed no detectable HIV-1 DNA by qPCR. Finally, 
microchimerism analysis confirmed that only 0.0004% to 0.001% of PBMC were of host origin 
in these two transplant recipients214. 
 These findings prompted the investigators to initiate an analytical treatment interruption 
study, for which the two patients provided informed consent. Weekly viral load assays were to 
be performed in the first 10 weeks, followed by viral load testing every one or two weeks after 
week 10 to carefully assess whether rebound occurred. For the first patient, viral recrudescence 
occurred 84 days following cessation of ART, with a viral load of 904 copies of HIV-1 RNA per 
milliliter of plasma 14 days after a negative viral load assay. The second patient remained HIV-1 
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DNA negative in PBMC at weeks 5 and 18 following treatment interruption, but the patient 
experienced flu-like symptoms on day 219 post-ART cessation, and was found to have a viral 
load of 1.9 million copies per milliliter of plasma on day 225 post-ART cessation. This was only 
14 days after a negative clinical viral load result in plasma214. Virus that was present as HIV-1 
DNA in PBMC following resumption of ART was related to virus that was present as HIV-1 
DNA in PBMC from before transplantation, suggesting that the source of viral rebound was 
indeed extremely infrequent latently infected reservoir cells that were still present despite the 
near-complete replacement of the host’s immune system. 
These results are ultimately disappointing, both for the patients and for the field of HIV-1 
cure research. While disappointing, this study does provide some critical insight into the degree 
with which the reservoir must be reduced for an eradication cure of HIV-1 to be successful. 
There are some important differences between these patients and Mr. Brown, most notably that 
Mr. Brown received a stem cell transplantation from a donor that was CCR5delta32 
homozygous198, so his new immune system was protected from infection, at least from CCR5-
tropic virus. Mr. Brown also received a much more intensive conditioning regimen, including 
total body irradiation and graft versus host disease prophylaxis with rabbit anti-thymocyte 
globulin, perhaps leading to a more profound initial depletion of Mr. Brown’s reservoir. Finally, 
Mr. Brown also likely experienced a more severe graft versus host disease manifestation, 
including viscerally and in the central nervous system198; this may have also translated into a 
greater depletion of Mr. Brown’s own immune system, and also his HIV-1 reservoir.  
Despite these differences, it is important to note that the minimum reduction in HIV-1 
DNA from these two patients was approximately 1,000-fold, and yet these patients relapsed at 12 
weeks and 31 weeks after ART cessation. Interestingly, Hill et al. have predicted via virologic 
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modeling that a reduction in the size of the latent reservoir (as measured by viral outgrowth 
assays) of ~2,000-fold would be required to allow the cessation of ART for 1 year without 
relapse in most individuals, and that >10,000-fold reductions would be needed to completely 
prevent viral rebound in the absence of ART215. These results highlight the significant difficulties 
that will be associated with trying to deplete the reservoir of HIV-1; if the reservoir has been 
depleted to below the limit of detection, as it was in the Boston patients, it is likely that viral 
relapse will occur in one year following cessation of ART. This modeling work also suggests a 
disturbing outcome amidst the challenge of evaluating curative strategies, namely that the Berlin 
patient could one day experience virologic relapse with a CXCR4-tropic virus, if any virus does 
indeed remain in his body. While this seems unlikely, it is still a possibility. 
Ongoing studies are attempting to replicate the success achieved with the Berlin patient, 
but these studies face several obstacles. The frequency of patients living with HIV-1 that require 
allogeneic stem cell transplantation is a limiting factor, as is the frequency of CCR5delta32 
homozygous individuals who could serve as stem cell donors. Finding an HLA-matched 
CCR5delta32 homozygous donor for an HIV patient requiring a stem cell transplantation is 
therefore quite challenging216. Follow-up studies in which patients did receive transplantation 
with CCR5delta32 homozygous stem cells have been attempted in at least 7 instances, but have 
not been successful. In all cases, the recipient has died within one year following transplant, and 
CXCR4-tropic virus has rebounded in each case217,218. Although repositories of CCR5delta32 
homozygous donors have been instituted219, it seems that the Berlin patient may truly be a unique 
case, serving primarily as inspiration to achieve a goal that is still quite far off. 
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1.4 HIV-1 LATENCY REVERSAL AS A CURATIVE STRATEGY 
The cure of Mr. Brown’s HIV-1 infection by allogeneic stem cell transplantation was important 
to the field of HIV-1 cure research because it demonstrated that an eradication cure could be 
achieved, albeit through extraordinary measures. While the allogeneic stem cell transplantation 
approach cannot be applied for the vast majority of those living with HIV-1, it does serve as a 
galvanizing force, leading to enthusiasm that a cure can be achieved and renewing interest in 
investigating curative strategies. 
1.4.1 Initial studies investigating HIV-1 latency reversal 
A preliminary ex vivo study conducted by Chun et al. in 1998 found that combinations of the 
cytokines IL-6, TNF-α and IL-2 led to the reactivation of HIV-1 expression from cultured resting 
CD4+ T cells220. These findings led to the hypothesis that perhaps IL-2 administration in vivo 
could be used to deplete the latent reservoir through viral cytopathic effects or immune mediated 
clearance221. This hypothesis was put to the test in a group of patients receiving suppressive ART 
based on one or two NRTI regimens combined with a protease inhibitor, who then received IL-2 
either subcutaneously or intravenously. IL-2 therapy had been given to many HIV-1 patients in 
past studies222-229, largely as a way to transiently increase CD4+ T cell counts prior to the 
development of effective ART regimens, and as such there was considerable clinical experience, 
as well as an appreciation that high dose IL-2 was associated with significant toxicity. A 
retrospective analysis of those who had received IL-2 therapy in three studies prior to 1995 
revealed increases in CD4+ T cell counts and a non-significant trend towards improved clinical 
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courses in those who had received IL-2 therapy230. However, a large scale prospective study 
published in 2009 that was appropriately powered to evaluate the clinical efficacy of IL-2 
therapy found that, despite significant increases in CD4+ T cell counts, there was no clinical 
benefit of IL-2 therapy in those with suboptimal CD4+ T cell counts on suppressive ART231.  
Bearing this extensive clinical experience with IL-2 therapy in mind, and the appreciation 
that high-dose IL-2 led to significant toxicity, Chun et al. gave low doses of IL-2 separated by up 
to 8 weeks. Viral outgrowth assays performed using resting CD4+ T cells isolated from a group 
of patients that received IL-2 showed statistically significantly lower levels of virus outgrowth 
compared to a group that did not receive IL-2. Additionally, some in the group that received IL-2 
had no detectable viral outgrowth from large numbers of cultured resting CD4+ T cells, or from 
resting CD4+ T cells isolated from lymph node biopsies, leading to the conclusion that IL-2 may 
deplete the reservoir in those on suppressive ART220. Another study by Prins et al. attempted a 
similar approach, except that an antibody (OKT-3) specific for CD3 was given in addition to IL-
2. This study revealed profound T cell activation and proliferation, and was associated with a 
dramatic increase in viremia in one of three patients; however, this study also caused transient 
renal failure and seizures in one of three patients232. As such, this intervention was deemed too 
toxic.  
Based on their preliminary results, Chun et al. initiated a treatment interruption study in 
two patients who had received IL-2 therapy and in whom no replication competent virus could 
be recovered. Both patients experienced viral rebound within 3 weeks, demonstrating that the 
virus had not been cleared in these patients233. This finding was considered conclusive enough to 
not pursue additional studies of treatment interruption in patients who had received IL-2 therapy. 
These findings, in conjunction with the failure of IL-2 therapy to improve outcomes in those with 
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sub-optimal CD4+ T cell recovery, will likely put an end to the study of IL-2 therapy in HIV-1 
infection. 
 In addition to the investigation of IL-2 to reduce the size of the latent reservoir, a study 
published in 2005 by Lehrman and Hogue et al.234 studied the size of the infectious reservoir in 
four patients who received ART intensification with enfurvirtide, followed by valproic acid (a 
weak histone deacetylase inhibitor235,236) twice daily orally for three months. This study found 
that there were substantial decreases in the size of the latent infectious reservoir in three of four 
study participants.  
Despite these initially promising findings, follow-up studies in larger cohorts revealed 
that the reservoir remained stable in those on suppressive therapy237 and that the reservoir only 
declined appreciably in a small number of participants following treatment with valproic acid for 
three months238. Another study revealed no changes in the amount of total or integrated HIV-1 
DNA in 11 patients receiving valproic aicd compared to 13 controls, and also found no change in 
the size of the replication competent reservoir239. This study also compared treatment 
interruption in three patients receiving valproic acid as part of a larger French cohort that 
underwent treatment interruption, and found that there was no difference in the time to viral 
rebound in the patients who received valproic acid compared to others239. Finally, a randomized 
cross-over style clinical trial studied the effects of valproic acid on the size of the latent reservoir 
in 56 participants on suppressive ART, and found that it had no effect240. These studies led to the 
conclusion that valproic acid does not have a substantial effect on the size of the latent reservoir 
in resting CD4+ T cells in vivo in those on suppressive ART. Taken together, these early studies 
using IL-2 or valproic acid to reduce the size of the reservoir indicate that safer, more specific, 
40 
 
and more potent latency reversing agents would be required to reduce the size of the latent 
reservoir. 
1.4.2 Histone deacetylase inhibitors and the kick and kill strategy 
Although valproic acid, the first histone deacetylase inhibitor (HDACi) tested, was ultimately 
found to be ineffective at reducing the size of the latent reservoir in patients on suppressive ART, 
others hypothesized that the rationale for use of an HDACi was not flawed, and that more potent 
HDACi were needed. Work elucidating that role of HDAC in suppression of expression from the 
long terminal repeat (LTR) of HIV-1 is rooted in a publication from 1994, and another from 
1997. These two publications together suggested that the transcription factors YY1 and LSF 
played a role in suppressing viral transcription from the LTR, but the complete mechanism was 
unclear241,242. It was discovered in 2000 that LSF recruits YY1 to the LTR to form a repressor 
complex, which then recruits the HDAC1 complex to the LTR, leading to molecular repression 
of the LTR243. A follow-up study demonstrated that HDAC1 associates closely with a 
nucleosome (nuc-1) that is adjacent to the transcription start site in the LTR244.  Other molecular 
studies soon followed that ascribed the recruitment of HDAC1 to nuc-1 via different 
transcription factors than originally proposed, such as NF-ΚBp50 homodimers245, c-Myc and 
Sp1246, and CBF-1247. Regardless of the specific mechanism of recruitment, it is clear that 
HDAC1 is recruited to the LTR of HIV-1, and leads to the suppression of viral transcription 
through the deacetylation of histones on nucleosomes associated with the LTR, leading to the 
close association between viral DNA and the histones and preventing the cellular transcription 
machinery from accessing the viral LTR. 
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Ex vivo evaluation of HDACi for their potential role in reversing latency was first 
performed with valproic acid248, which was found to be surprisingly effective in reversing 
latency given the limited responses observed in clinical trials. Two reports in 2009 were 
published regarding the ability of HDACi to reverse latency ex vivo, and once again HDACi 
were found to be surprisingly effective at reversing latency249,250. Vorinostat (also known as 
suberoylanilide hydroxamic acid or SAHA) was found to induce viral outgrowth from patient-
derived resting CD4+ T cells in these two studies, suggesting that SAHA was a potent latency 
reversing agent and that HDAC1 plays an important role in the maintenance of molecular latency 
of HIV-1. 
1.4.3 Clinical assessments of histone deacetylase inhibitors and disulfiram 
A number of clinical studies have been conducted to date to investigate the effects of putative 
latency reversing agents in terms of their ability to reactivate expression of latent proviruses. 
Studies have primarily focused on HDACi for the time being, given the literature suggesting the 
importance of HDAC1 in maintaining proviral latency, and due to the availability of FDA-
approved HDACi for use in the clinic, albeit for cancer-related indications.  
The first study of SAHA in people came from Archin, et al. and was published in 2012 in 
Nature. This study sought to evaluate the effects of a single dose of oral vorinostat on levels of 
cellular HIV-1 RNA in resting CD4+ T cell isolated from participants on suppressive ART. The 
authors studied eight patients, and found that levels of cellular HIV-1 RNA increased in each of 
these individuals, with a mean increase of 4.8-fold over baseline251. Levels of cell-free HIV-1 
RNA in plasma were also measured, but did not change. This study was touted as proof of 
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principle that reversal of proviral latency can be achieved in vivo by targeting known 
mechanisms of proviral latency. However, the study raised more questions than answers, namely 
whether de novo reactivation of transcription was occurring or whether levels of basal 
transcription were merely being increased, and whether the increases in cellular HIV-1 RNA 
were associated with depletion of the latent reservoir. These questions served as the impetus for a 
key portion of my  dissertation work.  
Two additional studies of SAHA followed the initial report by Archin, et al. One study, 
from the same group that published the initial report, was a multi-dose evaluation of vorinostat 
three days in a row, once a week, for eight weeks. The authors found that levels of cellular HIV-
1 RNA expression in resting CD4+ T cells increased in only three of the five participants studied 
after doses 11 and 22, indicating that the responsiveness to SAHA may wane over time252. By 
contrast, a study by Elliot et al. that evaluated the effect of daily 400 mg oral doses of SAHA for 
14 consecutive days on the size of the latent reservoir in 20 participants on suppressive ART 
found that levels of cellular HIV-1 RNA transcription in total CD4+ T cells increased in 18/20 
study participants. The median peak fold-increase was found to be 7.4-fold, but plasma viremia, 
total and integrated HIV-1 DNA, and levels of infectious virus as measured by viral outgrowth 
were unchanged. Intriguingly, in this study, levels of cellular HIV-1 RNA in total CD4+ T cells 
remained elevated for 70 days following the last dose of SAHA253. The results of these two 
studies are discordant, likely due to effects from the different numbers of participants studied and 
the assessment of HIV-1 RNA transcription in total CD4+ T cells in one study versus resting 
CD4+ T cells in the other study. 
Other clinical studies of putative latency reversing agents quickly followed the initial 
description of SAHA. While mostly HDACi have been studied to date, disulfiram is a notable 
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exception. Disulfiram is thought to reactivate HIV-1 latency through reduction in levels of 
phosphatase and tensin homolog (PTEN) protein, the absence of which causes increased 
phosphorylation of protein kinase B (also known as Akt), leading to activation of NF-κB254. A 
pilot study of 500mg of disulfiram administered daily for 14 days was evaluated for latency 
reversal effects in a cohort of 16 study participants. Disulfiram was found to not have an effect 
on the size of the latent reservoir, and did not substantially increase plasma HIV-1 RNA levels, 
although it may have transiently increased viremia immediately post-dosing in a subset of 6 
individuals who were closely monitored255. In an expanded study of 34 participants recently 
published by Elliot et al., administration of disulfiram for three days at doses 500mg, 1000mg 
and 2000mg was safe and well-tolerated, and increased levels of cellular unspiced HIV-1 RNA 
significantly, albeit only 1.7-fold above baseline post-dose and 2.1-fold above baseline in the 
timepoint after dosing256. No dose effect was observed, and the overall magnitude of the latency 
reversal effect was minimal.  
Two other HDACi, panobinostat and romidepsin, that are more potent than vorinostat 
have also been studied clinically. In a phase I/II clinical trial of 20 mg of oral panobinostat given 
three times per week every other week for eight weeks in 15 study participants, the authors found 
that levels of cellular HIV-1 RNA in total CD4+ T cells increased significantly, with a median 
increase of 3.5-fold (ranging from 2.1-fold to 14-fold)257. Panobinostat also increased levels of 
HIV-1 RNA in plasma, although this was assessed with a transcription mediated amplification 
assay and therefore could not be quantified other than positive or negative. An analytical 
treatment interruption was also performed, but the median time to viral rebound was 17 days 
(ranging from 14 to 56 days), suggesting that panobinostat did not have a large impact on the 
size of the latent reservoir 257. 
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The study of the potent HDACi romidepsin was performed in a group of 6 study 
participants with viremia suppressed on ART. These participants received 5 mg/m2 of 
romidepsin by infusion over a 4-hour period once weekly for 3 weeks, and levels of cellular 
HIV-1 RNA were quantified in total CD4+ T cells. Levels of cellular HIV-1 RNA in total CD4+ 
T cells were found to increase, with fold increases in the range of 2.4- to 5.0-fold. Plasma HIV-1 
RNA also increased from <20 copies per milliliter of plasma by Roche COBAS 
AmpliPrep/TaqMan at multiple timepoints in 5 of 6 study participants, ranging from 46 to 103 
copies per milliliter of plasma. From these finding, the authors concluded that romidepsin was a 
safe and effective latency reversing agent. 
Taken together, clinical experience with latency reversing agents to date has focused 
mostly on HDACi, although disulfiram has also been investigated. The results of trials have 
generally found that latency reversal agents increase expression of unspliced cellular HIV-1 
RNA in either total CD4+ T cells or resting CD4+ T cells. While SAHA and disulfiram have not 
been found to increases in levels of plasma HIV-1 RNA, panbinostat and romdepsin have 
reportedly led to increases in plasma viremia. Overall, the effects observed from these latency 
reversing agents have generally been weak, and have not led to profound reductions in the size of 
the latent reservoir in vivo, as evidenced by the short time to rebound in the panobinostat study 
and a lack of change in the size of the infectious reservoir by viral outgrowth in the romidepsin 
study. If we are going to substantially deplete the size of the latent reservoir with the kick and 
kill approach, it seems that drugs that are better tolerated and that more potently reactivate the 
latent reservoir will be required. 
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1.4.4 Pre-clinical assessment of LRAs targeting mechanisms of viral persistence 
In addition to the above described HDACi that target chromatin structure to reverse latency, 
other compounds targeting different known aspects of proviral latency have been proposed and 
studied in various in vitro and ex vivo systems. It is worth noting that in vitro models of HIV-1 
latency have a high degree of variability of responses to different latency reversing agents. Spina 
et al. recently investigated 5 different in vitro models of HIV-1 latency compared with ex vivo 
measures using patient cells, and found that the responsiveness of any one cell model did not 
necessary translate to the other cell models, or measures of latency reversal from patient cells ex 
vivo258. This study acutely highlighted the difficulty associated with using model systems to 
replicate an extremely complex in vivo situation. This problem also extends to the discovery of 
HIV-1 latency reversing agents at the level of screening systems often used by pharmaceutical 
companies, namely that a cell line with a predictable response is required for compound 
screening. Results from any one in vitro system should therefore be interpreted with caution, and 
for this reason ex vivo systems using latently infected cells from patients should primarily be 
used to evaluate promising latency reversal candidates.  
 Mechanisms of proviral latency are complex and multifactorial, and have been reviewed 
extensively elsewhere259-262. The first step required for the transcription of viral messenger RNA 
is the ability of the cellular transcriptional machinery to access the LTR. The relevance of 
chromatin structure, as it relates to suppression of transcription initiation, is described in the 
sections above about HDACi. Another potentially relevant molecular mechanism of 
transcriptional suppression is methylation of histones and direct methylation of proviral DNA. 
Histone methylation has been extensively studied in HIV-infected cell lines, with data showing 
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that di- (me2) and tri-methylation (me3) of histone H3 at lysine residue 9 (H3K9me2 and 
H3K9me3), and tri-methylation at histone H3 lysine 27 (H3K27me3) in the histones forming a 
complex with nuc-1 in the HIV-1 LTR are associated with HIV-1 transcriptional repression263-
268. The cellular enzymes Suv39H1264, G9a266, and EZH2265 are known to be responsible for the 
H3K9me3, H3K9me2 and H3K27me3 repressive methylation of histones, respectively, 
suggesting that inhibition of these enzymes could lead to the reversal of latency. 
This hypothesis has been tested in an ex vivo system269 with chaetochin, an inhibitor of 
Suv39H1-mediated H3K9me3270, and BIX-01294, an inhibitor of G9a-mediated H3K9me2271,272. 
Bouchat et al. found that chaetochin treatment led to virus production in the culture supernatant 
from 50% of CD8-depleted PBMC cultures and 86% of resting (in this case, CD3+CD4+HLA-
DR-) CD4+ T cell cultures, and that BIX-01294 led to reactivation from 80% of resting (in this 
case, CD3+CD4+CD25-CD69-HLA-DR-) CD4+ T cells269. Although significant proportions of 
cultures became positive for HIV-1 RNA, it is important to note that levels of HIV-1 RNA 
produced were higher than maximum reactivation with T cell activation in some donors and were 
substantially lower than T cell activation in other donors. Additionally, the authors also treated 
the CD8-depleted PBMC and resting CD4+ T cells with the histone methyltransferase inhibitors 
(HMTI) for a supra-physiological exposure time of 6 days, and provided no measurements of 
non-specific T cell activation or cellular viability after culture, raising concerns about the 
relevance of the reported findings. In vitro experiments with EZH2 inhibitors have inconsistently 
led to viral reactivation265,273, and inhibition of EZH2 in a primary cell model suggested that it 
may prime cells for subsequent responsiveness to HDACi treatment274. Overall, the lack of a 
FDA-approved HMTI, limited evidence of the ex vivo efficacy of HMTI, and probable off-target 
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effects from general inhibition of histone methylation contribute to an unclear path forward for 
use of these compounds for HIV-1 latency reversal. 
Methylation of proviral HIV-1 DNA has also been suggested as a mechanism of proviral 
latency. A cDNA screen in the J-Lat cell line by Kauder et al. identified methyl-CpG binding 
protein 2 as a major regulator of HIV-1 latency via association with two CpG islands 
surrounding the transcription start site in the LTR, and that treatment with the DNA 
methyltransferase inhibitor 5-aza-2’deoxycytidine (5-aza-dC) synergized with NF-κB activators 
to cause viral gene expression275. Blazkova et al. also found that CpG methylation in the LTR 
was associated with proviral latency ex vivo276. However, a follow-up study by Blazkova et al. 
found that methylation of CpG islands within the proviral LTR was relatively infrequent, with 
only 2.4% of nucleotides methylated in the 5’-LTR of resting CD4+ T cells by sodium bisulfite 
sequencing. Finally, a study by Bouchat et al. found that treatment with 5-aza-dC did not 
substantially reactivate virus production from latently infected resting CD4+ T cells, but rather 
led to high levels of virus production when used to pre-treat cells prior to treatment with 
HDACi277. Taken together, the role of DNA methyltransferase inhibitors such as 5-aza-dC in 
reactivating HIV-1 transcription may be limited due to infrequent methylation of the CpG islands 
located within the 5’ LTR in latently infected resting cells isolated from patients on long term 
suppressive therapy.  
In addition to the suppressive chromatin structure facilitated by histone acetylation and 
methylation, many other transcriptional blocks are associated with post-integration HIV-1 
latency. After chromatin has been opened sufficiently, key transcription factors can access their 
cognate binding sites on the HIV-1 genome, and can recruit the cellular RNA polymerase II 
machinery. The cellular transcription factors Sp1 and NF-κB are both important for the initiation 
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of HIV-1 transcription278-280. While the p50 homodimers of NF-κB present in non-activated cells 
favor the recruitment of suppressive transcriptional complexes245, the p50/RelA heterodimers of 
NF-κB present in activated cells facilitate the recruitment of transcriptional machinery (including 
p300/CBP), leading to the recruitment of RNA polymerase II to the LTR281. As such, the 
presence of NF-κB heterodimers is thought to be an important step in the reactivation of HIV-1 
from latency.  
Once NF-κB has been activated, the next step of transcriptional reactivation is the 
recruitment of the RNA polymerase II machinery, and the interaction between P-TEFb, Tat and 
RNA polymerase II. The P-TEFb complex, consisting of cyclin T1 and CDK9282, is utilized via 
interaction with Tat to drive high-level, full length transcription of HIV-1 RNA283,284. However, 
analogous to the sequestration of the activate version of NF-κB in non-activated cells, P-TEFb is 
also sequestered in a suppressive 7SK snRNP complex285. The bromodomain protein Brd4 can 
interact with P-TEFb, freeing it from the suppressive 7SK snRNP complex and allowing it to 
function as part of the super elongation complex286,287. However, the interaction of Brd4 with P-
TEFb competes with the interaction of Tat and P-TEFb, so the presence of high levels or Brd4 
can inhibit reactivation of HIV-1 by preventing high levels of full length transcription286,287. An 
inhibitor of Brd4 named JQ1288 is being investigated for the potential to reactivate HIV-1 by 
freeing P-TEFb for interaction with Tat289. Different Brd4 inhibitors are currently in early stage 
development for cancer290. 
The importance of the mechanisms of latency described above has been highlighted by 
the investigation of compounds targeting specific mechanisms of latency. Chromatin structure 
can be altered by the inhibition of histone acetyl transferases with the HDACi described above, 
such as SAHA, panobinostat, and romidepsin. The activation of NF-κB can be achieved by 
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protein kinase C (PKC) agonists, ideally leading to the reactivation of HIV-1 due to the 
availability of NF-κB heterodimers. Prostratin was initially used as a PKC agonist291, but more 
recently bryostatin has been studied due to its use in vivo in cancer trials292,293. Ingenol 
derivatives are also potent in vitro PKC agonists294.  
Bullen et al. published a study in 2014 showing that no latency reversing agents induced 
viral outgrowth from patient-derived resting CD4+ T cells, and that also showed that single 
agents were ineffective at increasing the transcription of properly poly-adenylated cellular 
unspliced HIV-1 RNA transcripts, with the notable exception being the PKC agonist 
bryostatin295. This reinforced the appreciation of HIV-1 latency as a multifactorial process and 
has led recent groups to evaluate combinations of latency reversing agents, rather than single 
agents. Initial combination studies have focused on the best-described mechanisms of proviral 
latency, combining HDACi with either PKC agonists or Brd4 inhibitors. Laird and Bullen et al. 
investigated combinations of latency reversing agents and found that agents targeting PKC and 
HDAC, and PKC and Brd4 led to substantial latency reversal and exhibited synergy in their 
reactivation of HIV-1 transcription296. Additional studies published recently by Darcis and Kula 
et al. and Jiang et al. identified combinations of the PKC agonists bryostatin or ingenol-b with 
JQ1 as potent latency reversing compounds297, and ingenol-3-angelate and JQ1 as a potent 
combination of latency reversing compounds273, respectively. These ex vivo studies have 
demonstrated that combinations of latency reversing agents containing PKC agonists with either 
HDACi or Brd4 inhibitors are the most potent reactivators of latency across studies. This may be 
due, in part, to the partial activation of CD4+ T cells as a result of treatment with a PKC 
agonist298.  
50 
 
One theme that is universal across these studies is that bulk populations of resting or total 
CD4+ T cell were treated with latency reversal agents, and the relative activity of the latency 
reversal agents was inferred from the bulk response. It is important to carefully evaluate these 
individual and combinations of latency reversal compounds at the level of individual proviruses 
to ensure that they have significant potency when compared to full T cell activation and 
unstimulated levels of virion production. Evaluating the effects of these latency reversal agents at 
the level of individual proviruses, and ascertaining whether these agents have had any effect on 
the size of the latent reservoir ex vivo will be a substantial focus of the ensuing dissertation.  
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2.0  HYPOTHESIS AND SPECIFIC AIMS 
Hypotheses 
 
H1: A latent reservoir of infectious HIV-1 persists in the resting CD4+ T cells of 
individuals receiving suppressive ART. Latency reversing agents have been proposed to drive 
proviruses out of latency, leading to depleting of the latent reservoir, but the potency of these 
agents has yet to be evaluated at the level of individual proviruses. We hypothesize that the 
currently available latency reversing agents will reactivate only a small minority of HIV-1 
proviruses to produce virions ex vivo compared with T cell activation. Similarly, the available 
latency reversal agents will not lead to significant depletion of the reservoir from viral cytopathic 
effects. 
H2: Viral persistence can readily be detected in those receiving suppressive ART, but it 
is unknown how measures of viral persistence are related to the size of the inducible reservoir 
and to each other. We hypothesize that analysis of molecular measures of viral persistence in 
peripheral blood will reveal that the frequency of HIV-1 infected cells and their transcriptional 
activity are positively associated with the size of the spontaneous and inducible reservoirs, and 
can serve as in vivo biomarkers of the inducible reservoir. 
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H3: Finally, we hypothesize that there is a greater number of inducible and infectious 
proviruses within total CD4+ T cells compared with resting CD4+ T cells, and the size of the 
inducible reservoir in total and resting CD4+ T cells will be positively associated with the 
magnitude of infectious virus outgrowth in both total and resting CD4+ T cells. 
 
Specific Aims 
 
The hypotheses described above will be evaluated by pursuing the following three specific aims: 
 
1. Quantify the fraction of proviruses in latently infected resting CD4+ T cells isolated 
from patients on suppressive antiretroviral therapy that can be reactivated to produce 
virions following ex vivo T cell activation or treatment with latency reversal agents, 
and determine whether latency reversal leads to a reduction in the size of the 
inducible reservoir. 
 
2. Investigate the underlying clinical and/or virologic factor(s) that are associated with 
the size of the spontaneous and inducible reservoir in resting CD4+ T cells ex vivo. 
 
3. Evaluate the levels of inducible and infectious virus ex vivo in total and resting 
CD4+ T cells to determine if the inducible and infectious reservoirs are larger in 
total versus resting CD4+ T cells, and to determine if there is a relationship between 
the size of the inducible reservoir and the magnitude of infectious viral outgrowth in 
total and resting CD4+ T cells.  
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3.0  OVERALL MATERIALS AND METHODS 
Patient cohorts studied. The work described in this dissertation was performed using peripheral 
blood samples donated by study participants. Study participants were enrolled either through the 
University of Pittsburgh Center for AIDS Treatment (PACT) clinic or through Quest Clinical 
Research (San Francisco, CA). Regardless of where participants were enrolled, local review 
boards approved the study protocols, and participants provided informed written consent.  
 
Peripheral blood samples. The samples obtained from study participants were either large 
volume blood phlebotomy (180 milliliters of whole blood, or 360 milliliters of whole blood 
spread across two 180 milliliter blood draws separated by ~1 hour), or were from leukapheresis 
products. All blood samples were drawn into either EDTA phlebotomy tubes or leukapheresis 
bags coated with acid citrate dextrose as anticoagulants. Blood samples were processed as soon 
as possible, always within 4 hours of phlebotomy. 
 
Processing of peripheral blood samples. When processing whole blood, plasma was first 
separated from whole blood by centrifuging blood at 500xg for 10 minutes. Plasma was then 
removed, ensuring that the cellular fraction was left behind. The plasma was then spun a second 
time at 1350xg for 15 minutes to remove any cellular contamination, and then was divided into 
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1.5 milliliter aliquots and stored at -80°C for downstream testing. For some leukapheresis 
donors, plasmapheresis was performed in parallel, and the plasma was processed as described 
above.  
After removing plasma from whole blood, the remaining cellular components were 
diluted with 37°C phosphate buffered saline containing 10% fetal bovine serum (PBS/FBS). The 
diluted whole blood was then carefully layered over Ficoll-Paque, and spun at 400xg for 40 
minutes at room temperature, with the centrifuge brake turned off to prevent mixing of the 
separated layers during deceleration of the centrifuge rotator. The peripheral blood mononuclear 
cells present at the Ficoll boundary where then carefully removed and pooled into one tube. The 
pooled PBMC were then washed with warm PBS/FBS, counted in a hemocytometer with Trypan 
blue, and were either cryopreserved or used fresh for experiments. 
 
Isolation of total or resting CD4+ T cells. Isolation of total CD4+ T cells was performed using 
the total CD4+ T cell isolation kit from Stem Cell Technologies, as per the manufacturer’s 
recommendations. This kit isolates CD4+ T cells through negative selection by depleting cells 
expressing CD14, CD16, CD19, CD20, CD36, CD56, CD66b, CD123, and glycophorin A using 
magnetic bead conjugates and a magnet299. Briefly, PBMC are resuspended at 50x106 cells per 
milliliter of RoboSep fluid, and 50 μL of negative selection antibody mixure were added per 
milliliter of sample. The sample and depletion cocktail were then mixed and incubated for 5 
minutes, and then 50 μL of magnetic beads per milliliter of sample were added, and the sample 
was diluted with RoboSep buffer according to whether the EasySepTM or the BigEasyTM magnet 
was to be used. Cells were placed on the respective magnet for 5 minutes, allowing the negative 
selection beads to be drawn towards the outside of the tube due to the magnet field. After the 
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depletion beads equilibrated to the magnetic field and were firmly adhered to the outer interior 
portion of the tube, the supernatant containing total CD4+ T cells was removed. This procedure 
resulted in >95% purity of isolated total CD4+ T cells (see flow cytometry materials and 
methods below). The isolation of resting CD4+ T cells was performed in two separate ways. For 
initial studies, total CD4+ T cells were purified by negative selection using the CD4+ T cell 
Isolation Kit II from Miltenyi Biotec, according to the manufacturer’s recommendations, 
followed by resting CD4+ T cells isolation from total CD4+ T cells by negative selection using 
anti-CD69, anti-CD25 and anti-HLA-DR antibodies from Miltenyi to deplete activated cells300. 
In later studies, a custom kit from Stem Cell Technologies containing all the antibodies described 
above for the isolation of total CD4+ T cells plus antibodies to CD25, CD69, and HLA-DR was 
used to isolate resting CD4+ T cells directly from PBMC following the same procedure 
described above for isolation of total CD4+ T cells from Stem Cell Technologies. Both of the 
methods used to isolate resting CD4+ T cells resulted in >95% purity by flow cytometry (see 
below). The method used in each section of this dissertation is clearly indicated. 
 
Routine cell culture conditions. Routine cell culture is here defined as any cell culture that does 
not require limiting dilution or viral outgrowth. Isolated cells (e.g., PBMC, total CD4+ T cells, 
and resting CD4+ T cells) were cultured at 1x106 cells per milliliter in 1 milliliter of culture 
medium in 48 well plates. Cells were not cultured in the exterior row of the culture plates;  these 
wells were filled with PBS to prevent evaporation of culture medium. Cells were cultured in 
RPMI-1640 without the phenol red indicator and containing 10% (vol/vol) fetal bovine serum, 
1% L-glutamine and 0.6% penicillin/streptomycin. To prevent viral replication, HIV-1 infected 
cells were cultured in 300 nM efavirenz. For pooled virus recovery assays, up to 6 replicate wells 
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containing 1x106 total or resting CD4+ T cells were activated with phorbol myristate acetate 
(PMA; 50ng/mL) and ionomycin (500ng/mL) for 7 days, and then the culture supernatants were 
removed, pooled, and frozen at -80°C for downstream assessment of virion-associated HIV-1 
RNA. Alternatively, we also performed cultures in 6 well plates, with 15x106 PBMC per well in 
5 milliliters of culture medium and 24 well plates with 5x106 resting CD4+ T cells per well in 2 
milliliters of culture supernatant in the presence of 100 nM efavirenz and 100 nM elvitegravir; 
these cultures were similarly activated with PMA/ionomycin, but were harvested after either 5 
days (PBMC) or 7 days (resting CD4+ T cells). In some instances, cells were reactivated with 
anti-CD3/CD28 microbeads at a concentration of 3 beads per cell. The culture conditions used 
for various experiments are clearly stated in the text of this dissertion. Cellular viability was 
confirmed on the day of harvest using CellTiter-Fluor viability assay, as per the manufacturer. 
Importantly, cells were counted by hemocytometer prior to CellTiter-Fluor viability assays to 
ensure that equivalent numbers of cells were assessed for fluorescence viability.  
 
Limiting dilution cultures to quantify fractional provirus expression. To assess the fraction of 
proviruses that have been reactivated by different treatment conditions, it is necessary to perform 
a limiting dilution culture setup such that there will be wells that are positive and negative for the 
viral outcome being assessed (e.g., cellular HIV-1 RNA transcription, virion production, 
infectious virion production)301. This was achieved in two separate formats. The first format was 
12 replicate wells (10 wells of treatment condition and 2 wells of medium control) in 1 milliliter 
of culture medium in 48-well plates beginning at 667,000 resting CD4+ T cells per well, and 
diluting serially, 3-fold, down to 304 cells per well. In these experiments, resting CD4+ T cells 
were activation with magnetic beads coated with antibodies to CD3 and CD28 (anti-CD3/CD28 
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activation beads). Subsequently, we setup experiments with fewer replicates (5 replicates per 
dilution) and beginning at 1x106 resting CD4+ T cells per well, and diluting serially, 3-fold, 
down to 457 cells per well. Supernatants were harvested after 7 days of culture for all 
experimental conditions, and were frozen at -80°C for downstream assessment of virion-
associated HIV-1 RNA. The number of proviruses present per well at each dilution was 
determined by qPCR for total HIV-1 DNA (see Quantification of cellular proviral DNA below), 
and a maximum likelihood estimate was used to determine the fraction of proviruses that have 
been reactivated with any given treatment (see statistical analysis section below).  
 
Latency reversal agents. To assess the potency of latency reversing agents for their ability to 
reactivate proviruses compared with no stimulation and full T cell activation controls, we first 
pulse treated resting CD4+ T cells with latency reversal agents in a dose- and time-dependent 
manner reflective of compound exposure that would be achieved with in vivo dosing. Resting 
CD4+ T cells were first pulse-treated with latency reversing agents in 25 cm2 flasks in 10 
milliliters of medium, and were then washed, counted, serially diluted and cultured for 7 days to 
allow the release of virions into the culture supernatant. The specific concentrations of latency 
reversal agents, and the timing of the pulse treatments, are described in the results section of 
Chapter 3. When assessing whether latency reversal agents had any effect on the size of the 
latent reservoir, a fraction of latency reversing agent-treated resting CD4+ T cells were washed 
to remove residual compound, and cultured for 5 days in 25 cm2 flasks. These cells were then 
counted, serially diluted and maximally activated for 7 days with either anti-CD3//CD28 
activation beads or PMA and ionomycin, for a total of 13 days in culture. CellTiter-Fluor cell 
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viability assays and staining for the assessment of activation marker expression by flow 
cytometry was performed on days 5 and 13, as described below.  
 
Quantitative viral outgrowth assays. Quantitative viral outgrowth assays were performed on 
isolated total and resting CD4+ T cells using the methods described in Siliciano and Siliciano, 
2005302. Briefly, prior to the isolation of patient-derived resting CD4+ T cells or total CD4+ T 
cells, PBMC from an HIV-negative donor were isolated and CD8-depleted, then activated with 
PHA to generate target cells for viral outgrowth. On the day of the blood draw from the HIV-
positive participant, another blood draw from a negative donor was performed, and whole blood 
from the HIV-negative donor was gamma-irradiated to generate feeder cells. Once the patient-
derived resting or total CD4+ T cells were isolated by negative selection (see above for isolation 
method), they were then serially diluted in 5-fold serial dilutions beginning with 106 cells per 
well. A total of 12 replicate wells of 106 cells per well, and two replicate wells of all subsequent 
dilutions were utilized for viral outgrowth. The patient-derived cells were mixed with the 
irradiated feeder cells and allogeneic blasts, and the culture was carried out for up to 21 days, 
with weekly splitting of the cultures and addition of fresh donor blasts to serve as target cells. 
Viral outgrowth was scored in each well as positive or negative by p24 ELISA on days 14 and 
21. A maximum likelihood estimate for the number of cells responsible for infectious virus 
production was then evaluated (see statistical analysis section below). 
 
Quantification of virion-associated HIV-1 RNA in culture supernatants. To assess levels of 
virion-associated HIV-1 RNA in the cell culture supernatants, supernatants were harvested after 
pre-specified culture times, and were spun at 500xg for 5 minutes to remove cellular debris. 
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Supernatants were then frozen at -80°C until assessment of virion-associated HIV-1 RNA was 
performed. Supernatants were then diluted two-fold (for assessment of fractional provirus 
expression) or were run undiluted (for pooled virus recovery), and HIV-1 RNA was measured by 
quantitative real-time polymerase chain reaction (qRT-PCR) using the Roche COBAS 
AmpliPrep/TaqMan version 2.0. The limit of detection was 40 copies of HIV-1 RNA per 
milliliter of sample for fPVE experiments, and was 20 copies of HIV-1 per milliliter of sample 
for all pooled virus recovery samples (as these samples were not diluted). Previous control 
experiments showed that centrifugation of culture supernatants at 24,000xg for 1 hour was 
sufficient to pellet the virion-associated HIV-1 RNA. Further evidence of the HIV-1 RNA being 
virion-associated was the fact that it was resistant to DNase I treatment300. 
 
Quantification of low-level plasma viremia. Plasma viremia (HIV-1 RNA) was quantified in 
three different ways. First, routine qRT-PCR using the Roche COBAS AmpliPrep/TaqMan 
version 2.0 platform was performed to assess viral load down to 20 copies per milliliter of 
plasma. Two distinct single copy HIV-1 RNA assays were also used. The original single copy 
assay (referred to as “gSCA” due to the fact that the PCR target is gag) was performed as 
described112. A newer single copy assay (refered to as “iSCA” due to the fact that the PCR target 
is integrase) was also developed during the course of this dissertation303, and uses improved 
extraction methods and primers/probe targeting a more highly conserved region of the HIV-1 
genome compared to the original gSCA. Large volume adaptations of the iSCA (“mega-iSCA”) 
were implemented in studies in this dissertation to lower the limit of detection and to provide a 
more accurate assessment of low level viremia, as previously described303. The specific assay 
used, of the three available, is clearly indicated in the text of this dissertion. 
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Quantification of cellular unspliced HIV-1 RNA and total HIV-1 DNA. Quantification of cellular 
unspliced HIV-1 RNA and total HIV-1 DNA was performed as previously described300,304,305. 
Briefly, nucleic acid was isolated from 2x106 million by first pelleting the cells, then adding 
guanidinium hydrochloride and proteinase K solution, followed by sonication and then 
incubation at 42°C for 1 hour. After this incubation period, guanidinium isothiocyanate was 
added with glycogen, and an equal volume of 100% isopropanol was added to the extract, 
followed by centrifugation at 21,000xg for 15 minutes. Next, the supernatant was aspirated, 
leaving the glycogen/nucleic acid pellet. To wash the pellet, 1 milliliter of 70% ethanol was 
added, and the sample was once again spun at 21,000xg for 15 minutes. The extract was then 
resuspended and split into two fractions; one fraction was frozen at -80°C for downstream 
quantification of DNA, and the other was treated with DNAase I to remove all cellular and HIV-
1 DNA. This DNAase treated sample was then re-extracted as described above (without the 
addition of glycogen). For quantification of HIV-1 DNA, real-time qPCR was performed in 25 
μL reactions with 10 μL of input template. If the concentration of the DNA extract was greater 
than 170 ng/μL by spectroscopy at A260, the sample was diluted to 170 ng/μL. Triplicate HIV-1 
DNA reactions using primers/probe targeting integrase303 were performed, and duplicate 
reactions targeting CCR5 were performed to normalize for input cell number306. For 
quantification of unspliced HIV-1 RNA, a two-step real-time qPCR was used, with triplicate 
reactions for HIV-1 RNA targeting integrase303 and duplicate reactions for the housekeeping 
gene IPO8300. If the final concentration of RNA in the extract was greater than 30 ng/μL, the 
extract was diluted to 30 ng/μL. cDNA synthesis was performed with 10 μL of input RNA in 20 
μL of reverse transcription master mix, and real-time qPCR was carried out using the entire 
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cDNA reaction with 30 μL of LightCycler480® Probes Master real-time PCR cocktail. The 
iSCA primer probe pair also amplified Vif RNA, but this accounts for approximately 0.21% of 
the family of 4.0-kb spliced RNA species, and therefore minimally contributes to the 
measurement of unspliced cellular HIV-1 RNA307. 
 
Flow cytometric analysis. To assess cell surface phenotypes, we performed flow cytometry using 
the follow fluorophore conjugated antibodies: CD3-PacBlue, CD4-FITC, CD8-PerCP/Cy5.5, 
CD25-PE, PD-1-PE/Cy7, HLA-DR-APC. All antibodies were purchased from BD Biosciences. 
Prior to cell surface staining, cells were stained with a Live/Dead Aqua dye, as per the 
manufacturer’s recommendation. Cells were then washed and stained with fluorochrome 
conjugated antibodies in stain buffer from BD. Cells were then washed, and fixed with 
CytoFixTM fixation buffer from BD for 15 minutes on ice prior to running the fixed cells on an 
LSRII flow cytometer. Acquisition was perfomed using FACS Diva on the LSRII. A minimum 
of 10,000 events were acquired for all experiments. Cells were first gated on singlet live 
lymphocytes, followed by populations of interest. Analysis and gating was performed using 
FlowJo.  
 
Statistical analysis and generation of figures. All figures were generated in GraphPad Prism, 
with the exception of the correlograms which were generated using R308, using the reshape309 and 
ggplot2310 packages. All statistical analysis was performed using R308. Fractional provirus 
expression was quantified by using a maximum likelihood estimate in R through a generalized 
linear model with a binomial distribution and a log link function300. Paired and unpaired 
Wilcoxon signed rank T tests were used to assess differences between groups. Spearman’s 
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correlation was used to assess correlative relationships, and Pearson’s correlation was sparingly 
used to generate 95% confidence intervals for correlation coefficients to compare results between 
patient groups. Mixed linear effects analysis was performed using the lme4 package311, with the 
exception of a preliminary study where the nlme package312 in R was used; this is noted where 
appropriate in the body of this dissertation. Type III ANOVA was performed using the 
Companion to Applied Regression package313 in R. False discovery rates were corrected using 
the method of Benjamini and Hochberg314. Post-hoc power assessments were performed using 
the Basic Functions for Power analysis package315 in R. In all cases, two-sided tests were used, 
and α<0.05 was considered statistically significant. All values that were below the limit of 
detection for any assay were interpolated as 50% of the limit of detection for the given assay. 
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TO QUANTIFY HIV-1 LATENCY REVERSAL IN RESTING CD4+ T CELLS FROM 
PATIENTS ON SUPPRESSIVE ART  
Anthony R. Cillo1, Michele Sobolewski1, Ronald Bosch2, Elizabeth Fyne1, Michael Piatak, Jr.3, 
John Coffin4, John W. Mellors1 
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4.1 PREFACE 
A portion of the work described in this chapter has been previously published300, and is cited 
where appropriate. As per the Proceedings of the National Academy of Sciences, authors retain 
the copyright of individual articles, while the Academy retains an exclusive license to publish 
these materials. This work has also been presented in part at the Conference on Retroviruses and 
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Opportunistic infections in 2013 as part of a themed discussion. This work was funded by the 
Pitt AIDS Research Training Program 5 T32 AI065380-08, the Science Applications 
International Corporation (SAIC) 25XS119 through the National Cancer Institute, and by the 
American Cancer Society with support from the F.M. Kirby Foundation. 
This work presented in this chapter is in partial fulfillment of dissertation aim 1. John 
Mellors, John Coffin, and Anthony Cillo designed the experiments; Anthony Cillo, Michele 
Sobolewski, and Elizabeth Fyne performed the experiments; and Anthony Cillo, John Mellors 
and Ronald Bosch analyzed the data. Anthony Cillo and Ronald Bosch performed statistical 
analysis. All other authors contributed technically, conceptually or intellectually to the 
development of the project described in this chapter.  
4.2 INTRODUCTION 
As described in the introduction to this dissertation, small molecule latency reversing agents 
(LRAs) are being rigorously investigated both ex vivo273,295-297,316 and in vivo251-253,255-257,317. To 
date, ex vivo studies have sought to evaluate whether a given LRA is capable of disrupting 
known mechanisms of proviral latency by measuring either cellular HIV-1 RNA as a marker of 
viral gene expression or virus production from cultured peripheral blood mononuclear cells or 
isolated total or resting CD4+ T cells. Histone deactylase inhibitors (HDACi), most notable 
suberoylanilide hydroxamic acid (SAHA)249,250, have been used most extensively ex vivo and in 
several clinical trials251-253,257,317. HDACi have been chosen for evaluation clinically based on 
evidence that they disrupt the nucleosome structure surrounding the HIV-1 LTR, allowing access 
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of transcriptional machinery and transcription of HIV-1 RNA318, as described in the Introduction 
to this dissertation. Clinically, latency reversal has been assessed by measures HIV-1 
transcription in PBMC, or as increases in low level plasma viremia. 
While changes in transcription of HIV-1 RNA or levels of plasma viremia can be readily 
measured, it is currently unclear how these results should be interpreted. Several problems exist 
with currently used methods for the evaluation of latency disruption. First, from bulk measures 
of cellular HIV-1 RNA or virion-associated HIV-1 RNA from culture, it is not possible to 
ascertain whether levels of transcription or virion production have been increased de novo, or 
whether LRAs are merely modulating transcription or virion production from cells that are 
already expressing viral RNA or virions. Second, the potency of latency reversal agents cannot 
be readily compared at the level of individual proviruses due to the fact that varying numbers of 
proviruses are likely to produce virions in a bulk culture. Specifically, the same number of total 
cellular HIV RNA molecules or virions could be produced from a few or many proviruses.  
Therefore, we sought to develop an ex vivo culture system in which LRAs could be compared at 
the level of individual proviruses300. 
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4.3 RESULTS 
4.3.1 Establishment of a limiting dilution culture assay to quantify reversal of HIV-1 
latency 
To evaluate the magnitude of de novo latency reversal that is attainable with maximum activation 
or with latency reversing agents, we have elected to measure the proportion of proviruses 
detectable by quantitative polymerase chain reaction (qPCR) that can be reactivated with any 
given treatment. Quantification of HIV-1 latency reversal at the level of individual proviruses 
requires the segregation of HIV-1 infected cells capable of producing virions into individual 
replicate wells in a serial dilution culture experiment. The precedent and groundwork for this 
experimental design is based a relatively crude assay format that was first used in 198999 to 
quantify levels of infectious virus from plasma and peripheral blood mononuclear cells of HIV-1 
infected patients. Improvements to the statistical underpinnings of dilution culture assays was 
described in 1994 by Myers et al. who developed a maximum likelihood framework based on a 
parametric binomial distribution for assessing the number of events in a given cell population301. 
In the case described by Myers et al., an event is a cell harboring an HIV-1 provirus that is 
replication competent. The maximum likelihood estimation for a limiting dilution culture assay 
can be described by a simple equation (Figure 1), where the likelihood is equal to n choose x 
times one minus e to the negative C times H, times e to the negative C times H. In this equation, 
C is a parameter value (in our case, the fraction of proviruses that have been reactivated) that is 
varied to find the maximum likelihood, and H is the number of proviruses per well. Alternative 
methods to identify the number of events in a cell populations (or any given population) rely on 
67  
identifying dilutions in which ~50% of tested reactions are positive, or identifying the endpoints 
of different assays. However, these methods are much less robust than maximum likelihood 
estimates, and have notable biases (see the discussion in this chapter for details). The method is 
described graphically in Figure 2, and can be readily adapted to other assay formats (i.e., the 
fraction of proviruses that have been reactivated to express unspliced cellular HIV-1 RNA). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Likelihood equation for a limiting dilution culture assay. The likelihood is equal to the product of 
dilution one through dilution D of n choose x times the probability of a positive well, times the probability of a 
negative well at a given dilution. By a first order Taylor approximation, this is equal to e-CH minus one times  
e-CH, where C is the fraction of proviruses that have been reactivated and H is the number of proviruses per well. 
 
 
 
In figure 2, the plot showing the log likelihood demonstrates a varied value of C as described 
above, where C is the fraction of proviruses that have been reactivated to produce virions. The 
value of C that maximizes this likelihood plot is the maximum likelihood estimate for fractional 
provirus expression (fPVE). 
This assay platform can be used to assess the fraction of proviruses that can produce 
virions in the absence of stimulation, following full T cell activation, or following treatment with 
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any given latency reversal agent. Using the Roche COBAS AmpliPrep/TaqMan v2.0 platform 
further facilitates the assay in a higher throughput format, as cell culture supernatants can be 
removed and up to 42 samples can be run in parallel by automated nucleic acid extraction and 
qRT-PCR. It is worth noting that the production and release of a virion only requires the 
expression of gag protein319, so using qRT-PCR as an endpoint measures virions that contain 
genomic HIV-1 RNA. This assay is not only applicable to the endpoint of virion production, but 
could also be used to assess the proportion of proviruses that are transcribing HIV-1 RNA in the 
absence of stimulation, with full T cell activation or following treatment with any given LRA. 
For these experiments, we elected to culture the rCD4 cells for 7 days for all conditions, as 
preliminary experiments demonstrated that virion production peaked at 7 days following T cell 
activation (data not shown). To assess the potency of SAHA as an LRA, we cultured rCD4 cells 
with constant exposure to 0.5 μM SAHA for 7 days of culture.
  
 
 
 
Figure 2. Dilution culture assay to quantify the frequency of proviral latency reversal by a maximum likelihood estimate. A) Peripheral blood mononuclear 
cells are first isolated from large volume blood draws (as in this study) or leukapheresis product. Resting CD4+ T cells are then isolated by negative selection, 
serially diluted, and seeded into plates. Total HIV-1 DNA in resting CD4+ T cells is assessed by qPCR. Supernatants are harvested from wells after 7 days in 
culture, and HIV-1 RNA is quantified by Roche COBAS AmpliPrep/TaqMan. As the number of cells per well decreases, the number of inducible proviruses 
increases per well until an endpoint is reached. B) The number of proviruses per well and the number of positive wells are then tabulated. C) The tabulated table is 
then used to perform a maximum likelihood estimate in R using a generalized linear model with a binomial distribution and a log link function. The red circle 
represents the maximum likelihood, and the fPVE value at this point is the resulting fPVE from the dilution culture data, in this case yielding an fPVE of 1.5% of 
proviruses have been reactivated to produce virions. 
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4.3.2 Validation of fractional provirus expression for quantification of latency reversal 
Following the theoretical framework described above, we sought to evaluate whether a limiting 
dilution culture-based assay could be used to ascertain the fraction of proviruses that had been 
reactivated following any given ex vivo treatment of samples obtained from HIV-1 infected 
patients on long-term suppressive ART. To evaluate fPVE ex vivo, we first performed large-
volume phlebotomy (180 mL), and isolated peripheral blood mononuclear cells (PBMC) by 
ficoll-density gradient centrifugation from N=13 study participants on long-term suppressive 
ART (Table 1). Study participants were male and female, had a mean age of 54 years old, and 
were suppressed for a mean of 8 years (ranging from 2 to 16 years) on a variety of ART 
regimens. 
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Table 1. Participant characteristics for establishment of the fractional provirus expression assay 
Participant ID Sex Age 
Current CD4+ count 
(cells/mm3) 
Current antiretroviral therapy 
Years plasma HIV-1 RNA <50 
copies per milliliter 
1 Female 56 846 EFV/FTC/TDF 12 
2 Male 57 563 ETR/FTC/RAL/TDF/ZDV 4 
3 Female 45 477 DRV/FTC/r/TDF 2 
4 Female 59 825 EFV/FTC/TDF 7 
5 Female 55 1,373 EFV/FTC/TDF 12 
6 Male 57 774 EFV/FTC/TDF 3 
7 Male 53 1,111 3TC/ABC/NVP/ZDV 10 
8 Male 50 380 EFV/FTC/TDF 11 
9 Male 65 748 EFV/FTC/TDF 4 
10 Male 57 934 EFV/FTC/TDF 16 
11 Male 51 534 3TC/ABC/RAL 16 
12 Male 43 367 3TC/ABC/RAL 3 
13 Female 51 1,131 FTC/RAL/TDF 2 
Mean ± SD ND 54 ± 6 774 ± 309 ND 8 ± 5 
 
SD = standard deviation; ND = not done; 3TC = lamivudine; ABC = abacavir; DRV = darunavir; EFV = efavirenz; ETR = etravirine; 
FTC = emtricitabine; NVP = nevirapine; r = ritonavir; RAL = raltegravir; TDF = tenofovir disoproxil fumarate; ZDV = zidovudine 
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From PBMC, we then isolated resting CD4+ T cells (i.e., CD3+CD4+CD25-CD69-HLA-
DR-) by sequential bead-based isolation. First, total CD3+CD4+ T cell were isolated by negative 
selection using the T Cell isolation Kit II from Miltenyi. From these isolated total CD4+ T cells, 
resting CD4+ T (rCD4) cells were isolated by depleting CD25+/CD69+/HLA-DR+ cells by 
magnetic separation using Miltenyi columns. This isolation method routinely resulted in >95% 
purity of isolated rCD4 cells (data not shown). Isolated rCD4 cells were chosen for analysis 
based on their relative enrichment as reservoir cells for HIV-1124,126. These rCD4 cells are 
quiescent, and are considered to be long-lived cells that facilitate life-long persistent infection of 
HIV-1 by harboring latent, intact proviruses124,128,131. Results for assessment of low-level viremia 
and total HIV-1 DNA in rCD4 cells are shown in Table 2. We have found previously that 2-LTR 
circles contribute in a minor way (<5%) to the detection of total HIV-1 DNA in samples isolated 
from those on suppressive ART (data not shown), and as such total HIV-1 DNA is a close 
approximation of integrated HIV-1 DNA. At the time of the genesis of this study, a prominent 
clinical trial had also investigated transcription of cellular HIV-1 RNA in rCD4 cells as an 
endpoint251 after treatment with vorinostat, with the hypothesis that increases in cellular HIV-1 
RNA in rCD4 cells would represent true disruption of the latent reservoir.  
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Table 2. Plasma viremia and total HIV-1 DNA in resting CD4+ T cells for establishment of the fractional provirus expression assay 
Participant 
ID 
Plasma HIV-1 RNA by Roche COBAS 
AmpliPrep/TaqMan 
(HIV-1 RNA copies per milliliter) 
Low-level plasma HIV-1 RNA by 
the single copy assay 
(HIV-1 RNA copies per milliliter) 
Total HIV-1 DNA in resting 
CD4+ T cells 
(copies per 106 cells) 
1 TND <0.25 136 
2 <20 1.5 1,458 
3 <20 <0.25 1,110 
4 TND 1.8 1,551 
5 TND 7.2 2,678 
6 <20 6.0 887 
7 <20 2.2 350 
8 TND 1.3 978 
9 TND 2.8 1,957 
10 TND 1.8 2,849 
11 <20 2.1 2,132 
12 TND 3.1 1,503 
13 <20 3.3 1,128 
Mean ± SD ND 2.6 ± 2.0 1,440 ± 811 
  
SD = standard deviation; ND = not done
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We sought to evaluate fPVE by maximum likelihood estimation in N=13 donors, 
focusing on medium control and anti-CD3/CD28 treatment in all 13 donors and evaluating the 
potency of putative LRA vorinostat (suberoylanilide hydroxamic acid; SAHA) compared to 
medium control and anti-CD3/CD28 activation beads in N=5 donors (Figure 3, Table 3). rCD4 
cells were cultured for 7 days with medium, anti-CD3/CD28 activation beads, and continuous 
exposure to 0.5 μM SAHA. 
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Figure 3. Levels of fractional provirus expression with medium control, anti-CD3/CD28 and SAHA Treatments. 
From N=13 donors, we found that the median fraction of proviruses that produced virions for medium only 
treatment, anti-CD3/CD28 treatment and SAHA treatment was 0.041%, 1.5% and 0.12%, respectively. These 
results are consistent with HIV-1 latency in that few virions were produced in the absence of stimulation, and full 
T cell activation led to high levels of virion production. However, only a small proportion of proviruses could be 
maximally reactivated, and a much smaller fraction of proviruses were reactivated with SAHA treatment. A linear 
mixed effects model was used with the nlme package312 in R to assess differences between treatment groups, with 
treatment as a fixed effect and the individual participants as a random effect. This model was significant, and anti-
CD3/CD28 was the only significant variable (p<0.001, and an asterisk indicates this statistical significance). Some 
samples did not have detectable virion production at  the  lowest  cell  dilutions,  and  therefore  had  undetectable  
fPVE  for  virion production. The fPVE values for undetectable samples were calculated by assuming that one 
well at the lowest dilution was positive. Open symbols denote samples that had undetectable fPVE for virion 
production. 
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These results reveal the median fraction of proviruses in rCD4 cells that produce virions 
in the absence of stimulation was 0.041%, the median maximal fraction of proviruses that could 
be reactivated to produce virions with one round of full T cell activation was 1.5%, and the 
median fraction of proviruses that were reactivated to produce virions following treatment with 
SAHA was 0.12%. Individual results from each donor are tabulated in Table 3. In order to 
ascertain the statistical significance of these findings, a linear mixed effects model, with the 
treatment condition (i.e., medium control, anti-CD3/CD28, SAHA) as fixed effects and the 
individual participants as random effects. A mixed effects model was chosen over an analysis of 
variance (ANOVA) for the analysis of these data due to unbalanced design and the repeated 
measures; a modified ANOVA controlling for the unbalanced design and repeated measures 
could be used, but a linear mixed effects model is more flexible and requires less assumptions, 
and was chosen for these reasons. 
This mixed effects analysis revealed that the only significant treatment group in this 
model was anti-CD3/CD28 treatment (p<0.001) while medium control fPVE (p=0.46) and 
SAHA fPVE (p=0.93) were not significantly different from each other. 
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Table 3. Quantification of HIV-1 latency reversal using fractional provirus expression for virion production 
Participant ID 
Medium Control 
fPVE 
Anti-CD3/CD28  
fPVE 
SAHA 
fPVE 
1 <0.52% 2.4% ND 
2 <0.058% 1.5% ND 
3 <0.064% 0.58% ND 
4 <0.045% 1.5% ND 
5 <0.039% 0.34% ND 
6 <0.23% 1.1% ND 
7 <0.59% 0.16% ND 
8 0.21% 0.35% ND 
9 0.031% 2.4% 0.12% 
10 0.022% 2.5% 0.08% 
11 0.14% 2.3% 0.28% 
12 0.041% 2.8% 0.03% 
13 0.15% 4.1% 0.14% 
Median 
(IQR) 
0.041% 
(0.03% to 0.15%) 
1.5% 
(0.6% to 2.4%) 
0.12% 
(0.08% to 0.14%) 
P value 0.46 <0.001 0.93 
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 Next, we sought to quantify latency reversal by assessing the fraction of proviruses that 
were reactivated to transcribe unspliced cellular HIV-1 RNA in various treatment conditions. A 
benefit of using the limiting dilution culture is that multiple endpoints for viral reactivation can 
be evaluated for fPVE, including the fraction of proviruses that are producing virions. To 
evaluate the fPVE for cellular HIV-1 RNA, nucleic acid was isolated from cultured rCD4 cells 
(see Overall materials and method section for details) after 7 days of treatment with medium 
control, anti-CD3/CD28 activation beads or SAHA from the experiments described above. Total 
RNA was then reverse transcribed into cDNA, and cellular unspliced HIV-1 RNA was quantified 
by qRT-PCR along with IPO8 mRNA as an internal control. By quantifying cellular HIV-1 RNA 
from replicate wells at each dilution, the maximum likelihood estimate could be adapted to 
assess the fraction of proviruses that are transcribing HIV-1 RNA (Table 4).  
 
Table 4. Quantification of HIV-1 latency reversal by fractional provirus expression for cellular HIV-1 RNA 
Participant 
ID 
Medium 
Control 
fPVE 
Anti-CD3/CD28 
fPVE 
SAHA 
fPVE 
SAHA fPVE 
Anti-CD3/CD28 fPVE 
12 0.37% 6.8% 0.093% 0.014 
13 0.054% 8.2% 0.19% 0.023 
Mean ± SD 0.21% ± 0.22% 7.5% ± 0.96% 0.14% ± 0.066% 0.018 ± 0.0067 
 SD = standard deviation 
Evaluating fPVE for cellular HIV-1 RNA revealed that the mean levels of fPVE for 
medium control treated rCD4 cells was 0.21%, while maximum activation with anti-CD3/CD28 
resulted in 7.5% of proviruses produced cellular HIV-1 RNA. SAHA treatment was found to 
reactivate 0.14% of proviruses, which is a very small fraction of proviruses compared to the 
fraction of proviruses that could be maximally reactivated to produce cellular HIV-1 RNA. The 
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median value for cellular HIV-1 RNA fPVE for SAHA was actually less than that for medium 
control. Of the two donors assessed for cellular HIV-1 RNA fPVE, one showed decreased fPVE 
following treatment with SAHA. 
4.3.3 Assessment of relationships between virion production and cellular HIV-1 RNA 
transcription 
Following the assessment of the fraction of proviruses that could be reactivated to produce 
virions or transcribe cellular HIV-1 RNA following treatment, we next asked whether levels of 
cellular HIV-1 RNA transcription were related to levels of virions produced following one round 
of T cell activation with anti-CD3/CD28 activation beads or following treatment with SAHA 
(Figure 4).  
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Figure 4. Relationships between virion production and cellular HIV-1 RNA expression. A) Virion production 
from anti-CD3/CD28 treated rCD4 cells is statistically significantly associated with expression levels of cellular HIV-
1 RNA (rho=0.67, p<0.001, analysis corrected for repeated measures320). B) Virion production from SAHA treated 
rCD4 cells is unrelated to expression levels of cellular HIV-1 RNA (rho=0.21, p=0.99, analysis corrected for 
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repeated measures
320
).  Open circles denote  samples  that  were  undetectable  for  virion  production, unspliced 
cellular HIV-1 RNA, or both. 
 
This analysis revealed that the levels cellular HIV-1 RNA were strongly correlated with 
virion production in the context of one round of T cell activation (rho=0.67, p<0.001), but that 
this relationship did not hold up following treatment with SAHA (rho=0.21, p=0.99). This 
finding is consistent with SAHA non-specifically altering cellular transcription, but not leading 
to virion production. The failure to produce virions despite the upregulation in expression of 
cellular HIV-1 RNA in rCD4 cells treated with SAHA may be due to the quiescent nature of 
rCD4 cells compared with activated CD4+ T cells. 
 
 
 
 
 
4.4 DISCUSSION 
 
 
 
 
In this series of experiments, we developed an assay to measure the fraction of proviruses that 
have been reactivated to produce virions or unspliced cellular HIV-1 RNA. The dilution culture 
assay format, combined with a rigorous maximum likelihood estimate statistical framework, can 
be readily used to assess the fraction of proviruses that have been reactivated to produce virions 
or cellular HIV-1 RNA following latency reversal with T cell activation or treatment with 
putative latency reversal agents. Alternative methods of assessing the frequency of an event 
based on a dilution culture assay with replicates scored by dichotomous results include methods 
by Spearman and Karber, Reed and Muench, Dragstedt and Behrens, Litchfield and Wilcoxon, 
and moving average nonparametric calculation methods301,321,322. These methods have generally 
been applied to the estimate the dilution at which 50% of the replicates would be expected to be 
positive (ED50). The ED50 and frequency of events in a given population as determined by a 
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maximum likelihood estimate are inherently interchangeable, and can be readily calculated from 
each through any of the methods described above. However, in terms of performance 
characteristics and assumptions required by each model, the parametric method described by 
Myers et al. and adopted for fPVE is the most favorable of these assay formats. 
Using this novel assay format, we found that the median fraction of proviruses that could 
be maximally reactivated was 1.5% in this small group of study participants, and that only 0.12% 
of proviruses could be reactivated to produce virions following treatment with SAHA. These 
data indicate that the vast majority of the latent reservoir is not reactivated following SAHA 
treatment.  
We also assessed levels of fPVE for cellular HIV-1 RNA following treatment with anti-
CD3/CD28 and SAHA, finding that up a median of 7.5% of proviruses were reactivated to 
transcribe cellular HIV-1 RNA following T-cell activation, whereas only 0.14% of proviruses 
were reactivated to transcribe cellular HIV-1 RNA following treatment with SAHA. In 
participant 12, the fPVE for cellular HIV-1 RNA transcription was 2.4-fold higher compared 
with virion production, while in participant 13 the fPVE for cellular transcription of HIV-1 RNA 
was 2-fold greater compared with virion production. However, with SAHA treatment, in 
participants 12 and 13, the fPVE for cellular transcription fPVE to virion production was 3.1-and 
1.3-fold higher. Thus, there seems to be a consistent ratio between the levels of fPVE for viral 
transcription and virion production in the context of full T cell activation, but the ratio seems to 
vary following SAHA treatment. 
The findings that full T cell activation only reactivates a small proportion of proviruses to 
produce virions is striking, and implies that 98.5% of proviruses cannot be reactivated to produce 
virions in one round of T cell activation. While a somewhat higher proportion of proviruses can 
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be reactivated to transcribe cellular HIV-1 RNA, these results still suggest that only a small 
number of the proviruses that are detectable by qPCR are capable of undergoing latency reversal 
following T cell activation. These results are consistent with recent findings by Ho et al., who 
found that the majority of integrated proviruses that are not replication competent harbor large 
deletions, are severely mutated by APOBEC, or are missing other key components of the 
genome151. The presence of proviruses that are intact, but that did not replicate in one round of 
activation in work by Ho et al. suggests that either i.) more proviruses might be able to produce 
virions following additional rounds of reactivation; or ii.) some of the intact proviruses that did 
not replicate did indeed produce virions, but these virions did not efficiently infect the allogeneic 
target cells and lead to subsequent cycles of replication. Which of these two outcomes explain 
the findings should be pursed in future studies. 
The finding that SAHA does not lead to substantial virion production ex vivo from rCD4 
cells compared with medium control is consistent with findings from Blazkova et al.316, but 
differs from earlier findings by Archin et al. in which higher concentrations of cells and a less-
sensitive p24 assay was used for detection of virions249. Clinical trials of SAHA have been 
mixed, with initial reports that single-dose SAHA reversed latency by measuring unspliced 
cellular HIV-1 RNA in rCD4 cells251, while multiple doses of SAHA did not consistently up-
regulate HIV-1 RNA transcription252. Elliot et al. found that multiple does of SAHA led to a 
protracted up-regulation of cellular HIV-1 RNA expression, both generally and for HIV-1 
RNA253, but subsequent modeling work showed minimal depletion of infected cells323. These 
studies have been consistent in that no study showed significant increases in plasma HIV-1 RNA 
following SAHA administration. 
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In this study, we found that there was a statistically significant relationship between 
levels of virion production and cellular HIV-1 RNA following treatment with anti-CD3/CD28 
activation beads, but not following SAHA treatment. The relationship between cellular HIV-1 
RNA transcription and virion production following T cell activation is likely due to a shift in T 
cell biology that occurs following activation, where the transcriptional and metabolic profiles of 
T cells change following activation324,325. This process of T cell activation leads to reversal of 
transcriptional blocks to latency (e.g., chromatin structure326,327, release of sequestered key 
transcription factors245,328) and post-transcriptional blocks (e.g., transport of multiply-spliced 
Tat/Rev transcripts329) to proviral latency. Alternatively, the majority of unspliced cellular HIV-1 
RNA transcripts that are produced following treatment with SAHA might be read-through 
transcripts295 that will never be properly translated into HIV-1 proteins. Intriguingly, our results 
also potentially provide ex vivo evidence for an interpretation of the in vivo results of clinical 
trials of SAHA, where levels of cellular HIV-1 RNA are increased following treatment with 
SAHA, but no substantial virion release (as measured by virion-associated HIV-1 RNA in 
plasma) was observed following 7 days of culture. 
Finally, these data demonstrate that SAHA reactivates a very minor proportion of the 
total inducible proviruses within the rCD4 cell population. More potent latency reversing agents 
or combinations of agents targeting multiple factors that contribute to HIV-1 latency will be 
necessary to achieve latency reversal on a similar magnitude to that achieved by T cell 
activation. However, care must be taken to find latency reversing agents that do not lead to T cell 
activation and subsequent cytokine release, as this would represent a significant risk to people 
who are otherwise healthy on stably suppressive ART. Using the methods described in this 
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chapter, we can assess the potency of putative LRAs at the level of individual proviruses to 
determine which (if any) are viable candidates for clinical use. 
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5.0  CHAPTER 2. INVESTIGATION OF PUTATIVE LATENCY REVERSAL 
AGENTS IN RESTING CD4+ T CELLS ISOLATED FROM PATIENTS ON 
SUPPRESSIVE ANTIRETROVIRAL THERAPY 
5.1 PREFACE 
Anthony R. Cillo1, Michele Sobolewski1, Taylor Simmons1, Elizabeth Fyne1, Joshua Cyktor1, 
John W. Mellors1 
1University of Pittsburgh, Division of Infectious Diseases 
 
The work presented in this chapter is in partial fulfillment of Aim 1 of this dissertation. Anthony 
Cillo, Michele Sobolewski, Taylor Simmons, Elizabeth Fyne and Joshua Cyktor performed the 
isolation of resting CD4+ T cells from leukapheresis products, set up extensive limiting dilution 
cell culture experiments, harvested cell culture supernatants and cells following treatment, and 
assessed viability of cultured cells. Anthony Cillo, Michele Sobolewski, Elizabeth Fyne and 
Taylor Simmons performed COBAS AmpliPrep/TaqMan v2.0 for quantification of HIV-1 RNA 
from culture supernatants. Anthony Cillo performed qRT-PCR for cellular HIV-1 RNA and 
DNA. Joshua Cyktor performed and analyzed flow cytometry experiments for assessment of 
activation markers. Anthony Cillo and John Mellors conceived of the project, and Anthony Cillo 
analyzed the data and performed statistical analysis. 
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The work in this chapter was funded by the Pitt AIDS Research Training Program 5 T32 
AI065380-08, a research grant from Gilead Sciences, and COBAS AmpliPrep/TaqMan kits 
provided by Roche.  
5.2 INTRODUCTION 
Following the establishment of an assay that is capable of determining the potency of latency 
reversal at the level of individual proviruses, we next sought to investigate putative latency 
reversal agents and to compare their potency to virion production from medium control and T 
cell activation conditions. We have chosen to evaluate virion production as the major endpoint in 
our assessment of latency reversal, as the production of virions guarantees that all blocks to 
proviral latency have been overcome. One could make an argument that infectious virion 
production should be measured, but assessment of viral outgrowth is technically challenging, 
particularly at higher cells dilutions, in addition to being labor- and time-intensive; so as such, 
we chose to evaluate total virion production as an endpoint. As described above, ex vivo studies 
have generally evaluated changes in cellular HIV-1 RNA as an endpoint to determine whether 
latency reversal has been achieved273,295,296. Some groups have also looked at virion 
production295-297. In order to achieve true latency reversal, at a minimum translation of viral 
proteins must occur. Transcription of cellular viral HIV-1 RNA does not necessarily mean that 
viral proteins have been translated, and if no viral proteins have been produced, the cell is likely 
still invisible to immune surveillance and therefore is still in a state of latency. It is also possible 
to have viral protein translation in the absence of virion production, but it is not currently 
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possible to evaluate viral protein expression at the sensitivity required for infected cells derived 
from study participants on suppressive ART. Therefore, we have chosen to focus on virion 
production, as increases in transcription of cellular HIV-1 RNA does not mean that latency has 
been reversed or that viral mRNAs have been translated into viral protein, while virion 
production can serve as a minimum estimate of the amount of HIV-1 protein production. 
In this section, we extend our findings from preliminary assessments of fPVE to a more 
thorough evaluation of putative latency reversing agents targeting known mechanisms of proviral 
latency. The latency reversing agents we studied can be thought of as tools to evaluate whether 
known mechanisms of latency that have been described in vitro are relevant ex vivo, and whether 
these mechanisms can be targeted and latency reversed without causing global T cell activation. 
Quantifying the proportion of proviruses that can be reactivated to produce virions with latency 
reversing agents, compared with full T cell activation, will provide new insights into the potency 
of these LRAs at the level of individual proviruses.  
5.3 RESULTS 
5.3.1 Mechanisms of action of putative latency reversal agents studied 
To assess mechanisms of latency in rCD4 cells ex vivo, we selected a number of latency 
reversing agents (LRAs) to test in our fPVE assay format. These compounds were selected based 
on the following criteria: 
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1. The LRA or combination of LRAs must target known factor(s) associated with proviral 
latency. 
2. The LRA or combination of LRAs must not activate T cells. 
3. The LRA or combination of LRAs must have a favorable pharmacokinetic and 
pharmacodynamic profile for in vivo dosing. 
4. The LRA or combination of LRAs must not have significant toxicity in vitro, ex vivo, 
in animals, or in humans. 
 
With the above criteria above in mind, we choose 6 putative latency-reversing agents, 
with 4 single agents (2 HDACi, a Brd4 inhibitor (Brd4i) and a PKC agonist) and 2 combinations 
of agents (HDACi and BRD4i combination, and an HDACi and PKC agonist combination). 
Table 5 summarizes the LRAs tested, their mechanisms of action, and the concentration and 
durations of exposure. The concentrations of LRAs used and the duration of treatment were 
chosen to mimic as closely as possible known or estimated in vivo pharmacokinetic and 
pharmacodynamics properties of the agents. Combination treatments were performed in the 
presence of both compounds, with the compound requiring a shorter duration of pulse treatment 
added at the end of the incubation with the first compound. The design of these experiments is 
more rigorous compared with other ex vivo studies that have used non-physiological durations 
and concentrations. 
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Table 5. Putative latency reversal agents, proposed mechanism of latency reversal,  
and ex vivo treatment conditions 
Compound 
General class of 
compound 
Putative mechanism of 
latency reversal 
Concentration of dose 
and duration of 
treatment ex vivo 
Romidepsin 
Histone deacetylase 
inhibitor 
Relaxation of 
chromatin structure 
surrounding HIV-1 
LTR249,318 
40 nM, 4 hours330 
Panobinostat 
17.5 nM, 30 
minutes331(FARYDA
K package insert) 
JQ1 BRD4 inhibitor 
Free P-TEFb for 
interaction with Tat289 
25 μM, 30 minutes 
(JQ1 Users Guide, 
Bradner Lab) 
Bryostatin 
Protein kinase C 
agonist 
Activation of NF-kB 
and interaction with 
HIV-1 LTR291 
10 nM, 1 hour332,333 
Romidepsin + JQ1 HDACi + BRD4i 
Relaxation of 
chromatin249,318 and 
free P-TEFb289 
40 nM, 4 hours330 +  
25 μM, 30 minutes 
(JQ1 Users Guide, 
Bradner Lab) 
Bryostatin + 
Romidepsin 
PKC agonist + 
HDACi 
Activation of NF-kB291 
and relaxation of 
chromatin249,318 
10 nM, 1 hour332,333 + 
 40 nM, 4 hours330 
 
5.3.2 Patient characteristics and latency reversal agents studied 
After selecting the LRAs listed above, we next assessed the potency of each compound 
compared with medium control and full T cell activation by anti-CD3/CD28 antibody-coated 
beads. To do this, we required large numbers of resting CD4+ T cells; accordingly, we enrolled 
N=9 study participants who were willing to undergo leukapheresis to obtain sufficient PBMC for 
isolation of adequate numbers of resting CD4+ T cells for the simultaneous assessment of 
multiple LRAs and controls. Participant characteristics are shown in Table 6. Four males and 
five females were enrolled, with Caucasian and African American races represented. The mean 
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age of the study participants was 50 years old, and all study participants had high CD4+ T cell 
counts at the time of leukapheresis. All study participants were on suppressive ART (plasma 
viremia <50 copies per milliliter of plasma) for a mean of 8 years, ranging from 3 years to 17 
years with. The participants were on a variety of ART regimens (Table 6). 
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Table 6. Participant characteristics for the evaluation of putative latency reversing agents 
Participant 
ID 
Sex Race Age 
Current CD4+ 
count (cells/mm3) 
Current 
antiretroviral therapy 
Years plasma HIV-
1 RNA <50 copies 
per milliliter 
1 Male Caucasian 51 ND 3TC/ABC/RAL 17 
2 Female Caucasian 45 ND EFV/FTC/TDF 3 
3 Female African American 36 809 FTC/RPV/TDF 10 
4 Female African American 57 380 ATV/FTC/r/TDF  5 
5 Male Caucasian 51 603 EVG/c/FTC/TDF 7 
6 Male Caucasian 42 ND 3TC/RAL/ZDV 8 
7 Male Caucasian 46 714 3TC/ABC/EFV  5 
8 Female African American 57 1426 FTC/RPV/TDF 15 
9 Female African American 62 1033 DTG/FTC/TDF  10 
Mean ± SD ND ND 50 ± 8  828 ± 365 ND 9 ± 5 
 
SD = standard deviation; ND = not done; 3TC = lamivudine; ABC = abacavir; ATV = atazanavir; c = cobicistat; DTG = dolutegravir; 
EFV = efavirenz; EVG = elvitegravir; FTC = emtricitabine; r = ritonavir; RAL= raltegravir; RPV = rilpivirine; TDF = tenofovir 
disoproxil fumarate;  ZDV = zidovudine
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From the leukapheresis product, rCD4 cells were isolated by negative selection in a 
single step from Ficoll-Hypaque purified PBMC. This single-step isolation was achieved by 
using magnetic depletion beads from Stem Cell Technologies that targeted all major non-CD4+ 
T cell lymphocyte populations as well as the antigens CD25/CD69/HLA-DR (see Overall 
materials and methods for more details). This magnetic bead based separation is efficient, does 
not require columns, and routinely achieves high purity of the isolated rCD4 cells (>95% 
CD3+CD4+CD25-CD69-HLA-DR-; data not shown). Levels of total HIV-1 DNA in rCD4 cells 
were quantified by real-time qPCR using established assays, and the resulting values are shown 
in Table 7. The mean level of total HIV-1 DNA was 1,770 copies per million rCD4 cells, 
although there was substantial variation, with the range being 29 to 3,597 copies per million 
rCD4 cells. 
 
Table 7. Levels of total HIV-1 DNA in resting CD4+ T cells for the assessment of latency reversal agents 
Participant identifier 
Total HIV-1 DNA per  
106 resting CD4+ T cells 
1 3597 
2 428 
3 1545 
4 3207 
5 985 
6 29 
7 822 
8 1725 
9 3589 
Mean ± SD 1770 ± 1374 
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The isolated rCD4 cells were then cultured in the presence of medium control, anti-
CD3/CD28 antibody-coated beads, or the LRAs of interest in the presence of 300 nM efavirenz 
to prevent subsequent cycles of viral replication. rCD4 cells were pulse-treated with putative 
latency reversing agents in 25 cm2 flasks at the concentrations and durations described in Table 5 
for each LRA; cells from the medium only treatment and activation control conditions were 
immediately serially diluted and placed into wells for culture. Following pulse treatments, treated 
rCD4 cells were then counted, serially diluted, and placed in serial 3-fold limiting dilution 
cultures from 106 cells per well to 457 cells per well, with 5 replicates at each dilution. These cell 
were then cultured for 7 days, and individual supernatants were removed and spun at 500xg to 
pellet cell debris, and were then frozen individually at -80°C for downstream assessment of HIV-
1 RNA levels by Roche COBAS AmpliPrep/TaqMan. Each LRA or combination of LRAs was 
assessed in rCD4 cells isolated from at least 3 separate donors. 
 
5.3.3 Virion production following treatment of resting CD4+ T cells with latency 
reversing agents 
We first assessed virion production from the replicate wells of 106 rCD4 cells per well to 
evaluate the effect of the LRAs on overall virion production from bulk cultured rCD4 cells 
compared with medium control and anti-CD3/CD28 activation beads (Figure 5). After 7 days of 
culture, there was substantial virion production from anti-CD3/CD28 treated rCD4 cells (median 
virion production of 6,464 copies per milliliter of culture supernatant, interquartile range: 3,009 
to 51,291 copies per milliliter of culture supernatant), and minimum virion production detection 
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from medium control rCD4 cells (virion-associated HIV-1 RNA was only detected in 3 of 9 
donors in the absence of stimulation or treatment with LRAs). Pulse treatment of rCD4 cells to 
mimic in vivo dosing of LRAs resulted in modest virion production. Most LRAs achieved greater 
virion production than medium control, but generally produced small amounts of virus compared 
to T cell activation. Median levels of virion production following romidepsin, JQ1, bryostatin + 
romidepsin and romidepsin + JQ1 treatment were 61, 60, 29, and 449 and copies per milliliter of 
culture supernatant, respectively; other LRAs did not have median values above medium control 
(20 copies per milliliter of supernatant, which was used as the interpolated limited of detection). 
The average fold-changes in HIV-1 RNA above medium control for romidepsin, JQ1, bryostatin 
+ romidepsin and romidepsin + JQ1 were 3-, 3-, 1.5, and 22-fold, respectively. 
To rigorously analyze these results, we applied a linear mixed effects model, using the 
treatment condition as a fixed effect and the individual participants as a random effect. A Type II 
Wald chi-squared one-way analysis of variance (ANOVA) found that the linear mixed effects 
model was statistically significant (p=0.014). Unpaired Wilcox tests were then used to assess 
individual differences in virion production across treatment conditions, as there were uneven 
numbers of replicate treatments between conditions. Anti-CD3/CD28 was found to be 
statistically different (p<0.02) from all treatments with the exception of the romidepsin + JQ1 
treatment (p=0.063 for comparison). Romidepsin + JQ1 was also found to be statistically 
different from medium control (p=0.03), suggesting that this condition significantly reverses 
latency. However, romidepsin + JQ1 was not statistically significant higher than romidepsin 
(p=0.13) or JQ1 alone (p=0.11). 
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Figure 5. Virion production from bulk cultures of 106 resting CD4+ T cells. Median virion production from 
individual wells containing 106
 
rCD4 cells are shown for the treatment conditions listed. Median and interquartile 
ranges are shown as summary statistics. A linear mixed effects model, followed by unpaired Wilcox tests were used 
to assess differences in virion production between treatment conditions. Anti-CD3/CD28 produced significantly more 
virions than all other treatment conditions (**; p<0.02), with the exception of romidepsin + JQ1 (p=0.063) (N.S., not 
significant). Romidepsin + JQ1 produced significantly more virions than medium control (p=0.03). All other 
treatments were not statistically significantly higher than medium control. Open circles denote wells that were 
negative for virion production. Results were only available from 333,333 rCD4 cells per well for JQ1 and bryostatin 
from 1 donor, leading to higher levels of undetectable virion production after normalization to 106 cells per well.
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We next assessed whether romidepsin + JQ1 synergistically led to higher virion 
production from treated rCD4 cells compared with romidepsin and JQ1 alone. Testing for Bliss 
independence 273,296,334 leads to a value, Δf, where Δf = 0 is an additive effect of the compounds 
tested, Δf>0 is synergistic, and Δf<0 is antagonistic. By applying tests for Bliss independence, 
we found that the mean Δf was -0.003, which is very close to the Δf = 0 for additivity. As such, 
in the 3 donors studied here with physiologically relevant pulse treatments of LRAs, we did not 
find evidence of synergy with romidepsin + JQ1. 
5.3.4 Quantification of fractional provirus expression following treatment of resting 
CD4+ T cells with latency reversing agents 
When evaluating the levels of virion production following treatment of rCD4 cells with LRAs, 
we found very modest but quantifiable levels of virion production with the LRAs studied. The 
levels of virions produced were generally more than were produced with medium only treatment, 
but were minimal in magnitude compared with latency reversal following maximum T cell 
activation with anti-CD3/CD28 beads. To better understand the potency of these LRAs at the 
level of individual proviruses, we utilized the fractional provirus expression assay described in 
detail in the previous chapter. The fPVE assay format involved limiting dilutions of rCD4 cells 
from 106 rCD4 cells per well to 457 rCD4 cells per well in serial 3-fold dilutions. The results of 
virion production from 106 cells per well (the highest concentration of cells tested with fPVE) 
were presented in the previous section. The results of the maximum likelihood analysis for fPVE 
with the LRAs tested, as well as medium control and anti-CD3/CD28 are now shown in Table 8 
and Figure 6. 
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 The median fPVE for virion production from medium only treated rCD4 cells was 
0.033% of proviruses were reactivated to produce virions, whereas for anti-CD3/CD28 treated 
cells, a median of 3.8% of proviruses were activated to produce virions. All the LRAs tested 
reactivated very few proviruses compared with anti-CD3/CD28 treated rCD4 cells, suggesting 
that their activity is very limited at the level of de novo activation of individual proviruses.
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Table 8. Percentage of proviruses that are reactivated to produce virions with a given treatment 
Participant 
ID 
Fractional provirus expression (% of proviruses reactivated per treatment) 
Medium 
Control 
Anti-
CD3/CD28 
Romidepsin Panobinostat JQ1 
Romidepsin 
+ JQ1 
Bryostatin 
Bryostatin + 
Romidepsin 
1 0.015 1.9 0.01 0.019 0.0043 ND ND ND 
2 <0.074 9.4 0.36 0.045 0.08 0.64 ND ND 
3 0.033 3.6 0.09 <0.026 <0.043 0.12 ND ND 
4 0.043 8.2 0.062 ND 0.012 0.088 ND ND 
5 <0.024 3.4 0.043 ND ND ND 0.090 0.15 
6 <1.4 4.1 <0.77 ND ND ND <0.83 <0.77 
7 <0.068 3.8 0.083 ND ND ND <0.023 0.022 
8 <0.023 3.5 0.019 ND ND ND <0.017 0.0094 
9 <0.008 4.5 0.039 ND ND ND 0.0073 0.083 
Median 0.033 3.8 0.062 0.019 0.017 0.12 0.012 0.083 
 
ND = not done
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The ratio between medium control and anti-CD3/CD28 is 118-fold, demonstrating that 
full T cell activation leads to profound reversal of latency at the level of individual proviruses. It 
is clear from Table 8 that LRAs do not achieve anywhere near the degree of latency reversal 
compared with anti-CD3/CD28. Consistent with levels of virion production, romidepsin + JQ1 
treatment reactivated the greatest proportion of proviruses with rCD4 cells. Figure 6 shows a 
graphical summary of the fraction of proviruses reactivated with given LRAs. 
To formally assess differences in fPVE for virion production between groups, we 
generated a linear mixed effects model, once again with treatment as a fixed effect and individual 
participants as a random effect. This model was found to be highly statistically significant by 
Wald’s test (p<0.001), and unpaired Wilcoxon tests revealed that anti-CD3/CD28 was 
statistically significant different from all treatment conditions. When analyzing latency reversal 
by fPVE, romidepsin + JQ1 was not statistically different from medium control (p=0.064). This 
analysis shows that the only treatment to significantly reactivate more proviruses compared with 
medium control was anti-CD3/CD28. 
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Figure 6. Assessment of fractional provirus expression for medium control, anti-CD3/CD28 and 6 putative 
LRAs. The fraction of proviruses reactivated in each treatment condition was assessed using a linear mixed effects 
model, with treatment condition as a fixed effect and individual participants as a random effect, and was found to be 
statistically significant (p<0.001). Subsequent unpaired Wilcoxon tests revealed that only anti-CD3/CD28 led to 
significantly more virion production compared to all treatment conditions (*). Median and interquartile range is shown 
for each treatment as summary statistics. Open circles denote samples that were below the limit of detection of fPVE. 
The limit of detection is based on the number of proviruses detectable by qPCR from each donor. 
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To assess the relative potency of the LRAs tested, we next used the fPVE value for anti-
CD3/CD28 from each individual donor to normalize the magnitude of latency reversal by fPVE 
(Table 9).  
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Table 9. Fractional provirus expression normalized for the percent of maximal reactivated proviruses achieved with anti-CD3/CD28 treatment 
Participant 
ID 
Percent of proviruses reactivated, normalized for maximum reactivation 
([fPVE LRA/fPVE anti-CD3/CD28]*100%) 
Medium 
Control 
Anti-
CD3/CD28 
Romidepsin Panobinostat JQ1 
Romidepsin 
+ JQ1 
Bryostatin 
Bryostatin + 
Romidepsin 
1 0.79 100 0.53 1.0 0.23 ND ND ND 
2 <0.39 100 3.8 0.48 0.85 6.8 ND ND 
3 0.92 100 2.5 <0.36 <0.60 3.3 ND ND 
4 0.52 100 0.76 ND 0.15 1.1 ND ND 
5 <0.71 100 1.8 ND ND ND 2.7 4.4 
6 <34 100 <19 ND ND ND <20 <19 
7 <1.8 100 2.18 ND ND ND <0.61 0.58 
8 <0.66 100 0.54 ND ND ND <0.49 0.27 
9 <0.18 100 0.87 ND ND ND 0.16 1.84 
Median 0.52 100 1.8 0.48 0.26 3.3 0.31 1.8 
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The results from this analysis are in agreement with the data presented above, but Table 9 
contextualizes the relative potency compared with the maximal size of the latent reservoir that is 
reactivated in one round of maximum T cell activation. When analyzed as a percentage of 
maximally inducible proviruses within an individual study participant, we find that romidepsin 
alone, romidepsin + JQ-1, and bryostatin + romidepsin were the most potent LRAs, but only 
activated 1.82%, 3.3%, 1.84%, respectively, of the proviruses that were reactivated with anti-
CD3/CD28.  
5.3.5 Relationships between fractional provirus expression, virion production from bulk 
culture 
To assess relationships between fPVE for virion production and the mean levels of virus 
produced from bulk-cultured rCD4 cells, we first evaluated whether the fraction of proviruses 
reactivated to produce virions was correlated by Spearman’s correlation to the levels of virus 
produced into the culture supernatant from replicate wells of 106 rCD4 cells (Figure 7). This 
result revealed that there was no relationship (rho=0.02, p=0.98) between the levels of virus 
produced in the culture supernatant and fraction of proviruses that had been reactivated.  
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Figure 7. Relationship between mean virion production from 106 resting CD4+ T cells and the proportion of 
proviruses that were reactivated. Mean levels of HIV-1 RNA production in the culture supernatant were compared 
to the fraction of proviruses reactivated. The percent of proviruses that were maximally inducible following treatment 
with anti-CD3/CD28 was unrelated to mean virion production, likely due to the different number of proviruses 
present per 106
 
rCD4 cells, and the variation in the number of proviruses reactivated. 
 
 
 
Several factors likely contribute to the lack of an observed relationship between between fPVE 
for virion production and mean virion production. First, as shown in Table 7, there are different 
numbers of proviruses per million rCD4 cells. This, combined with variations in the number of 
proviruses reactivated, likely leads to substantial variation. To correct for these differences, we 
instead evaluated whether the number of proviruses that were reactivated per million cells (that 
is, the fraction of proviruses that were reactivated times the number of proviruses per million 
rCD4 cells) was related to the levels of virion production in bulk culture (Figure 8). Although the 
relationship is still not statistically significant, a trend is readily apparent compared to Figure 7. 
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Figure 8. Relationship between the number of proviruses reactivated and mean virion production from resting 
CD4+ T cells. To determine the number of proviruses reactivated per 106
 
rCD4 cells, the total number of proviruses 
per 106
 
rCD4 cells was multiplied by the fraction of proviruses that were reactivated to produce virions from a given 
donor. This analysis revealed an improved trend, though still not statistically significant relationship, between virion 
production from bulk culture and the number of proviruses that were reactivated. 
 
 
 
The relatively weak relationship between the amount of virions produced from bulk culture and 
the number of proviruses reactivated is likely explained by the fact that individual reactivated 
proviruses do not produce identical amounts of virions. We have previously described large 
differences in the number of virions produced from individual reactivated cells335. Over a large 
number of wells, the number of proviruses reactivated and the number of virions produced would 
positively correlate, but the variation in the amount of virions produced per provirus complicates 
this  correlative assessment.  This  also  highlights  the importance of using fPVE, rather than 
simply assessing levels of virus production from bulk cultured cells to infer the potency of 
LRAs. 
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5.3.6 Expression of cell surface activation markers on resting CD4+ T cells treated with 
LRAs 
An important consideration in the assessment of LRAs is whether they lead to changes in 
expression of cellular activation markers (i.e., CD25, CD69 and HLA-DR) on treated rCD4 cells. 
Increased expression of activation markers, and associated T cell activation, is likely to be 
associated with cytokine release and the potential for toxicity in vivo. Therefore, LRAs that lead 
to marked increases in expression of activation markers should probably be pursued with 
caution. 
To assess the levels of activation marker expression following treatment with medium 
control, romidepsin, bryostatin and bryostatin + romidepsin, we performed flow cytometric 
analysis of cells was performed with fluorchrome-conjugated antibodies to CD3, CD4, CD25, 
CD69 and HLA-DR on rCD4 cells on after 5 days of culture (see Overall materials and methods 
for more information). We found that most treatment conditions did not increase the expression 
of activation markers, and therefore allowed rCD4 cells to maintain a resting quiescent 
phenotype (Figure 9). However, levels of CD69 expression were substantially increased in 
participants 5 and 9 following treatment with bryostatin and bryostatin + romidepsin, and 
somewhat up-regulated in participant 8 following treatment with bryostatin + romidepsin. 
Increased expression of CD69 seems to be driven by bryostatin, as cells that were treated with 
only romidepsin did not exhibit this increase in CD69 expression, but those treated with the 
combination therapy did. 
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Figure 9. Changes in percent CD4+ T cells expressing activation markers following treatment with LRAs. In 4 donors, levels of activation marker expression 
following treatment with medium control, romidepsin, bryostatin and romidepsin + bryostatin were assessed. Significant elevation of CD69 expression was 
observed in participant 5 and 9 following romidepsin and romidepsin + bryostatin treatment, and in participant 8 following bryostatin + romidepsin treatment. 
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After  observing  the  increased  CD69  expression  on  the  cell  surface,  we  next  asked 
whether the level of CD69 expression was associated with the magnitude of latency reversal 
observed by fPVE for virion production in these donors. The fraction of proviruses that were 
reactivated with bryostatin + romidepsin treatment (following normalization for the maximal 
inducible fraction of proviruses from that donor) was strongly positively associated with the 
levels of CD69 (R=0.86, p=0.14), although this correlation was not statistically significant due to 
the small number of participants in which bryostatin + romidepsin was studied (Figure 10). 
 
 
 
 
 
 
 
5 
R = 0.86 
4 p = 0.14 
 
3 
 
2 
 
1 
 
0 
0 20 40 60 80 100 
CD69 Expression 
(%CD69+CD4+ T cells) 
 
 
Figure 10. Relationship between CD69 expression and bryostatin + romidepsin fPVE. Levels of CD69 
expression on CD4+ T cells on day 5 following pulse treatment with bryostatin + romidepsin was strongly associated 
(though not statistically significant given the small sample size) with the fPVE for virion production from bryostatin + 
romidepsin treated rCD4 cells obtained after 7 days of culture. This suggests that the potency of bryostatin + 
romidepsin is related to cellular activation. 
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This relationship suggests that the expression of CD69 may be associated with the 
pharmacokinetic response of rCD4 cells to bryostatin, and indeed activation of NF-κB 
expression via the PKC pathway leads to increased CD69 expression336. Additionally, this result 
also suggests that the potency of bryostatin + romidepsin is likely related to partial activation of 
CD4+ T cells following treatment. 
5.4 DISCUSSION 
In this study, we sought to evaluate the potency of diverse LRAs to activate latent proviruses to 
produce virions. We elected to focus on virion production as our endpoint, rather than cellular 
HIV-1 RNA transcription, because virion production indicates full latency reversal, i.e., 
transcription of cellular HIV-1 RNA, translation of viral proteins, and release of virions. 
Focusing on cellular transcription of HIV-1 RNA does not indicate whether viral proteins have 
been produced. 
When evaluating latency reversal purely by measuring levels of virion production in 
culture, we found that fold change in virion production from LRA treated to medium control 
ranged from 1.5- to 22-fold, but that only romidepsin + JQ1 was statistically significantly higher 
than medium control in the small numbers of donors studied (N=9). The combination of 
romidepsin + JQ1 for virion production was found to be additive in this study, despite the 
independent mechanisms of action of romidepsin and JQ1. Other studies have generally found 
LRAs to be ineffective in the absence of a PKC agonist295, with the notable exception being 
romidepsin296,330. Recent studies have also identified combinations of the PKC agonists 
111 
 
bryostatin or ingenol and JQ1 to be synergistic for the reactivation of latency273,296,297. While we 
did observe latency reversal with bryostatin + romidepsin in this study, the magnitude of latency 
reversal was not as high as has been reported elsewhere. Difference in the patient cohorts 
studied, including the duration of viral suppression, and differences in treatment duration and 
timing of assessment of latency reversal by virion production or cellular HIV-1 RNA 
transcription may have all contributed to the differences observed. Importantly, the pulse 
treatment conditions chosen for ex vivo use to closely reflect durations and concentrations that 
could be achieved in vivo likely contributed to differences between other studies and ours. Others 
have used overnight, 6 hour, or 48 hour treatments273,296 or 6 days of continuous treatment297, 
none of which represent concentrations or durations of drug exposure that are pharmacologically 
relevant. 
After evaluating levels of virion production from replicate wells of 106 rCD4 cells, we 
next assessed the proportion of proviruses that could be reactivated following treatment with 
LRAs or full T cell activation with anti-CD3/CD28 activation beads. Similarly to our initial 
findings, we found that a small fraction of proviruses (3.8% of all proviruses detectable by 
qPCR) were inducible to produce virions following maximum reversal of latency with full T cell 
activation, which agrees with previous findings, where 1.5% of all proviruses detectable by 
qPCR were capable of producing virions300. The fraction of proviruses that produced virions 
from unstimulated rCD4 cells is similar as well in both studies, with 0.044% of proviruses 
spontaneously producing virions in Cillo et al., and 0.035% of proviruses being responsible for 
spontaneous virion production in the current study. 
The best LRAs in this study achieved a modest 5-6 fold increase in the fraction of 
proviruses that have are activated to produce virions compared with medium control. 
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Correspondingly, the best LRAs only achieved reactivation of ~2-3% of the maximum fraction 
of proviruses that can be induced to produce virions. Our finding that only a small fraction of 
inducible proviruses in rCD4 cells can be reactivated with current LRAs in a limiting dilution 
culture format is in contrast with the reported potency of the same LRAs using bulk culture of 
rCD4 cells273,296,297. 
When comparing our results from fPVE for virion production to levels of virions 
produced in bulk culture, we found that there was only a trend towards a positive correlative 
relationship when the number of proviruses reactivated was compared to the level of virion 
production. This finding is in agreement with our previously published results, where levels of 
virions produced from individual reactivated cells was highly variable335. The presence of 
individual proviruses that can produce larger amounts of virions compared to other proviruses, 
and the large degree of variation observed in the levels of virions produced from individual 
proviruses highlights the importance of assessing the potency of LRAs on the level of individual 
proviruses. 
Finally, we also identified substantial levels of CD69 expression following treatment with 
bryostatin and romidepsin + bryostatin. These elevated levels have been observed in other 
studies273,296,297, but have not been found to be associated with substantial levels of cytokine 
release from rCD4 cells273,296. The magnitude of CD69 expression in these studies is concerning, 
with levels of CD69 and HLA-DR expression reaching similar levels to that observed with 
PMA/ionomycin treatment in two studies following treatment with PKC agonists273,296; levels of 
CD69 and HLA-DR expression reached 40% and 20%, respectively in another study with 
bryostatin297. Both these studies also noted the downregulation of CD4 on the surface of T cells 
treated with PKC agonists, which is a hallmark of T cell activation337. Of note, the authors of two 
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studies conclude that this is beneficial, as it will prevent infection of CD4+ T cells with HIV-1. 
This conclusion can be questioned because PKC agonists are likely found to be efficient 
reactivators of latent virus because they activate T cells. Our results, demonstrating a trend 
towards a greater proportion of proviruses reactivated with bryostatin + romidepsin and higher 
expression of CD69, is consistent with T cell activation, and implies that partial T cell activation 
may underlie the mechanism of latency reversal in this context. Great care should be taken to 
evaluate the potential toxicity associated with PKC agonists, as trends towards general activation 
of T cells ex vivo may be problematic in vivo, and could lead to cytokine storms and substantial 
toxicity. 
To achieve substantial reductions in the size of the reservoir via a “kick and kill” strategy, 
it is clear that more potent latency reversing agents will be required. Reactivation of ~3% of total 
inducible proviruses will not lead to a functional cure of HIV-1. The potency of the LRAs 
currently being evaluated are not promising, and the trend towards use of PKC agonists that may 
causes T cell activation is not a clear path forward. Despite these findings, an important 
unanswered question is whether these LRAs have achieved a net decrease in the size of the 
inducible reservoir ex vivo. Although we have elected to use the production of virions as an 
endpoint for latency reversal, it is possible that viral cytopathic effects may occur prior to virion 
release. As such, evaluating the proportion of proviruses that remain inducible following 
treatment with LRAs is of interest, and is explored in the next chapter. 
 
114 
 
6.0  CHAPTER 3. QUANTIFICATION OF THE SIZE OF THE MAXIMALLY 
INDUCIBLE RESERVOIR FOLLOWING TREATMENT OF RESTING CD4+ T CELLS 
WITH LATENCY REVERSAL AGENTS EX VIVO 
6.1 PREFACE 
Anthony R. Cillo1, Michele Sobolewski1, Taylor Simmons1, Elizabeth Fyne1, Joshua Cyktor1, 
John W. Mellors1 
1University of Pittsburgh, Division of Infectious Diseases 
 
The work presented in this chapter is in partial fulfillment of Aim 1 of this dissertation, and 
explicitly is related to assessing whether LRAs can reduce the size of the inducible reservoir. 
Anthony Cillo, Michele Sobolewski, Taylor Simmons, Elizabeth Fyne and Joshua Cyktor 
performed the isolation of resting CD4+ T cells from leukapheresis products, treated isolated 
resting CD4+ T cells with LRAs, and set up many limiting dilution culture experiments in 
parallel. These same contributors also harvested individual wells of culture supernatants for 
downstream qRT-PCR. Anthony Cillo, Michele Sobolewski, Elizabeth Fyne and Taylor 
Simmons performed COBAS AmpliPrep/TaqMan v2.0 for quantification of HIV-1 RNA from 
culture supernatants. Anthony Cillo performed qPCR for cellular HIV-1 DNA. Joshua Cyktor 
performed flow cytometry experiments for assessment of activation markers, and analyzed flow 
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cytometry data. Anthony Cillo and John Mellors conceived of the project, and Anthony Cillo 
analyzed the data and performed statistical analysis. 
The Pitt AIDS Research Training Program 5 T32 AI065380-08, a research grant from 
Gilead Sciences funded the work described in this chapter. Roche provided COBAS 
AmpliPrep/TaqMan kits. 
6.2 INTRODUCTION 
In the previous two chapters, we have discussed the development and implementation of an 
assay capable of quantifying the magnitude of latency reversal at the level of individual 
proviruses. The results from these experiments have generally demonstrated that the fraction of 
proviruses that have been reactivated to produce virions following treatment with LRAs is 
several orders of magnitude smaller than the fraction of proviruses that can be reactivated to 
produce virions following full T cell activation with anti-CD3/CD28 beads. However, having 
chosen to use virion production as our endpoint, we have not evaluated whether LRA treatment 
leads to significant changes in expression of cellular HIV-1 RNA. Increases in cellular HIV-1 
RNA expression may be directly related to viral protein translation, which could cause death of 
cells harboring reactivated proviruses from viral cytopathic effects prior to virion release. 
In this chapter, we seek to extend the findings of previous chapters to evaluate whether 
viral cytopathic effects from LRA treatment alone can reduce the fraction of proviruses that are 
maximally inducible. We established a system where we first treat isolated resting CD4+ T cells 
with LRAs, and then maximally reactivate the T cells in a serial dilution culture format to 
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evaluate the fraction of proviruses that can be reactivated to produce virions. By comparing the 
fraction of proviruses that can produce virions between medium only treated cells and LRA 
treatment, we can assess whether a significant depletion of the inducible reservoir has occurred. 
Ex vivo studies to date have primarily assessed the magnitude of latency reversal and not whether 
a depletion of the  inducible reservoir has occurred273,295-297,316, with one notable exception being 
that SAHA treatment of PBMC ex vivo did not decrease the size of the infectious reservoir as 
measured by quantitative viral outgrowth (QVOA) in resting CD4+ T cells338. The study by Shan 
et al.339 also suggested that infected cells were not killed by viral cytopathic effects alone 
following latency reversal, and that primed cytotoxic T lymphocytes were required to deplete the 
reservoir, although the authors utilized an in vitro model to demonstrate this. Recent in vivo 
studies of panobinostat and SAHA have also not found reductions in the size of the reservoir 
following LRA treatment253,257,323. 
The assay format that we have devised is advantageous, as it allows for the overall 
assessment of changes in the inducible reservoir from viral cytopathic effects. It is possible that 
increased transcription of cellular HIV-1 RNA leads to increased levels of viral translation, 
potentially leading to viral cytopathic effects that would be missed by only assessing levels of 
virion production. As such, the methods established in this chapter are capable of assessing 
whether the size of the inducible reservoir is indeed reduced by LRA treatment. 
117 
 
6.3 RESULTS 
6.3.1 Quantification of the size the inducible reservoir following treatment with latency 
reversing agents 
To assess whether LRAs can reduce the size of the latent reservoir ex vivo, we first pulse treated 
purified rCD4 cells from the donors described in the previous chapter with LRAs, removed the 
LRA from the medium, and then cultured the cells for 5 days. After 5 days, rCD4 were serially 
diluted from 106 rCD4 cells per well to 457 cells per well and were maximally reactivated with 
anti-CD3/CD28 (donors 1 through 3) or PMA/ionomycin (donors 5 though 9) for 7 days to 
calculate fractional proviral expression (an aliquot of cells was also saved for quantification of 
proviral copy number). The two different activation stimuli (anti-CD3/CD28 beads and 
PMA/ionomycin) were found to lead to equivalent levels of virion production from rCD4 cells 
treated in parallel in control experiments (data not shown). After 7 days of culture, supernatants 
were individually harvested and spun at 500xg for 5 minutes, and were then stored at -80°C for 
downstream assessment of virion-associated HIV-1 RNA by Roche COBAS 
AmpliPrep/TaqMan. Individual wells were scored as positive or negative for virion production, 
and fPVE for virion production was calculated by maximum likelihood estimate as described in 
the previous chapters.  
We quantified changes in the size of the maximally inducible latent reservoir from these 
eight study participants by comparing fPVE for virion production after maximal T cell activation 
of LRA treated rCD4 cells to fPVE for virion production from medium only treated rCD4 cells. 
Total HIV-1 DNA levels were quantified by qPCR from cells that were frozen immediately prior 
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to maximum reactivation (on day 5) (Table 10). Levels of total HIV-1 DNA were not 
substantially altered by treatment with LRAs, with the exception of rCD4 cells from participant 6 
where a dramatic increase from 62 copies of total HIV-1 DNA per million rCD4 cells to 2,078 
copies of total HIV-1 DNA per million rCD4 cells occurred following treatment with romidepsin 
+ bryostatin. It is unclear why this increase in total HIV-1 DNA occurred, but it may be that an 
HIV-infected rCD4 cell clonally expanded following treatment with romidepsin + bryostatin. As 
described in the introduction of this dissertation, clonal expansion can occur in vivo149,150. 
Overall, the finding of no reduction in HIV-1 DNA is consistent with few proviruses being 
reactivated following treatment with LRAs, as described in the previous chapter. 
 
Table 10. Levels of total HIV-1 DNA per 106 rCD4 cells on day 5 following LRA treatment 
Participant ID 
Total HIV-1 DNA per 106 rCD4 cells on day 5 following treatment 
Medium Control Romidepsin Bryostatin 
Romidepsin + 
Bryostatin 
1 2900 967 ND ND 
2 356 415 ND ND 
3 1452 1851 ND ND 
5 825 1086 1188 1133 
6 62 123 37 2078 
7 1426 1470 1150 974 
8 2546 2326 1813 1642 
9 1650 1920 2422 1381 
 ND = not done 
To begin assessing whether LRAs can decrease the size of the inducible reservoir, we 
first assessed levels of virion production from replicate wells of 106 treated rCD4 cells (Figure 
11). Changes in the size of the maximally inducible reservoir were next quantified following 
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treatment with romidepsin (N=8), bryostatin (N=5) and bryostatin + romidepsin (N=5). There 
was a trend towards a reduction in the median amount of virion production following treatment 
with each LRA, with median virion production of 6,973, 1,548, 595 and 950 copies of HIV-1 
RNA per milliliter of culture supernatant for medium control, romidepsin, bryostatin and 
bryostatin + romidepsin treatments, respectively. Correspondingly, the fold reductions in median 
virion production between LRA treatment and medium only treatment were 4.5 fold for 
romidepsin, 11 fold for bryostatin and 7.1 fold for bryostatin + romidepsin. Despite these 
apparent substantial reductions in the levels of virions produced, a linear mixed effects model 
with treatment as fixed effects and individual participants as random effects was not statistically 
significant (p=0.15), suggesting that no treatment led to significantly fewer virions produced 
following maximal activation after treatment with LRAs. The lack of statistical significance 
observed is likely due to the overlapping interquartile ranges for each of the treatments. 
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Figure 11. Levels of maximal inducible virion production from rCD4 cells following treatment with LRAs. 
Levels of virion production were evaluated from replicate wells of 106
 
rCD4 cells activated with full T cell 
activation.  Trends towards reduced levels of virion production were observed following treatment with LRAs, but a 
linear mixed effects model with treatment as a fixed effect and individual participants as a random effect was not 
statistically significant (p=0.15). Median and interquartile range are shown as summary statistics, and the open 
circle denotes a sample with undetectable HIV-1 RNA. 
 
 
Next, the size of the inducible reservoir following treatment with LRAs was evaluated by 
assessing fPVE for virion production (Table 11 and Figure 12). Median fPVE from medium 
control was 1.0%, ranging from 0.12% to 3.4%, while the median maximum fPVE following 
treatment with LRAs was 0.43%, 0.71% and 0.20% of proviruses inducible for romidepsin, 
bryostatin, and romidepsin + bryostatin, respectively. However, as is clear from Figure 12, there 
was substantial inter-patient variability in changes in reservoir size following treatment with 
LRAs. 
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Table 11. Assessment of changes in the size of the inducible reservoir following treatment with LRAs 
Participant ID 
Maximal fraction provirus expression following treatment with LRAs 
(% of proviruses reactivated to produce virions with maximal activation) 
Medium Control Romidepsin Bryostatin 
Bryostatin + 
Romidepsin 
1 0.43 0.31 ND ND 
2 3.4 1.9 ND ND 
3 0.17 0.26 ND ND 
5 2.4 0.54 1.0 0.19 
6 1.4 1.6 0.70 0.12 
7 1.4 0.43 0.71 1.2 
8 0.12 0.31 0.30 0.4 
9 0.68 0.42 1.1 0.2 
Median 1.0 0.43 0.71 0.20 
 
For example, romidepsin caused a reduction in the size of the maximally inducible 
reservoir in five of eight participants, while the proportion of proviruses reactivated following 
romidepsin treatment in the other three participants increased. Similarly for bryostatin and 
romidepsin + bryostatin, changes in the proportion of proviruses that were reactivated differed 
between participants; the fraction of inducible proviruses decreased in three of five subjects for 
bryostatin and four of five subjects for bryostatin + romidepsin treatment. 
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Figure 12. Levels of maximum fPVE following treatment of rCD4 cells with LRAs. rCD4 cells were first treated 
with LRAs, and were then maximally reactivated with full T cell activation to assess whether LRAs have caused a 
reduction in the size of the inducible reservoir. While the median is reduced for all LRAs tested compared with 
medium control, there are substantial inter-participant differences. A linear mixed effects model with treatment as a 
fixed effect and individual participants as a random effect was not statistically significant (p=0.081), implying that 
fPVE for virion production was not different between treatment groups. Median and interquartile ranges are shown 
as summary statistics. 
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Part of the inter-patient variability observed can be reduced by normalizing the fPVE for virion 
production following treatment with LRAs by dividing by the fPVE for virion production from 
the medium only treatment by the fPVE for LRA treatment. Table 12 and Figure 13 show the 
fold reductions in the fraction of proviruses that are maximally inducible following treatment 
with LRAs. 
 
Table 12. Fold-change in the size of the inducible reservoir following treatment with  
LRAs versus medium control 
Participant ID 
Fold-reduction (Medium Control/LRA) in maximal fPVE 
following LRA treatment 
Romidepsin/Medium 
Control 
Bryostatin/Medium 
Control 
Bryostatin + 
Romidepsin/Medium Control 
1 1.4 ND ND 
2 1.8 ND ND 
3 0.67 ND ND 
5 4.3 2.4 13 
6 0.91 2.0 11 
7 3.2 2.0 1.2 
8 0.39 0.40 0.27 
9 1.6 0.62 3.5 
Median 1.5 2.0 3.5 
 
The median fold reductions in fPVE following treatment with romidepsin, bryostatin, and 
bryostatin + romidepsin were 1.5, 2.0, and 3.5, respectively, compared with medium control. The 
most profound reductions in the size of the inducible reservoir occurred with bryostatin + 
romidepsin treatment, where the fold reductions were as low as 13 and 11 for two donors when 
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comparing medium only treatment to bryostatin + romidepsin. However, there was also a 
substantial increase in the size of the latent reservoir in one subject with bryostatin + romidepsin, 
where the fold reduction was 0.27 for medium to bryostatin + romidepsin fPVE  treatment. For 
romidepsin treatment alone, changes ranged from a 3.2 fold reduction to a 0.39 fold reduction, 
and results were similar for bryostatin to medium only treatment comparisons, ranging from 2.4 
to 0.4 fold reductions. These dichotomous responses are clear in Figure 13, where some donors 
have substantial reductions in the proportion of proviruses that can be maximally reactivated 
following treatment with LRAs, demonstrating a heterogeneous response to LRAs across donors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Fold reduction in the size of the inducible reservoir following treatment with LRAs. Changes in the 
size of the inducible reservoir were assessed by measuring the fold reduction between fPVE for virion production 
from medium control treated and LRA treated rCD4 cells. Reductions in the size of the inducible reservoir were 
inconsistent between donors, with some donors have some substantial fold reductions and other having increases  
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in the size of the inducible reservoir.  Some substantial  reductions  in  individual  participants  for  romidepsin  + 
bryostatin were observed. 
 
 
6.3.2 Analysis of viability and activation marker expression on Day 13 for the assessment 
of responsiveness to maximal stimulation 
 
 
One major assumption of the assays we have performed to  assess whether the size of the 
inducible reservoir has changed following treatment with LRAs is that rCD4 cells treated with 
LRAs can be reactivated to the same magnitude as medium control treated rCD4 cells. If the 
LRA treated rCD4 cells are refractory to stimulation, the results of these assays will be difficult 
to interpret, as a decrease in the responsiveness to reactivation would be impossible to separate 
from a decrease in the size of the inducible reservoir. To assess the responsiveness of rCD4 cells 
to reactivation following treatment with LRAs, we evaluated the viability of the reactivated cells 
and the surface immunophenotype on day 13, which is 7 days after stimulation with anti- 
CD3/CD28 activation beads or PMA/ionomycin. 
The assessment of viability was performed on donors 7, 8 and 9 using CellTiter-Fluor 
(see Overall materials and methods for details). Importantly, the same number of cells was 
assayed for fluorescence viability from each treatment condition. It is clear from these analyses 
that the viability of the reactivated cells that were treated with romidepsin and bryostatin + 
romidepsin was lower compared to the levels of viability from rCD4 cells that served as the 
medium control (Table 13). 
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Table 13. Viability of reactivated cells following treatment with LRAs 
Participant 
Identifier 
Relative cellular viability following maximal reactivation 
(fluorescence units LRA/fluorescence units Medium control) 
Romidepsin/Medium 
control 
Bryostatin/Medium 
control 
Bryostatin+Romidepsin/Medium 
control 
7 0.45 1.0 0.80 
8 0.92 1.1 0.85 
9 0.53 0.98 0.49 
Mean 0.63 1.0 0.71 
 
Romidepsin substantially reduced the viability of cells following 7 days of treatment with 
full T cell activation in donors 7 and 9, though not substantially in donor 8. Bryostatin treatment 
did not affect viability, and bryostatin + romidepsin treatment somewhat reduced viability in 
donors 7 and 8, and substantially reduced viability in donor 9. Notably, donors 7 and 9 had 
substantial reductions in the size of the inducible reservoir following romidepsin treatment, and 
this was associated with lower viability of rCD4 cells following maximum reactivation. It is 
therefore unclear whether these were true reductions in the size of the inducible reservoir, or if 
virion production was prevented because the cells were less responsive to activation stimuli. For 
example, the substantial reduction in the size of the latent reservoir following treatment with 
bryostatin + romidepsin in donor 9 is likely related to reduced cell viability from bryostatin + 
romidepsin.  
To further assess the responsiveness of LRA treated cells to full T cell activation, 
activation marker expression was assessed in 5 of the 8 donors in whom we evaluated whether 
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LRAs caused a reduction in the size of the inducible reservoir (Figure 14). It is clear that 
activation marker expression following treatment with LRAs is heterogeneous, and differs 
between study subjects. For example, in donors 5 and 6, CD25 expression levels following full T 
cell activation are the same regardless of LRA treatment, while the levels of CD69 differ based 
on LRA treatment. However, in donor 6, levels of both CD69 and CD25 are affected by 
treatment with LRAs. In donors 5, 7, and 9 there were substantial decreases in the size of the 
inducible reservoir following treatment with romidepsin, but CD69 expression following 
treatment with RMD in these donors was also substantially lower, suggesting that the 
responsiveness of the cells may have been affected by treatment with LRAs. Similarly for 
bryostatin, a reduction in the size of the reservoir was observed for donors 5, 6 and 7, and levels 
of CD69 expression was lower under these conditions as well. Finally, reductions in the size of 
the latent reservoir were observed with romidepsin + bryostatin treatment in donors 5, 6, 8 and 9, 
with levels of CD69 effected in all donors with the exception of donor 9. 
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Figure 14. Activation marker expression on maximally reactivated cells following treatment with LRAs. Levels of activation markers on T cells treated 
with PMA/ionomycin following treatment of rCD4 with LRAs. Inconsistent levels of expression of CD25, CD69, HLA-DR and PD-1 were observed following 
treatment with LRAs from some donors, complicating analysis of changes in the size of the inducible reservoir following treatment with LRAs. 
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6.3.3 Relationships between the fraction of proviruses initially reactivated and the 
reduction in the size of the inducible reservoir 
 
 
We also sought to evaluate whether there were relationships between the fraction of proviruses 
that were initially reactivated, and the change in the size of the maximally inducible reservoir 
following treatment with a given LRA. Due to the small sample sizes and the inability to 
quantify fPVE due to sensitivity of the assay in some donors (and the relatively small number of 
proviruses reactivated), relationships between virion production in romidepsin treated rCD4 cells 
and romidepsin + bryostatin treated rCD4 cells were the only LRAs investigated in this manner 
(Figure 15). 
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Figure 15. Relationships between fPVE and the change in the size of the maximally inducible reservoir. A) The 
fraction  of  proviruses  that  were  initially  reactivated  to  produce  virions  following treatment with romidepsin was 
not significantly associated with the change in the size of the maximally inducible reservoir following LRA treatment. 
B) The fraction of proviruses that were reactivated  to  produce  virions  initially  was  strongly  negatively  related  to  
the  fraction  of proviruses  that  were  reactivated  to  produce  virions  (rho=0.9,  p=0.083).  Although this 
relationship did not reach statistical significance, there is a clear trend towards fewer proviruses
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being maximally reactivated following a larger percentage of proviruses initially reactivated following treatment with 
LRAs. 
 
In the rCD4 cells that were treated with romidepsin, we found no relationships between 
the fraction of proviruses that were initially reactivated and the fold reduction in the percentage 
of maximally inducible proviruses following. However, following treatment with romidepsin + 
bryostatin, we found a trend towards a strong positive relationship (i.e., the higher the percent of 
proviruses initially reactivated following treatment with romidepsin + bryostatin, the larger the 
reduction in the fraction of inducible proviruses that remained). The observed relationship 
between romidepsin + bryostatin treated fPVE and the maximal fraction of remaining inducible 
proviruses suggests that there is a proportionality between the fraction of proviruses that were 
reactivated following treatment with bryostatin + romidepsin, and the fraction of proviruses that 
undergo viral cytopathic effects following latency reversal. For the cells that were treated with 
romidepsin alone, the analysis is likely complicated by the fact that viability (and activation 
marker expression) is substantially reduced following maximal reactivation after romidepsin 
treatment, and the number of proviruses that are maximally inducible following treatment with 
romidepsin is artificially reduced due to reduced cellular responsiveness to activation stimuli, 
and not mechanistically linked to the fraction of proviruses that were initially reactivated. 
 
 
 
 
 
6.4 DISCUSSION 
 
 
Studies to date have focused on assessing whether LRAs are capable of reactivating the latent 
reservoir273,289,295-297,300,316,330, but have not evaluated whether the size of the inducible reservoir 
has been reduced following treatment with LRAs. In this study, we have developed a method to 
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assess whether the size of the inducible reservoir has been depleted following treatment with 
LRAs. Our method utilizes the previously described fPVE for virion production, and requires 
treatment of rCD4 cells with medium control or LRAs, followed by subsequent maximal 
reactivation of rCD4 cells to assess the proportion of proviruses remaining that can be induced to 
produce virions. 
We first assessed whether LRA treatment has any effect on the levels of total HIV-1 
DNA in rCD4 cells. With the LRAs tested in this study, we did not find a trend towards 
significant changes in the amount of total HIV-1 DNA per 106 rCD4 cells following treatment 
compared with medium control. This is consistent with the small fraction of proviruses that are 
likely to be reactivated following treatment with LRAs, as previously described300 and discussed 
in the previous chapter. Intriguingly, we also found a substantial increase in levels of total HIV-1 
DNA following treatment with romidepsin + bryostatin in one donor. The mechanism leading to 
this expansion is currently unknown, but we previously found that levels of HIV-1 DNA can 
increase upon cellular activation300. Given the increases observed in CD69 expression following 
treatments including bryostatin, it is possible that cellular activation occurred and led to proviral 
expansion. We can also speculate that treatment with romidepsin + bryostatin may have led to 
dramatic clonal expansion of a particular integration site in this donor149,150.  
Although levels of total HIV-1 DNA did not change across donors, we did find a trend 
towards a reduction in the amount of virions produced from LRA treated rCD4 cells compared 
with medium control treated rCD4 cells. These fold reductions ranged from 4.5 to 11 fold 
reductions in the amount of virions produced following LRA treatment, but were not statistically 
significant in a linear mixed effects model due to the overlapping interquartile ranges. However, 
extrapolating to findings from other studies, reduction in the amount of virions produced that 
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were observed here are in line with what would be expected if LRAs potently reversed latency 
and led to viral cytopathic effects to the degree that others have suggested273,297,330. 
Next, we used our fPVE for virion production to evaluate whether the fraction of 
proviruses that are inducible following treatment with LRAs was substantially reduced compared 
with medium control. Using fPVE, we found that the median fold-change in the fraction of 
proviruses that were inducible was 1.5, 2.0 and 3.5, respectively, for romidepsin, bryostatin and 
romidepsin + bryostatin compared to medium control. At the level of individual donors, 
romidepsin led to decreases in maximal fPVE for six of eight donors, while bryostatin led to 
decreases in four of six donors and romidepsin + bryostatin led to decreases in five of six donors. 
In order to control for the variation in the fraction of proviruses that were inducible from 
the medium control condition from each donor, we next evaluated fPVE for virion production as 
a fold-change for LRAs over medium control. It is clear from this analysis that when normalizing 
for the maximum fraction of proviruses that can be reactivated in each donor, the fraction of 
proviruses that can be reactivated has not been substantially reduced following LRA treatment. 
Although the medians are lower for LRA treated conditions, the interquartile ranges are 
overlapping. Despite the lack of a consistent decrease across donors, it does appear that some 
donors have a drop in the fraction of proviruses that are inducible following treatment with 
LRAs. However, the lack of a consistent decrease across donors is in line with a previous study 
by Shan et al. that quantified the size of the infectious viral reservoir by quantitative viral 
outgrowth following treatment of rCD4 cells ex vivo with SAHA, and found that there was no 
change339. Lack of an observed change in the size of the reservoir following treatment with 
LRAs is also consistent with the results from in vivo studies, where treatment with panobinostat 
did not lead to a change in the length of time to viral rebound following cessation of ART257, and 
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treatment with romidepsin317 did not lead to changes in the size of the reservoir as measured by 
TILDA340 or QVOA302. 
An assumption of this experimental design is that the LRA-treated rCD4 cells are equally 
as responsive to T cell activation stimulus as cells in the medium control condition. To evaluate 
whether this assumption was true, cellular viability and the expression of activation markers 
following T cell activation for 7 days was assessed. In the three donors in whom we evaluated 
cellular viability, we found that romidepsin and bryostatin + romidepsin treatment conditions 
reduced the cellular viability following T cell activation compared to medium control. This 
reduction in T cell viability following romidepsin treatment may be related to the impaired 
cytotoxic T cell response observed following treatment with romidepsin341. For romidepsin 
treatment, the reduction in cellular viability was nearly equivalent to the median fold-change in 
the fraction of inducible proviruses, suggesting that reductions in viability could explain the 
apparent reduction in the size of the inducible reservoir. Bryostatin treatment alone did not 
substantially reduce the viability following maximum reactivation, but viability for bryostatin + 
romidepsin treatment was somewhat reduced. While viability was reduced for bryostatin + 
romidepsin, the median fold-change in the fraction of inducible proviruses was greater than the 
drop in viability, suggesting that decrease responsiveness to activation may not fully explain the 
drop observed. 
Assessment of levels of activation marker expression following full T cell activation 
revealed that there was heterogeneity in the responsiveness to T cell activation following 
treatment with LRAs. In donors 5 and 7, there were reductions in the amount of CD69 
expression following treatment with LRAs, but levels of CD69 expression were nearly 
equivalent in the other donors. Donor 7 also had a decrease in levels of CD25 expression 
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following treatment with LRAs, whereas CD25 expression was consistent in other donors. There 
was not any clear relationship between viability and activation marker expression, or decreases 
in the fraction of proviruses that could be reactivated and activation marker expression. From 
these data, it appears that cellular viability may be a more important and consistent measure to 
evaluate ability of cells to respond to full T cell activation. However, both measures of cellular 
viability and activation marker are ultimately informative for the overall state of cells following 
reactivation. Future studies should also evaluate cytokine production between treatment 
conditions as a further assessment of equivalent reactivation between conditions.  
Finally, we sought to evaluate whether changes in the fraction of proviruses that were 
inducible following treatment with LRAs was related to the fraction of proviruses that were 
initially reactivated following treatment with LRAs. The only treatments that had sufficient 
results to perform this analysis were romidepsin and bryostatin + romidepsin treatment, as 
bryostatin did not lead to virion production in some donors. We found that the fraction of 
maximally inducible proviruses was related to the fraction that were initially reactivated for 
bryostatin + romidepsin treatment, but not for romidepsin treatment. This makes sense in the 
context of the viability data described above, where it appears that rCD4 cells treated with 
romidepsin alone were less responsive to T cell activation, while bryostatin + romidepsin treated 
cells were substantially more responsive. Therefore, the relationship between the fraction of 
proviruses initially reactivated by romidepsin is likely not related to the fraction of proviruses 
that can be maximally reactivated following treatment due to the reduced viability of the cells 
following romidepsin treatment. It is worth noting that this study is preliminary and involves a 
small number of donors. Future studies should evaluate bryostatin alone and romidepsin + 
bryostatin treatment in more donors, and should include thorough assessments of whether LRA 
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treated cells can be activated to the same degree as medium control cells. This could be assessed 
with cellular viability, activation marker expression, cytokine profiling of cytokines produced 
from activated cells and RNAseq to evaluate whether transcriptional signatures have changed 
between treatment conditions. Finally, sequencing of virions produced from activated cells could 
also be performed and compared to medium control to evaluate whether fewer proviral 
sequences are produced following treatment with LRAs, consistent with a reduction in the size of 
the inducible reservoir. 
In this chapter, we have extended our findings from assessments of potency of LRAs, to 
the impact that LRA treatment has on the fraction of proviruses that are inducible by maximum T 
cell activation. Given the relative impotency of LRAs to reactivate proviral expression, it is not 
surprising that only marginal reductions in the size of the latent reservoir were observed. 
Additionally, analysis of the fraction of proviruses that are maximally inducible following 
treatment with LRAs is complicated by the fact that the viability and expression of activation 
markers following T cell activation after treatment with LRAs is variable. Differences in 
viability and ability to be activated following treatment with LRAs is a key point, and prevents 
us from drawing strong conclusions as to whether the size of the inducible reservoir has truly 
been reduced.  
The analysis of LRAs from the proceeding chapters, in conjunction with this chapter, 
suggests that the ability of LRAs to disrupt the latent reservoir to the point of virion production 
are minimal ex vivo. Although increased levels of cellular HIV-1 RNA could lead to viral 
cytopathic effects from increased translation of viral proteins, our results indirectly argue against 
this possibility, as substantial reductions in the size of the reservoir were not observed, although 
interpretation is difficult due to the changes in viability and activation marker expression 
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following treatment with LRAs, as described above. While we did observe a relationship 
between reactivation and decreases in the fraction of proviruses that were inducible following 
treatment with bryostatin + romidepsin, the magnitude of the reduction was not impressive. It is 
possible that a larger portion of cells could produce viral proteins and be cleared by immune 
effector responses in vivo, but we did not seek to address this point in this study. Indeed, Shan et 
al. demonstrated in a primary cell model that primed cytotoxic T lymphocyte responses led to 
reductions in the size of the reservoir following treatment with SAHA339. Whether immune 
effector functions can be harnessed to facilitate clearance of the reservoir needs to be evaluated 
in future studies. Taken together, our results suggest that much more potent LRAs, and increased 
specificity of LRAs for HIV-1 expression, are needed to achieve a safe and effective kick and 
kill approach to achieve reservoir reduction. 
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7.0  CHAPTER 4. BIOMARKERS OF THE INDUCIBLE RESERVOIR OF HIV-1 IN 
PATIENTS ON LONG TERM SUPPRESSIVE ANTIRETROVIRAL THERAPY  
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The work presented in this chapter is in partial fulfillment of aim 2 of this dissertation. Angela 
Tsai, Alivelu Irrinki and Jasmine Kaur isolated PBMC and rCD4 cells from leukapheresis 
product, set up cultures of PBMC and rCD4 cells, harvested supernatants and assessed levels of 
virions produced in the supernatant. Anthony Cillo, Francis Hong and Mattie Follen performed 
qRT-PCR experiments for the quantification of persistence of HIV-1 in plasma, PBMC and 
rCD4 cells. Jacob Lalezari enrolled study participants for leukapheresis. Anthony Cillo, Derek 
Sloan, Jeffrey Murry, and John Mellors conceived of the study. Anthony Cillo, Jeffrey Murry 
and John Mellors analyzed the data, and Anthony Cillo performed statistical analysis. 
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7.2 INTRODUCTION 
In the era of modern antiretroviral therapy for HIV-1 infection, regimens are capable of 
completely suppressing viral replication as long as daily adherence is maintained79. As such, 
those living with HIV-1 now have lifespans approaching those of HIV-1 negative people342-347, 
although mortality remains higher from non-AIDS complications in the era of ART348. The 
transformation of HIV-1 infection from a death sentence to a manageable chronic disease is a 
triumph of modern medicine. This progress was achieved through careful clinical assessments of 
antiretroviral drugs, which would not have been possible without a biomarker of effective 
therapy. It was not until the discovery of plasma viremia in uncontrolled HIV-1 infection as a 
marker of the time to progression to AIDS108,109, that clinical progress could be evaluated with a 
molecular biomarker, rather than assessing a time- and cost-intensive clinical result such as time 
to development of AIDS or death. Therefore, identifying drug candidates that could durably 
suppress plasma viremia was the key to rapid development of the ART drugs that we have today. 
Despite the complete suppression of viral replication as long as therapy is maintained, 
HIV-1 persists indefinitely, and viral recrudescence occurs within days to weeks following 
cessation of therapy116,233,257,349, and seems to rebound from many sources within lymphoid 
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tissue simultaneously350. Persistence of HIV-1 can be detected with specialized assays, such as 
viral outgrowth assays from rCD4 cells302, as molecular species (i.e., proviral HIV-1 DNA and 
cellular HIV-1 RNA) from PBMC and other cellular subsets300, and as low level viremia in 
plasma on the order of 1 copy per milliliter of plasma112-114,303. Despite the ability of specialized 
research assays to quantify various forms of viral persistence, the clinical relevance of any given 
measure of persistence in those on suppressive therapy remains unknown. We are currently in a 
time period for the assessement of the clinical efficacy of curative interventions that is analogous 
to the time before the establishment of plasma viremia as a barometer of success. Testing of 
novel interventions to achieve a cure is occurring in clinical trials, but we do not have a 
biomarker that unequivocally demonstrates efficacy of any given approach. 
In this study, we sought markers of persistent HIV-1 reservoirs in persons on on long-
term suppressive ART and relationships between such markers. The makers we evaluated 
included molecular measures of HIV-1 persistence and culture-based measures of spontaneous 
and inducible virion production from both PBMC and rCD4 cells. Inducible virion production, 
namely levels of HIV-1 RNA in cell culture supernatants following treatment with PMA/iono, 
was chosen as a culture-based viral endpoint rather than the number of cells harboring infectious 
proviruses. This choice was made in part because of the tractability of measuring virion 
production over infectious virion production, but also because it eliminates one level of 
stochastics, as both virion production and infection of subsequent cells both are likely stochastic 
events351-355. Finally, virion production should logically correlate with the time to viral rebound 
following cessation of ART, as virions must be produced to infect new cell targets and lead to 
viral rebound. No studies to date have investigated relationships among makers, or evaluated 
whether any makers were correlated with inducible and spontaneous virion production from 
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cultured PBMC and rCD4 cells. We hypothesized that as the frequency of HIV-1 infected cells 
and their transcriptional activity increases, levels of spontaneous and inducible virion production 
will concomitantly increase. 
7.3 RESULTS 
7.3.1 Baseline characteristics of the participants studied 
To assess whether biomarkers of virologic persistence are related to levels of spontaneously 
released and inducible HIV-1 virions production by PBMC and rCD4 cells, we enrolled 21 
consecutive HIV-positive study participants who were on suppressive ART for ≥1 year to 
undergo leukapheresis (Table 14). Leukapheresis was preferred over large volume blood draws 
to allow for the setup of culture experiments with large number of rCD4 cells and PBMC in 
parallel. All leukaphereses were performed at Quest Clinical Research (San Francisco, CA), and 
all participants gave informed written consent. The median age of the study participants was 54 
years old, all patients had high CD4+ T cell percentages (median 34% of lymphocytes) and 
counts (median 725 cells/mm3) at the time of leukapheresis, and all study participants were male. 
Low-level viremia was assessed with a large-volume adaptation of the single-copy assay to allow 
for improved precision and a lower limit of detection303. Low-level viremia was quantifiable in 
13 of 19 participants tested, and the median level of viremia was 1.1 copies per milliliter of 
plasma. Total cellular HIV-1 proviral DNA and unspliced cellular HIV-1 RNA were quantified 
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in PBMC, with cellular HIV-1 DNA (CA HIV-DNA) quantifiable in all 21 study participants 
and cellular HIV-1 RNA (CA HIV-RNA) quantifiable in 20 of 21 participants.
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Table 14. Participant characteristics for the assessment of biomarkers of the inducible reservoir 
Participant ID Age 
CD4+ T cell 
count 
(cells/mm3) 
Percent 
CD4+  
T cells in 
lymphocytes 
Mega-iSCA 
(copies of 
HIV-1 RNA 
per milliliter 
of plasma) 
Cellular  
HIV-1 DNA  
(copies per 
106 PBMC) 
Cellular  
HIV-1 RNA  
(copies per 
106 PBMC) 
ART Regimen 
1 69 742 41.2 1.1 563 74 
EFV/FTC/TDF/ 
RAL 
2 54 653 36.3 <0.05 172 82 ND 
3 57 587 36.7 1.2 245 40 3TC/ABC/DTG 
4 55 762 23.8 1.7 192 3 3TC/ABC/DRV/r 
5 51 692 17.3 6 2972 355 
DRV/FTC/MVC/ 
r/RAL/TDF  
6 54 607 26.4 2.3 283 37 EFV/FTC/TDF 
7 61 1022 29.2 0.81 1061 92 ND 
8 58 632 23.4 11 636 177 ETR/MVC 
9 50 1345 26.9 6.3 80 35 
3TC/ABC/DTG/ 
DRV/LPV/r/ZDV 
10 54 590 26.8 <0.074 611 53 ND 
11 52 422 28.1 <0.046 78 4 
ATV/DTG/FTC/ 
r/TDF 
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12 53 958 38.3 4.0 504 90 
ETR/FTC/MVC/ 
RAL/TDF 
13 52 832 39.6 2.8 211 21 
3TC/ABC/ATV/ 
LPV/r 
14 64 725 48.3 0.67 453 70 ND 
15 64 538 33.6 <0.087 31 15 
3TC/ABC/ 
LPV/r/TDF 
ZDV 
16 39 556 39.7 <0.074 160 28 EFV/FTC/TDF 
17 56 882 42 ND 7 <1 
BMS663068/FTC/ 
RAL/TDF 
 
18 54 699 36.8 ND 366 13 3TC/ATV/TDF 
19 57 780 39 3.0 381 39 ND 
20 47 796 36.2 <0.10 289 11 DRV/DTG/r 
21 62 783 43.5 0.42 91 2 FTC/RAL/TDF 
Median 
(Interquartile range) 
54  
(52-58) 
725 
(607-796) 
34  
(27-40) 
1.1 
(0.047-2.9) 
283 
(160-504) 
37 
(13-74) 
ND 
 
ND = not determined; 3TC = lamivudine; ABC = abacavir; ATV = atazanavir; BMS663068 = fostemsavir; DRV = darunavir;  
DTG = dolutegravir; EFV = efavirenz; ETR = etravirine; FTC = emtricitabine; LPV = lopinavir; MVC = maraviroc; r = ritonavir; 
RAL = raltegravir; TDF = tenofovir disoproxil fumarate; ZDV = zidovudine
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The median level of CA HIV-DNA was 283 copies per 106 PBMC, while the median level of CA 
HIV-RNA was 37 copies per 106 PBMC. Participants had plasma viremia stably suppressed to 
<50 copies per milliliter of plasma on a variety of ART regimens, including regimens with 
protease inhibitors, nucleoside and non-nucleoside reverse transcriptase inhibitors, integrase 
inhibitors, and entry inhibitors.  
7.3.2 Correlograms of the relationships between variables 
 To begin assessing relationships between molecular biomarkers of HIV-1 persistence and 
culture-based measures of virion production ex vivo from participants on suppressive ART, we 
constructed a correlogram based on Spearman’s correlation between the 12 continuous variables 
assessed in this study (Figure 16). All variables studied are listed on both the x- and y-axis, with 
the top right hand side of the correlogram showing a heat map derived from the correlation 
coefficients from Spearman’s correlation (rho), with red indicating a strong positive correlation, 
blue indicating a strong negative correlation, and white representing no correlation. Correlation 
coefficients that were statistically significant based on uncorrected p values obtained from the 
pairwise Spearman’s correlations are marked with an asterisk (*). The bottom left side of the 
correlogram shows individual scatterplots of the data from each variable that was used to test for 
a correlation. From the 66 unique pairwise comparisons tested, we found that 26 were 
statistically significant when no effort was made to correct for the family-wise type-I error rate 
or the false discovery rate. It is evident from the correlogram that CA HIV-DNA and CA HIV-
RNA in PBMC are strongly correlated with numerous other variables, including measures of 
spontaneous and inducible virion production from PBMC and rCD4 cells. Levels of total HIV-1 
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DNA from rCD4 cells are also strongly correlated with some measures of spontaneous and 
inducible virion production. For culture-based measures of spontaneous and inducible virion 
production, 15x106 PBMC were plated in 5 milliliters of culture medium in 6 well plates, and 
5x106 resting CD4+ T cells were cultured 2 millilter of culture medium in 24 well plates (more 
details are provided in the Overall materials and methods section). 
  
Figure 16. Correlogram of relationships between continuous variables with uncorrected p values. The top right half of the correlogram is a heat map showing 
the strength of the correlation between variables listed on the x- and y-axis (with strong positive correlations appear red, strong negative correlations appearing 
blue, and no correlations appearing white). Statistically significant correlations based on uncorrected p values from Spearman’s correlations are marked with an 
asterisk (*). The bottom left half of the graph shows scatterplots of the data that were used for the correlations tested. 
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Since 66 pairwise comparisons were tested from the same data set in this study, it is 
important to control either the family-wise type-I error rate (FWER), or the false discovery rate 
(FDR). While keeping the FWER at α=0.05 (i.e., by using Holm’s correction356) prevents the 
inclusion of even one false positive discovery (i.e., rejecting the null hypothesis of no correlation 
when there is in fact not a statically significant correlation), it is overly conservative and will 
exclude correlations that actually reject the null hypothesis. As such, an attractive alternative is 
to control the FDR (i.e., by using the Benjamini and Hochberg correction314), and to allow for a 
proportion of the rejected null hypothesis to be erroneously kept. This method allows for the 
retention of more power, albeit by a slight tradeoff at the expense of the FWER. Another benefit 
of FDR correction over FWER correction is that it FDR is both adaptable (allows for a number 
of falsely rejected null hypothesis based on the total number of rejected null hypotheses) and 
scalable (the proportion of falsely rejected null hypotheses remains the same regardless of the 
number of hypotheses rejected)314. We elected to use the Benjamini and Hochberg (BH) method 
to control the FDR since we had a total of 26 null hypotheses rejected out of 66 tested 
hypotheses; controlling the FWER in this context would be overly conservative, and would 
likely eliminate many true alternative hypotheses.  
A correlogram showing the same relationships described in Figure 16, but with asterisks 
marking statistically significant correlations following correction of the p values from the 
Spearman’s correlations using the BH method. Overall, 19 of the previously identified 26 
correlations were retained after controlling the FDR. Importantly, all of the relationships between 
CA HIV-DNA and CA HIV-RNA and other variables were retained after controlling the FDR.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Correlogram showing significant correlations after controlling the false discovery rate. The layout of the correlogram is identical that that in Figure 
16, with the exception being that the p values for the Spearman’s correlations have been corrected to control the FDR. Of the 26 previously identified statistically 
significant relationships identified, 19 were retained after controlling the FDR, including all of the previously identified relationship involving CA HIV-DNA and 
CA HIV- RNA. 
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7.3.3 Assessment of relationships between individual variables 
 
 
 
 
After using the correlogram to evaluate general relationship between the variables 
studied, we next sought to specifically evaluate individual relationships in more detail. We first 
evaluated the relationship between CA HIV-DNA and CA HIV-RNA in PBMC, and found that 
the frequency of infected cells (CA HIV-DNA) was related to levels of transcription of unspliced 
HIV-1 RNA (CA HIV-RNA). This finding demonstrates that the great the frequency of infected 
cells, the higher the HIV-1 transcriptional activity per million PBMC (rho=0.78, FDR-corrected 
p=0.001). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Relationship between levels of cellular HIV-1 DNA and cellular HIV-1 RNA. The frequency of infected 
cells in PBMC, as measured by qPCR for cellular HIV-1 DNA, is related to levels of HIV-1 transcription, as measured 
by qRT-PCR for unspliced HIV-1 RNA transcripts. The open symbol denotes a sample with undetectable CA-RNA. 
The CA-RNA value was interpolated to be 0.5 copies per million PBMC. Asterisk indicates that the p-value has been 
corrected by controlling the FDR. 
150  
S
p
o
n
ta
n
e
o
u
s
 v
ir
io
n
 p
ro
d
u
c
ti
o
n
 f
ro
m
 P
B
M
C
 
(c
o
p
ie
s
 H
IV
-1
 R
N
A
 p
e
r 
m
ill
ili
te
r 
s
u
p
e
rn
a
ta
n
t)
 
S
p
o
n
ta
n
e
o
u
s
 v
ir
io
n
 p
ro
d
u
c
ti
o
n
 f
ro
m
 r
C
D
4
 c
e
ll
s
 
(c
o
p
ie
s
 o
f 
H
IV
-1
 R
N
A
 p
e
r 
m
ill
il
it
e
r 
o
f 
s
u
p
e
rn
a
ta
n
t)
 
After evaluating relationships between the frequency of infected cells and their 
transcriptional activity, we next assessed whether there was any relationship between levels of 
low-level viremia measured in plasma and measures of spontaneous virion production from 
cultured PBMC and rCD4 cells (Figure 19). 
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Figure 19. Mega-iSCA is associated with spontaneous virion production. Spontaneous virion release from ex vivo 
cultured PBMC and rCD4 cells was compared to low- level viremia as measured by mega-iSCA. A) There was a trend 
towards a positive correlation after controlling for the FDR between mega-iSCA and spontaneous virion release from 
PBMC (rho=0.52, p=0.066 controlling for FDR), while B) the relationship was statistically significant for virion release 
from rCD4 cells and mega-iSCA (rho=0.68, p=0.009 controlling for FDR). Open symbols denote samples that were 
negative by either Mega-iSCA, spontaneous virion production, or both. Undetectable values were interpolated as 50% 
of the limit of detection. Asterisks indicate that the p-values have been corrected by controlling the FDR. 
 
 
 
Low-level viremia, as measured by mega-iSCA, was statistically significantly correlated with 
spontaneous virion release from both unstimulated PBMC and rCD4 cells cultured ex vivo prior 
to correcting for the false discovery rate. However, after controlling for the FDR, there was still a 
trend towards a relationship between spontaneous virion release from PBMC and mega-iSCA 
although it was not significant (rho=0.52, p=0.066 controlling for FDR), while the correlation 
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remained  significant  for  spontaneous  virion  release  from  rCD4  and  mega-iSCA  (rho=0.68, 
 
p=0.009 after controlling for FDR). 
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Figure 20. Cellular HIV-1 DNA and RNA from PBMC is associated with spontaneous virion production. Levels 
of CA HIV-DNA and CA HIV-RNA in uncultured PBMC are significantly associated with levels of spontaneous 
virion production from both PBMC and rCD4 cells in culture. The frequency of infected cells, and their transcriptional 
activity, are related to the amount of spontaneous virion release ex vivo. All values remained statistically significant 
after correcting the FDR. Undetectable samples are represented by open symbols, and were interpolated as 50% of the 
limit of detection. Asterisks indicate that the p-value has been corrected by controlling the FDR.
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Next, we assessed whether CA HIV-DNA and CA HIV-RNA were associated with levels 
of spontaneous virion release from cultured PBMC and rCD4 cells (Figure 20). After controlling 
the FDR, we found that the frequency of infected cells in PBMC was associated with levels of 
spontaneous virion production from cultured PBMC (rho=0.55,p=0.034 controlling for FDR) and 
rCD4 cells (rho=0.69,p=0.004 controlling for FDR). Additionally, we found that levels of HIV-1 
RNA transcription in PBMC were significantly related to levels of spontaneous virion production 
from PBMC (rho=0.64,p=0.009 controlling for FDR) and rCD4 cells (rho=0.55,p=0.034 
controlling for FDR). The frequency of infected cells, and their transcriptional activity, in 
uncultured PBMC are significantly related to the levels of spontaneous virion production from 
cultured PBMC and rCD4 cells.  
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Figure 21. Cellular HIV-1 DNA and RNA from PBMC is associated with inducible virion production. Levels of 
inducible virion production were quantified and compared with the frequency of infected cells, and the number of 
cellular HIV-1 RNA transcripts per million uncultured PBMC. This analysis revealed that the frequency of infected 
cells in PBMC were related to inducible virion production from PBMC and rCD4 cells, and that cellular HIV-1 
transcription was also related to the amount of virions that could be produced following T cell activation. The open 
symbol represents the sample with undetectable CA-RNA, which was interpolated as 50% of the limit of detection. 
Asterisks indicate correction of p-values by controlling FDR. 
 
 
 
We next evaluated whether there was a relationship between the frequency of infected 
cells and their transcriptional activity in PBMC, and levels of virus that were produced following 
treatment of PBMC and rCD4 cells with PMA/ionomycin (Figure 21). We found that there were 
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strong positive relationships between CA HIV-DNA and CA HIV-RNA in PBMC, and the levels 
of inducible virion production from PBMC and rCD4 cells. Specifically, CA HIV-DNA was 
strongly associated with levels of virion production from PBMC (rho=0.64,p=0.009 controlling 
for FDR) and rCD4 cells (rho=0.72,p=0.002 controlling for FDR), demonstrating that the 
frequency of infected cells is related to the levels of virions that are produced following 
maximum T cell activation in culture. Levels of CA-RNA in PBMC were also strongly 
associated with inducible virion production from PBMC (rho=0.77,p=0.001 controlling for FDR) 
and rCD4 cells (rho=0.75,p=0.002 controlling for FDR), implying that the transcriptional activity 
of the infected cells in bulk uncultured PBMC is related to the levels of virions that are produced 
following full T cell activation.  
Finally, we evaluated whether the amount of inducible virion production from rCD4 cells 
was related to the amount of virion production following activation of PBMC in culture (Figure 
22). We reasoned that since rCD4 cells are contained within PBMC, levels of virions produced 
from rCD4 cells should be proportion to levels of virions produced from PBMC. We found that 
this was indeed the case, and there was a strong relationships between levels of virion production 
from PMA/ionomycin treated PBMC and PMA/ionomycin treated rCD4 cells in culture 
(rho=0.81,p=0.0005 controlling for FDR). 
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Figure 22. Inducible virion production from PBMC and rCD4 cells are strongly correlated. In parallel cultures of 
PBMC and rCD4 cells isolated from the same study participants at the same timepoint, we found that there was a 
strong positive relationship between the virions that were produced following treatment with PMA/ionomycin from 
both cellular populations. Asterisk indicates a corrected p-value by controlling for FDR. 
 
 
 
 
 
7.3.4 Interaction networks demonstrating interrelationships between variables 
 
 
 
 
From the data presented thus far, it is clear that there are many interrelationships between the 12 
variables that were studied, and particularly many relationships between measures of CA HIV- 
DNA and CA HIV-RNA and the levels of spontaneous and inducible virion production from 
PBMC and rCD4 cells. To better display these interrelationships, we constructed an interaction 
network based on the statistically significant Spearman’s correlations between the individual 
variables studied (Figure 23). In the interaction networks displayed, each node represents an 
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individual variable and each connection between nodes represents a statistically significant 
correlation, after correcting for the FDR. 
 
  
 
 
 
Figure 23. Interaction networks of relationships between virologic variables. Interaction networks are shown, demonstrating the interrelationships between virologic 
variables, and highlighting interactions between molecular measures of HIV-1 persistence and culture-based measures of virion production. In the interaction networks, each 
node represents a variable, and the connections between nodes represent statistically significant Spearman’s correlations after correcting for FDR. A) Relationships between 
molecular measures of viral persistence from PBMC (CA HIV-DNA and CA HIV- RNA from PBMC, the ratio of CA HIV-RNA/DNA in PBMC, and CA HIV-DNA in 
rCD4 cells) and plasma (mega-iSCA), and spontaneous virion production are shown. Notably, rCD4 CA HIV-DNA is related to spontaneous virion production from PBMC 
and rCD4 cells, and levels of persistent viremia in vivo (mega-iSCA) was related to spontaneous virion production from rCD4 cells. B) Relationships between molecular 
measures of persistence and culture-based measures of inducible virion production are shown. In this case, PBMC CA HIV-DNA and CA HIV-RNA were related to rCD4 
CA HIV-DNA, but unlike CA HIV-DNA/RNA from PBMC, CA HIV-DNA from rCD4 cells was only significantly related to inducible virion production from rCD4 cells 
and not from PBMC. 
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7.4 DISCUSSION 
Taken together, these results have demonstrated that spontaneous and inducible virion 
production from sufficient numbers of cultured PBMC and rCD4 cells are related to the 
frequency of infected cellsand their transcriptional activity following careful assessment by qRT-
PCR assays. From a total of 66 variables studied, we initially found that 26 correlations assessed 
by Spearman’s correlation were statistically significant. However, after controlling the false 
discovery rate, we found that 19 of the pairwise comparisons remained statistically significant, 
including all of the relationships between measures of total cellular HIV-1 DNA (CA HIV-DNA) 
and total cellular HIV-1 RNA transcription (CA HIV-RNA) in PBMC.  
 The relationship observed between the frequency of infected cells and levels of HIV-1 
RNA transcription suggests a proportionality between the number of infected cells, and the 
amount of HIV-1 RNA that is transcribed per million cells. In agreement with these results, this 
relationship has been recently observed in another study by Hong et al.304, demonstrating the 
reproducibility of these results across participant cohorts. While we can make no inference about 
the level of cellular HIV-1 RNA produced per infected cell or the number of cells that are 
responsible for virion production, we can deduce that there is proportionality between infected 
cell frequency and transcriptional activity across study participants. 
 The findings that CA HIV-DNA and CA HIV-RNA from PBMC are associated with 
spontaneous virion production from PBMC and rCD4 is novel, and indicates that there is a 
proportionality between the frequency of infected cells, their basal transcriptional activity, and 
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their ability to spontaneously release virions without further stimulation. This finding raises two 
interesting possibilities: i.) there is a reservoir of cells that are producing virions spontaneous and 
consistently in the absence of any further T cell activation; and ii.) the frequency of infected cells 
and their transcriptional activity is associated with the proportion of cells in the latent reservoir 
that are stochastically reactivated at any given time (i.e., more infected cells, the larger 
proportion that exits that latent reservoir as an activated T cell at a given time). These two 
possibilities are not mutually exclusive, and both could be driving the size of the spontaneously 
produced reservoir. The second possibility seems more likely to be a substantial driver of 
spontaneous virion production, as the prolonged production of HIV-1 antigens from long-lived 
cell sources would likely render them visible to immune-mediated clearance. From this data, it is 
not possible to conclude which of these mechanisms is the predominant factor driving 
spontaneous virion production. 
 Intriguingly, we also found a relationship between spontaneous virion production from 
rCD4 cells ex vivo and levels of persistent viremia in vivo by mega-iSCA. There was also a trend 
towards a relationship between mega-iSCA and the amount of virions spontaneously released 
from PBMC, though this relationship was not significant following control of the FDR. These 
findings highlight the value of this system for evaluating relationships between ex vivo variables 
and in vivo measurements of viral persistence. The relationship between levels of viremia in vivo 
and spontaneous virion production from rCD4 cells isolated from the periphery suggests that 
there is a biological relationship between spontaneous virion production and levels of virions in 
the periphery, and that measures of persistence in the periphery are associated with body-wide 
assessments of viral persistence. We did not find any relationships between viral persistence in 
plasma by mega-iSCA, and levels of CA HIV-DNA or CA HIV-RNA in the periphery, which is 
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in contrast to an earlier study by Chun et al. that found cellular HIV-1 DNA was associated with 
persistent plasma viremia357, though our study was not adequately powered to find the relatively 
weak relationship they identified.  
 In terms of assessing the size of the inducible reservoir, to date ex vivo studies aimed at 
quantifying reservoir size have focused predominantly on quantifying the size of the infectious 
viral reservoir by quantitative viral outgrowth assays (QVOA) from rCD4 cells. Accordingly, 
studies have sought to correlate other measures of viral persistence with infectious units per 
million (IUPM) rCD4 cells from QVOA. Previously, relationships have been observed between 
plasma viremia and QVOA358, and integrated HIV-1 DNA in PBMC and QVOA359, and the CA 
HIV-RNA to CA HIV-DNA ratio in rectal CD4+ T cells and QVOA359.  
Despite the widespread use of QVOA, it has numerous shortcomings, including a 
requirement for large number of rCD4 cells, irradiated feeder cells, allogeneic blasts as targets 
for viral infection, and requirements for specialized medium and up to 21-days of coculture. It 
also has a limited dynamic range due to the infrequency of infectious proviruses in participants 
on long-term suppressive ART. As such, we have utilized a new assay format, wherein replicate 
wells of rCD4 cells are plated and activated with PMA/ionomycin, and levels of HIV-1 RNA are 
assessed in the supernatant by Roche COBAS AmpliPrep/TaqMan, which greatly simplifies 
measurement of the inducible reservoir, at the cost of having no measurement of infectiousness 
of the induced viruses. 
 When comparing the frequency of infected cells and their HIV-1 transcriptional activity 
in PBMC, we found that both measures were associated with inducible virion production from 
both rCD4 cells and unfractionated PBMC. These findings were surprising, given recent work by 
Ho et al., showing that a large proportion of proviruses that were not found to be replication 
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competent after one round of T cell activation harbor substantial mutations and deletions, 
rendering them highly defective151. Regardless, approximately 12% of these non-induced 
proviruses were intact in the study by Ho et al., and were therefore potentially inducible. This 
finding likely complicates measures of the inducible reservoir with simple molecular measures, 
but the possibility also exists that the non-induced proviruses actually did produce virions and 
merely were not infectious. Overall, our results suggest that there is proportionality between 
levels of inducible virus, and total HIV-1 DNA detected by qPCR, which was not found in the 
study by Ho et al. 
 Our results demonstrate that simple molecular measures of persistence provide insight 
into the size of the inducible reservoir in rCD4 cells and PBMC. When broadly considering the 
factors that are required to permit virion production, it is logical that a greater frequency of 
infected cells leads to a great number of cells capable of producing virus. Levels of HIV-1 
transcription are also related to the size of the inducible reservoir, demonstrating that the 
frequency of infected cells and the level of transcription both seem to be factors that are 
associated with the frequency of cells that are capable of producing virions. Once again, this 
finding implies that there is proportionality between levels of proviruses that can transcribe HIV-
1 RNA in their basal state, and the total number of proviruses that are capable of undergoing 
virion production. 
 Regardless of the findings of ex vivo studies, the standard for the assessment of reservoir 
size in HIV-1 study participants on long-term suppressive therapy should be the time to viral 
rebound following cessation of ART. The time to viral rebound following cessation of ART is 
the most relevant measures of reservoir size, as it is a direct measure of the rapidity with which 
viral replication resumes, subsequently leading to immune activation, turnover of CD4+ T cells, 
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and increased risk of transmission and progression to AIDS over time. In vivo studies have thus 
far lent credence to the idea levels of cellular HIV-1 DNA and cellular HIV-1 RNA could serve 
as biomarkers of the reservoir. The SPARTAC group found a relationship between levels of 
cellular HIV-1 DNA and the time to viral rebound, using 400 copies per milliliter of plasma as 
the virologic endpoint360. Recently, Li et al. in the AIDS Clinical Trials Group found that time to 
virologic rebound was associated with levels of cellular HIV-1 RNA on suppressive ART361. 
These two studies contextualize the findings presented here, and demonstrate the feasibility of 
using molecular measures of cellular HIV-1 RNA and DNA as potential surrogates of the size of 
the reservoir in those on ART. Furthermore, the relationship between measures of cellular HIV-1 
RNA and DNA in PBMC and the size of the inducible reservoir from PBMC and rCD4 cells 
suggests that simply measuring virions produced in the culture supernatant following activation 
may be predictive of the time to viral rebound. This possibility is logical, but will need to be 
rigorously evaluated in future clinical studies of time to viral rebound.  
 The interrelationships that were uncovered in this study have yet to be elucidated 
elsewhere, and provide novel insight into the persistence of HIV-1 in patients on suppressive 
ART. Importantly, these findings assert that molecular measures of persistence are related to 
each other, and are significantly associated with measures of spontaneously virion release and 
inducible virion production. Future studies should seek to incorporate measures of infectious 
proviruses into similar data sets to evaluate quantitative relationships between other measures of 
persistence and the frequency of infectious proviruses. Ultimately, connecting these findings to 
the in vivo time to rebound following cessation of ART will be important for validating these 
biomarkers. Robust measures of the time to viral rebound have been elusive, but if these findings 
hold up in clinical studies, the timeline and complexity of studies to evaluate the effects of novel 
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therapeutics in vivo will both be greatly reduced. Expediency of clinical trials to evaluate 
interventions will likely be crucial to finding a means to reduce the size of the reservoir in those 
on suppressive ART, and as such the development of simple and robust biomarkers of the 
reservoir should be a high priority for curative HIV-1 research. 
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8.0  CHAPTER 5. ASSESSMENT OF THE SIZE OF THE INDUCIBLE AND 
INFECTIOUS RESERVOIR IN TOTAL AND RESTING CD4+ T CELLS 
8.1 PREFACE 
Anthony R. Cillo1, Michele Sobolewski1, Taylor Simmons1, Joshua Cyktor1, John W. Mellors1 
1University of Pittsburgh, Division of Infectious Diseases 
 
The work presented in this chapter is presented as partial fulfillment of aim 3 of this dissertation. 
Michele Sobolewski and Taylor Simmons isolated PBMC, total CD4+ T cells and resting CD4+ 
T cells from peripheral blood, set up cultures for pooled virus recovery and quantitative viral 
outgrowth, and performed Roche COBAS AmpliPrep/TaqMan v.2.0 and p24 to evaluate virus 
production and infectious virion production in culture, respectively. Joshua Cyktor performed 
flow cytometry for activation marker expression, and analyzed the results. Anthony Cillo 
performed qRT-PCR for the quantification of cellular HIV-1 RNA and DNA from PBMC, total 
CD4+ T cells and resting CD4+ T cells. John Mellors and Anthony Cillo conceived of the 
project and analyzed data. Anthony Cillo performed statistical analysis on the resulting datasets. 
The work in this chapter was funded by the Pitt AIDS Research Training Program 5 T32 
AI065380-08, an R21 from the NIH 1R21AI113102-01, and COBAS AmpliPrep/TaqMan kits 
provided by Roche.  
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8.2 INTRODUCTION 
HIV-1 is a lifelong persistent viral infection, and has been extensively characterized as persisting 
within resting CD4+ T cells123,124, and decaying with an extremely long half-life128,131. This 
reservoir persists throughout the lifetime of the patient due to immunologic memory of the 
resting CD4+ T cell population that have been exposed to antigens, and due to homeostatic 
proliferation as a normal biological function to maintain the pool of antigen-experienced memory 
CD4+ T cells362. As such, it is well established that the resting CD4+ T cell population serves as 
a reservoir of HIV-1 infection that is capable of reseeding viral infection following cessation of 
ART.  
The total CD4+ T cell population can be divided in many ways, including by naïve 
versus antigen experienced362,363, memory versus effector362-364, subsets of central memory CD4+ 
T cells362,364, stem cell-like lineages365, and resting versus activated CD4+ T cells366,367. While 
the reservoir of HIV-1 infection in resting CD4+ T cells has been thoroughly investigated, it is 
currently unknown whether the activated portion of the total CD4+ T (tCD4) cell population 
harbors a portion of the total HIV-1 reservoir that contributes to viral rebound following 
cessation of ART. HIV-1 DNA has been found in activated CD4+ T cells (i.e., 
CD3+CD4+CD25+/CD69+/HLA-DR+) cells previously366,367, but it remains unknown if the 
proviruses in activated cells are producing cellular HIV-1 RNA or virions, or are latent and 
inducible. Additionally, whether there is any relationship between the magnitude of virion 
production following activation for tCD4 cells and rCD4 cells, and that amount of infectious 
virus outgrowth remains unknown.  
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When evaluating total CD4+ T cells as a potential reservoir, it is important to bear in 
mind the criteria for latency and for a reservoir in HIV-1 infection368. To be truly latently 
infected, a population of cells must not produce virions in the absence of stimulation, but upon 
stimulation must produce replication competent virions. To be a reservoir, this cellular 
population must contribute to life-long persistence of HIV-1 and be capable of leading to viral 
recrudescence following cessation of ART. Although latent proviruses have been well-described 
in rCD4 cells, we hypothesized that the size of the latent and infectious reservoir would be larger 
from tCD4 cells compared with rCD4 cell, suggesting that cell expressing CD25/CD69/HLA-DR 
can contribute to the latently infected reservoir. 
8.3 RESULTS 
8.3.1 Study participant characteristics 
In this study, we enrolled 11 consecutive participants from the Pitt AIDS Center for Treatment in 
an IRB-approved study. All study participants gave informed, written consent at the time of 
enrollment. The participant characteristics are shown in Table 15. 
The participants enrolled in this study were Caucasian males and females and African 
American females. The median age at the time of blood draw was 49 years old. Study 
participants had a high percentage of CD4+ T cells in PBMC, and were on suppressive ART for 
a median of 9 years, ranging from 3 to 13 years. Prior to initiation of ART, study participants had 
a median viral load of 71,000 copies per milliliter of plasma, and a median CD4+ T cell count of 
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249 cells per mm3, consistent with the chronic stage of infection. Mega-iSCA confirmed that all 
participants had suppressed viremia, and median low-level plasma viremia was 0.37 copies per 
milliliter, with 2 of the 11 participants having undetectable viremia and the other 9 having 
quantifiable viral loads using the large volume adaptation of the single-copy assay303.
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Table 15. Participant characteristics for the assessment of inducible and infectious viral reservoirs in total and resting CD4+ T cells 
Participant 
ID 
Sex Race Age 
Pre-ART viral 
load (copies 
HIV-1 RNA 
per milliliter 
plasma) 
Nadir CD4 
(cell per 
mm3 blood) 
Mega-iSCA 
(copies HIV-
1 RNA per 
milliliter 
plasma) 
Percent 
CD4+ T 
cells in 
PBMC 
Percent 
CD8+ T 
cells in 
PBMC 
Duration of 
suppression 
(years) 
1 Female 
African 
American 
51 59,500 268 0.275 50 42 9 
2 Female 
African 
American 
36 802,000 20 0.37 40 53 10 
3 Male Caucasian 49 455,000 306 2.2 53 42 ND 
4 Female Caucasian 46 9,740 272 <0.092 24 11 4 
5 Male Caucasian 32 Unknown 259 1.49 48 47 7 
6 Male Caucasian 55 100,000 108 <0.092 69 15 13 
7 Female 
African 
American 
41 698,000 21 1.6 79 16 3 
8 Male Caucasian 51 3,369 536 0.092 45 49 9 
9 ND ND 55 80,300 157 0.18 56 35 8 
10 ND ND 57 61,600 263 1.7 44 51 4 
11 Male Caucasian 42 24,000 127 1.2 35 58 9 
Median 
(IQR) 
ND ND 
49  
(42-53) 
71,000  
(33,000-
370,000) 
259 
(118-270) 
0.37  
(0.14-1.5) 
48 
(42-56) 
42 
(26-50) 
9 
(5-9) 
ND = not done
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8.3.2 Magnitude of virion production is larger in total CD4+ T cells versus resting CD4+ 
T cells 
To isolate sufficient numbers of rCD4 and tCD4 cells in this study, we obtained large volume 
blood draws up to 360 mL by performing phlebotomy for 180 mL of whole blood twice, 
separated by ~1 hour. To begin to assess differences in the sizes of the inducible reservoir in total 
CD4+ T cells compared with resting CD4+ T cells, we first assessed the magnitude of 
spontaneous and inducible virion production from replicate wells of 106 tCD4 and rCD4 cells 
using an assay we refer to as pooled virus recovery (PVR). In PVR, replicate wells of 106 cells 
per well are cultured, and after 7 days of activation, the supernatants are removed, pooled 
together, and frozen in aliquots for downstream assessment of HIV-1 RNA levels by Roche 
COBAS AmpliPrep/TaqMan. Using PVR permits the assessment of virion production from 
larger numbers of rCD4 and tCD4 cells, and the pooled nature of the assay is useful for obtaining 
a population average without having to perform a large culture; as such, this assay format is 
amenable to scaling up or down with greater or fewer tCD4 or rCD4 cells following isolation 
from PBMC (see Overall materials and methods for more information). 
To establish the presence of a reservoir within CD4+ T cells that contributes to inducible 
virion production, it is first important to establish that there is a latent population of proviruses in 
tCD4 cells. To assess whether this is the case, we cultured tCD4 cells and rCD4 cells in the 
absence of any stimulation for 7 days in culture with 300 nM efavirenz and 100 nM raltegravir, 
and quantified virion-associated HIV-1 RNA in culture supernatants by Roche COBAS 
AmpliPrep/TaqMan v.2.0. We found that the median levels of virion production from both tCD4 
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cells and rCD4 cells was <20 copies per milliliter of culture supernatant (interpolated value of 10 
copies per milliliter of supernatant, which is 50% of the limit of detection of the assay), 
demonstrating that spontaneous virus production was below the limit of detection for the assay in 
most individuals (Figure 24). Additionally, spontaneous virion release from rCD4 cells was 
higher than tCD4 virion release in 4 of the 5 donors that had detectable levels of spontaneous 
virion production, indicating that despite the presence of activated CD4+ T cells within tCD4 
cells, levels of spontaneous virion production were not different (p=0.44, paired Wilcox test). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Levels of spontaneous virion production from cultured tCD4 and rCD4 cells. We found that of the 11 
participants in this study, 5 had detectable spontaneous virion release from unstimulated cultured tCD4 or rCD4 cells; 
the other 6 had undetectable levels of virion production from tCD4 and rCD4 cells. In cells from the 5 participants that 
had detectable virion release, rCD4 cells spontaneously produced more virions in 4 of the 5 donors assessed. These 
results indicate that there are not appreciable increases in spontaneous virion release from the cultured activated 
CD4+ T cells within the total CD4+ T cell population. 
171 
 
Using PVR, we next assessed the levels of virion produced from rCD4 cells and tCD4 
cells isolated from study participants on long term suppressive ART following 7 days of 
activation in culture with PMA/ionomycin in the presence of efavirenz (300 nM) and raltegravir 
(100 nM). We previously determined that 7 days of culture led to peak virion production with 
full T cell stimulation (data not shown). Median levels of virions produced following T cell 
activation of tCD4 cells was 4,299 copies per milliliter of culture supernatant, while median 
virion production from rCD4 cells was 1,728 copies per milliliter of culture supernatant (Figure 
25). Overall, the levels of inducible virion production from tCD4 cells were a median of 348-fold 
higher than spontaneous virion release from these cells. In rCD4 cells, the median fold-increase 
in inducible virion production over spontaneous virion production was 118-fold, demonstrating 
the presence of a latent and inducible reservoir within tCD4 cells that is larger than the reservoir 
within only rCD4 cells. 
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Figure 25. Virion production from pooled virus recovery (PVR) assays on tCD4 and rCD4 cells. Levels of virions 
produced following activation of tCD4 and rCD4 from the same study participants was assessed in parallel cultures. 
Median levels of virion production from tCD4 cells were 4,299 copies per milliliter of culture supernatant, while 
rCD4 cells produced a median of 1,728 copies. Total CD4+ T cells produced more virions compared to rCD4 cells in 
8 of 11 participants, while rCD4 cells produced more virions in 3 of 11, although donor 8 only produced 86 copies of 
HIV-1 RNA from tCD4 cells and 110 copies of HIV-1 RNA from rCD4 cells. Total CD4+ T cells produced 
statistically significant more virions compared with rCD4 cells (p=0.024, paired Wilcox test). 
 
The observed difference in virion production was statistically significant (p=0.024, paired 
Wilcox test) in this set of 11 study participants, suggesting that there are more cells capable of 
producing virions present in tCD4 cells versus rCD4 cells. Since rCD4 cells are present as a 
subpopulation within tCD4 cells, this result implies that there are inducible proviruses present in 
the activated population of tCD4 cells (i.e., CD3+CD4+CD25+/CD69+/HLA-DR+ cells). 
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8.3.3    Overall transcription of HIV-1 RNA is associated with inducible virion production 
 
 
 
 
To begin to assess variables that are associated with the size of the inducible reservoir in tCD4 
and rCD4 cells, we first quantified total cellular HIV-1 DNA and unspliced cellular HIV-1 RNA 
in PBMC (Figure 26). The mean (±standard deviation) for total HIV-1 DNA was 274 (±208) 
copies per million PBMC, while the mean (±standard deviation) level of cellular unspliced HIV- 
1 RNA transcription was 127 (±114) copies per million PBMC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Cellular unspliced HIV-1 RNA and total DNA from PBMC. Levels of cellular  unspliced  HIV-1  RNA  
and  total  HIV-1  DNA  from  PBMC  were assessed using previously described qRT-PCR assays300,304. A) Levels of 
total HIV-1 DNA per million PBMC ranged from 16 to 768 copies per million PBMC, with a mean value of 
274 (±208) copies per million PBMC. B) Levels of unspliced cellular HIV-1 RNA ranged from 24 to 414 copies per 
million PBMC, with a mean of 127 (±114) copies per million PBMC. Cellular HIV-1 RNA was detectable in all 
donors, but sufficient cells were not available for assessment of HIV-1 RNA in donors 4 and 6. ND = not determined, 
due to inadequate numbers of cells available for qRT-PCR analysis. 
 
After assessing levels of total cellular HIV-1 DNA and unspliced HIV-1 RNA in PBMC, 
we next sought to evaluate factors that were associated with levels of virion production from 
tCD4 and rCD4 cells.  This analysis revealed that the levels of virions that were produced 
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following activation of tCD4 and rCD4 cells were significantly related to the levels of overall 
 
cellular transcription of unspliced HIV-1 RNA per million PBMC (Figure 27). 
 
 
 
 
Figure 27. Overall levels of transcription of unspliced cellular HIV-1 RNA is related to inducible virion 
production. Inducible virion production from tCD4 cells and rCD4 cells is related to the levels of cellular 
HIV-1 RNA transcription in PBMC. A.) Levels of inducible virions from tCD4 cells are significantly related 
to HIV-1 RNA transcription in PBMC (rho=0.81, p=0.008). B.) PBMC cellular HIV-1 RNA transcription is 
related to inducible virion production from culture rCD4 cells (rho=0.68, p=0.044), although not as strongly 
as the relationship in tCD4 cells. 
 
 
Compared with the findings present in the previous chapter, it was surprising that cellular 
HIV-1 DNA in PBMC was not associated with levels of inducible virion production from rCD4 
cells. In this study, the correlation coefficient between cellular HIV-1 DNA in PBMC and 
inducible virion production from rCD4 cells was rho=0.38, p=0.25 using the nonparametric 
Spearman’s correlation (data not shown). Although the results for indicuble virion production 
from rCD4 cells were found to be non-Gaussian (p<0.001 by Shapiro-Wilk test for normality), if 
Pearson’s correlation is used to generate 95% confidence intervals, the resulting confidence 
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interval for r is from -0.60 to 0.60, which overlaps with the 95% confidence interval using 
Pearson’s correlation for the data relating PBMC cellular HIV-1 DNA levels to inducible virion 
production from rCD4 cells (r=0.57 to r=0.92) from the last chapter. Accordingly, a post-hoc 
power assessment from this study demonstrated that this study only had ~53% power to detect a 
correlation of r=0.60. Additionally, a correlation between cellular HIV-1 DNA and cellular HIV-
1 RNA was not observed in this study (rho=0.52, p=0.15; data not shown), but inspection of the 
95% confidence interval using Pearson’s correlation (r=  -0.49 to r=0.79) demonstrated near 
overlap with the previously described data (r=0.81 to r=0.97). 
8.3.4 Relationships between molecular measures of persistence and inducible virion 
production 
After evaluating differences between the size of the inducible reservoir in tCD4 and rCD4 cells, 
we next assessed whether differences in molecular measures of persistence (i.e. total cellular 
HIV-1 DNA and unspliced cellular HIV-1 RNA) in tCD4 or rCD4 cells were related to inducible 
virion production. Shown in Figure 28 is the frequency of infection and cellular HIV-1 RNA 
expression per million tCD4 or rCD4 cells. The mean (±standard deviation) level of infection in 
tCD4 cells was 727 (±578) copies per million tCD4 cells, and the mean (±standard deviation)  
level of cellular HIV-1 RNA in tCD4 cells was 257 (±211) copies per million tCD4 cells. The 
mean levels of total HIV-1 DNA in rCD4 cells was 695 (±492) copies per million tCD4 cells, 
and mean levels of cellular HIV-1 RNA in rCD4 cells was 342 (±309) copies per million rCD4 
cells. The frequency of infection was similar in both populations, suggesting that the overall 
frequency of infection of activated CD4+ T cells is likely similar to that of resting CD4+ T cells, 
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given that 38% of the tCD4 cells express CD25/CD69/HLA-DR. The trend towards greater 
levels of cellular HIV-1 RNA present in the resting CD4+ T cell population also implies that 
overall transcription is lower in the activated CD4+ T cell population within the tCD4 cell 
population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Levels of total HIV-1 DNA and unspliced cellular HIV-1 RNA in total and resting CD4+ T cells. A) 
Levels of total cellular HIV-1 DNA ranged from 139 to 1802 copies per million cells in tCD4 cells, and 20 to 1671 
copies per million cells in rCD4 cells. Total HIV-1 DNA was higher in tCD4 cells than rCD4 cells in 8 of 11 
donors, was essentially equivalent in 2 donors, and was greater in rCD4 cells versus tCD4 cells in 1 donor. B) Levels 
of unspliced cellular HIV-1 RNA ranged from 61 to 500 copies per million cells in tCD4 cells, and 43 to 802 copies 
per million cells in rCD4 cells. Cellular unspliced HIV-1 RNA was greater in rCD4 versus tCD4 cells in 6 of 10 
evaluable participants, and was greater in tCD4 versus rCD4 cells in 4 of 10 participants. 
 
 
When comparing relations between tCD4 and rCD4 cells, we found that they were highly 
interrelated (Figure 29 and Table 16). Given the interrelated nature of measures of molecular 
persistence in tCD4 and rCD4 cells, these data are presented as an interaction network, with a 
corresponding table providing the correlation coefficients and p values. The frequency of 
infection in both tCD4 cells and rCD4 cells was significantly associated with levels of cellular 
transcription in both tCD4 and rCD4 cells. We also found that the frequency of infection and 
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cellular transcription in tCD4 cells was related to the frequency of infection and levels of HIV-1 
RNA transcription in rCD4 cells. The frequency of infection in tCD4 or rCD4 cells was not 
related to the frequency of infection per million PBMC (data not shown), nor were the levels of 
transcription in tCD4 or rCD4 cells related to the level of cellular HIV-1 RNA transcription per 
million PBMC (data not shown), suggesting that there is variability in the overall percentage of 
CD4+ T cells as a constituent of PBMC. 
In addition to the interrelationships between the viral measures of persistence in the tCD4 
cells and rCD4 cells, there were also two noteworthy positive associations between levels of total 
HIV-1 DNA in tCD4 cells and cell frequencies in PBMC as measured by flow cytometry. 
Specifically, higher levels of HIV-1 DNA in tCD4 cells were positively associated with both a 
higher frequency of activated CD4+ T cells in PBMC (i.e., CD3+CD4+CD25+/CD69+/HLA-
DR+) and the frequency of CD3+CD8+ T cells in PBMC.  
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Figure 29. Interrelations between frequency of infection and transcription in tCD4 and rCD4 cells. The relationships 
between frequency of infection and transcription in tCD4 and rCD4 cells shown as an interaction network. Consistent with 
previously presented interaction networks, the nodes in this figure are variables, and the lines connecting the nodes represent 
statistically significant Spearman’s correlation coefficients. Frequency of infection and levels of viral transcription are 
highly interrelated. Total HIV-1 DNA within tCD4 cells was also significant related to the percent of activated CD4+ T 
cells within the PBMC population (i.e., CD3+CD4+CD25+/CD69+/HLA-DR+) and the percent of CD8+ T cells within the 
PBMC population (i.e., CD3+CD8+). 
 
 
Although the interconnected nature of the relationships between measures of viral 
persistence in tCD4 and rCD4 are not surprising due to fact that rCD4 cells are a cellular 
population nested within tCD4 cells, it is striking that the correlative relationships are so strong 
in some cases. Specifically, total cellular HIV-1 DNA in rCD4 and tCD4 are strongly correlated 
(rho=0.91, p<0.001), and cellular unspliced HIV-1 RNA are strongly correlated in rCD4 and 
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tCD4 cells (rho=0.70, p=0.031) (Table 16). The strength of the relationship between the 
frequency of infection between tCD4 and rCD4 cells suggests that there is a proportionality 
between the levels of infection that occurred prior to ART-initiation in both tCD4 cells and rCD4 
cells, where higher infection in tCD4 cells is related to higher infection in rCD4 cells. It is 
intriguing that higher levels of transcription in rCD4 cells are related to higher levels of HIV-1 
DNA in tCD4 cells; this suggests that the higher the frequency of infection in tCD4 cells, the 
higher the frequency of infection and transcriptional activity in rCD4 cells. 
 
Table 16. Relationships between frequency of infection and viral transcription on tCD4 and rCD4 cells 
Variable 1 Variable 2 Spearman’s rho P value 
tCD4 CA HIV-DNA 
tCD4 CA HIV-RNA 0.69 0.031 
rCD4 CA HIV-DNA 0.91 <0.001 
rCD4 CA HIV-RNA 0.98 <0.001 
PBMC %CD4 Act. 0.67 0.028 
PBMC %CD8 0.70 0.021 
tCD4 CA HIV-RNA 
rCD4 CA HIV-RNA 
0.70 0.031 
rCD4 CA HIV-DNA 0.94 <0.001 
 
 
Next, we sought to assess whether there were factors that were related to the fold-
difference in the size of the inducible reservoir between tCD4 cells and rCD4 cells. We found 
that the differences in the size of the inducible reservoir in between these two cell populations 
was not directly related to any one measure of viral persistence within any cell population (i.e. 
PBMC, tCD4 or rCD4 cells). The only factor found to be weakly associated with the ratio of 
virion production from tCD4 cells compared to rCD4 cells was the percent of activated cells 
within the tCD4 cell population (Figure 30; rho=0.74, p=0.046). 
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Figure 30. Percent of activated CD4+ T cells is related to the ratio of inducible virion production from tCD4 
versus rCD4 cells. The ratio of inducible virion production in tCD4 versus rCD4 cells was positively related to the 
percentage of activated cells within the tCD4 cell population. This correlation is shows that as the frequency of 
activated cells within tCD4 cells (that is, non-resting CD4 cells) becomes greater, the level of virion production in 
the tCD4 cell population becomes greater relative to that in the rCD4 cell population. 
 
While it is unclear exactly why the ratio of inducible virion production from tCD4 cells 
compared to rCD4 cells increases as the percent of activated CD4+ T cells in the tCD4 cell 
population increases, we do know that levels of HIV-1 DNA in tCD4 cells increases as the 
percent of activated tCD4 cells increases, as shown in Figure 29. We showed in the previous 
chapter that as levels of HIV-1 DNA rise in PBMC and rCD4 cells, levels of inducible virion 
production from rCD4 cells also rises. Applying the same logic here, as levels of HIV-1 DNA in 
tCD4 cells rise, there are likely more cells that can produce virions within the tCD4 cell 
population. Importantly, there is no statistically significant relationship between levels of 
activation in tCD4 cells and levels of cellular HIV-1 DNA in rCD4 cells (rho=0.62, p=0.12; data 
not shown). This means that as the frequency of activated CD4+ T cells increases, the levels of 
rCD4 HIV-1 DNA do not necessarily direct increase (at least not at the same rate that levels of 
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HIV-1 DNA in tCD4 cells increase), and correspondingly, the number of cells that can produce 
virions therefore does not increase as quickly as in tCD4 cells. This could potentially lead to a 
lower ratio of virion production from rCD4 compared to tCD4 as the percent of activated cells 
within tCD4 cells increases.  
8.3.5 Clinical factors associated with the size of the inducible reservoir 
One interesting factor that was inversely associated with levels of inducible virion production 
from both tCD4 cells and rCD4 cells was found to be the age of the study participant. 
Specifically, the older the study participant, the smaller the amount of virion production that was 
observed from both tCD4 cells and rCD4 cells (Figure 31). These inverse correlations were of a 
similar magnitude in both the tCD4 and rCD4 cell populations (rho= -0.77, p=0.006 for tCD4 
cells; rho= -0.76, p=0.006 for rCD4 cells). Duration of suppression was not directly associated 
with the size of the inducible reservoir in tCD4 cells (rho= -0.098, p=0.79) or rCD4 cells (rho= -
0.20, p=0.59). Importantly, the age of the study participant was not related to the duration of 
suppression of the study participant (rho=0.08, p=0.825; data not shown), demonstrating that this 
observed inverse correlation between age and inducible virion production was not based on 
duration of suppression.  
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Figure 31. Inverse relationships between age of study participant and inducible virion production. Across the 11 
participants in this study, age was found to be significantly inversely associated with age. A.) Inverse correlation 
between age and inducible virion production from tCD4 cells by PVR (rho= -0.77, p=0.006). B.) Inverse correlation 
between age and inducible virion production from rCD4 cells (rho= -0.76.  p=0.006), of a very similar magnitude  to  
the relationship between age and inducible virion production from tCD4 cells. 
 
After finding that the age of the participant was inversely related to levels of virions 
produced, we next evaluated whether other clinical factors were associated with the size of the 
inducible reservoir. We found, in this cohort of study participants, that the nadir CD4+ T cell 
count was negatively correlated with the amount of inducible virion production from rCD4 cells, 
but not tCD4 cells (Figure 32). It is particularly interesting that the nadir CD4+ T cell count from 
prior to the initiation of ART is related to the size of the inducible reservoir in rCD4 cells 
following years of suppressive ART. 
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Figure 32. Negative correlation between nadir CD4+ T cell counts and inducible virion production from rCD4 
cells. Levels of inducible virion production after years of suppressive ART are significantly inversely correlated with 
the nadir CD4+ T cell count prior to initiation of ART (rho= -0.65, p=0.034). This finding suggests that the extent of 
disease progression prior to the initiation of ART is related to the size of the inducible reservoir (i.e., lower nadir 
CD4+ T cell counts, larger inducible reservoir). 
 
 
 
This finding is intriguing, and suggests that the more extensive the disease progression of 
HIV-1 prior to the initiation of ART, the larger the size of the inducible reservoir in rCD4 cells, 
but not necessarily tCD4 cells. This also suggests that there are two distinct reservoirs, one in 
tCD4 cells and another in rCD4 cells, and that the seeding of each reservoir may be through 
distinct mechanisms. Analysis of single genome sequences from the virions produced from the 
tCD4 cells and rCD4 cells could provide insight into whether these are indeed distinct 
populations; if sequences are found in tCD4 cells that are not present in rCD4 cells, it would 
suggest that cells expressing CD25/CD69/HLA-DR constitute a distinct reservoir. 
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8.3.6    Size of the infectious virus reservoir in tCD4 cells and rCD4 cells 
 
 
 
 
In parallel to our evaluation of the size of the inducible reservoir in both tCD4 and rCD4 cells, 
we also assessed the size of the infectious reservoir in both tCD4 cells and rCD4 cells in parallel 
from the same donors using the quantitative viral outgrowth assay (QVOA; see Overall materials 
and methods for more information). When assessing levels of infectious viruses in tCD4 and 
rCD4 cells, we found that tCD4 cells produced infectious virions at a quantifiable level in 7 of 
the 11 donors studied, while rCD4 cells produced infectious virions in 6 of the 11 donors studied 
(Figure 33). Of the donors that were negative for infectious virus outgrowth, virus failed to grow 
out in both tCD4 cells and rCD4 cells in 4 donors. If infectious virus was quantifiable in rCD4 
cells, it was also quantifiable in tCD4 cells. In one case, tCD4 cells produced infectious virions, 
but rCD4 cells were negative for viral outgrowth. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33. Infectious units per million cells by QVOA from tCD4 and rCD4 cells. In parallel cultures, levels of 
infectious viral outgrowth were quantified by QVOA from both tCD4 cells and rCD4 cells. In the 7 donors in which 
infectious virus was produced from tCD4 or rCD4 cells, 6 donors had higher levels of virion production from tCD4 
cells (mean fold- difference from tCD4 versus rCD4 cells was 2.9-fold; p=0.11 by paired Wilcox test). 
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In the 7 donors in which infectious virus was produced from either tCD4 or rCD4 cells, 6 
donors had higher levels of infectious virions produced from tCD4 cells. The mean infectious 
units per million (IUPM) tCD4 cells was 0.86, while for rCD4 cells, the mean IUPM was 0.60; 
the mean fold-difference between tCD4 IUPM versus rCD4 IUPM was 2.9-fold. Although these 
results are not statistically significant, it is suggestive of a trend towards higher levels of 
infectious virus in tCD4 cells versus rCD4 cells. These data, combined with sparse spontaneous 
release of virions and high levels of inducible virion production from tCD4 cells, suggest that a 
latent, inducible and infectious reservoir is present in tCD4 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34. Correlation between duration of suppression and the ratio of the magnitude of viral outgrowth 
between tCD4 and rCD4 cells. The duration of viral suppression in the 10 study participants with a known duration 
of suppression was negatively associated with the ratio of infectious virus outgrowth in tCD4 cells versus rCD4 cells 
(rho= -0.67, p=0.037). Those with shorter durations of viral suppression tend to have a higher ratio of infectious 
virus in tCD4 cells versus rCD4 cells, and this ratio decreases to approximately 1 (i.e., equal amounts of infectious 
virus in tCD4 and rCD4 cells) with a longer duration of suppression. Open circles denote participants that had  
undetectable levels of viral outgrowth in both tCD4 and rCD4 cells; two participants had 9 years of viral suppression 
and a ratio of infectious virus outgrowth of 1, and were therefore overlapping on the graph.
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In the study participants with a known duration of suppression, we found that there was a 
negative correlation between the duration of suppression and viral outgrowth. The ratio of 
infectious virus outgrowth was higher in those with short durations of suppression, and 
approached a ratio of 1 over almost a decade of viral suppression. It is worth nothing that 4 of 
these 10 study participants had undetectable viral outgrowth in both tCD4 cells and rCD4 cells, 
resulting in a ratio of 1 that may partially drive this correlation. 
 
 
 
 
 
8.3.7 Virologic factors associated with the size of the infectious reservoir in tCD4 and 
rCD4 cells 
 
 
We next evaluated whether there were virologic factors that were related to the size of the 
infectious virus reservoir in tCD4 cells and rCD4 cells. The first measure of persistence that we 
evaluated for relationships to the infectious viral reservoir was low-level viremia by mega-iSCA. 
From this  analysis,  we  found  that  the  levels  of  viremia  in  plasma  following  long-term 
suppression of viral replication by suppressive ART were related to the size of the infectious 
viral reservoir in rCD4 cells, but not tCD4 cells (Figure 35). 
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Figure 35. Mega-iSCA is associated with the size of the infectious viral reservoir in rCD4 cells. Relationships 
between low-level virema as measured by mega-iSCA and the infectious units per million rCD4 cells as measured by 
QVOA. A) Correlation between mega-iSCA and the infectious units per million rCD4 cells (rho=0.69, p=0.019), 
demonstrating that the levels of infectious virus in rCD4 cells is related to the level of virus present in plasma at any 
given time. Open circles represent samples that were undetectable by mega-iSCA or QVOA. B) Exact logistic 
regression with dichotomous outcome (i.e. positive or negative by QVOA) as the dependent variable, and levels of 
plasma viremia by mega-iSCA as a continuous independent variable. In this model, mega-iSCA was found to be a 
statistically significant predictor (p=0.047), and for each log-increase in mega-iSCA, the log odds of a positive IUPM 
goes up by 8.6. 
 
 
 
The positive correlation between IUPM from rCD4 cells and mega-iSCA suggests that as 
the viral load increases, the level of IUPM from rCD4 cells increases. This can also be assessed 
by evaluating the data using an exact logistic regression model. This model indicates that mega- 
iSCA is a significant predictor of positive or negative viral outgrowth from rCD4 cells, and that a 
10-fold increase in mega-iSCA corresponds to a log-odds increase of 8.6 in the odds of positive 
IUPM result. This analysis also reveals that when plasma viremia is over 0.28 copies per 
milliliter, infectious viral outgrowth from rCD4 cells is always positive. 
Next, we assessed whether there was a relationship between the levels of inducible virus 
produced in PVR from activated tCD4 cells versus levels of infectious viral outgrowth from 
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tCD4 cells. This analysis revealed that the levels of virus production from activated tCD4 cells 
from PVR was statistically significantly correlated with infectious virus outgrowth from tCD4 
cells (Figure 36). 
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Figure 36. Inducible virion production from tCD4 cells is correlated with viral outgrowth from tCD4 cells. 
Statistically significant relationships between levels of inducible virion production from tCD4 cells and infectious virus 
outgrowth from tCD4 cells. A) The levels of inducible virus production are statistically significant correlated with 
levels of IUPM from tCD4 cells (rho=0.87, p=0.0005). Open circles are negative for IUPM from tCD4 cells. B) Exact 
logistic regression for the relationship between positive or negative viral outgrowth from tCD4 cells, and levels of 
inducible virion production from tCD4 cells. Inducible virion production from tCD4 cells was a significant predictor of 
negative or positive viral outgrowth (p=0.048), and a log increase in inducible virion production is associated with a 
log-odds increase of 3.5 for the odds of positive viral outgrowth. 
 
These data demonstrate that there is a quantitative relationship between the levels of 
virions that are produced following T cell activation, and the levels of virions that are infectious. 
While there is a strong correlation between the levels of virions produced and the infectious units 
per million tCD4 cells, an exact logistic regression analysis reveals that although there is a trend 
towards infectious virion production following increasing levels of inducible virus production, 
there is no clear point where levels of inducible virion production are associated with infectious 
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viral outgrowth. Instead, increasing levels of inducible virion production increase the odds of a 
positive viral outgrowth culture. 
Finally, we assessed whether there was a relationship between levels of inducible virion 
production from rCD4 cells and infectious virion production from rCD4 cells. We once again 
found that there was a statistically significant relationship between levels of virion production 
and infectious virion production, consistent with results from tCD4 cells (Figure 37). 
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Figure 37. Inducible virion production is correlated with infectious virus production in rCD4 cells. Inducible 
virion production from rCD4 cells is statistically significant correlated with the number of infectious units per million 
rCD4 cells. A) Levels of virion production as measured by PVR were statistically significantly correlated with IUPM 
from rCD4 cells as evaluated by QVOA (rho=0.68, p=0.022). B) Exact logistic regression with negative or positive 
QVOA from rCD4 cells as the dependent variable, and levels of inducible virion production from rCD4 cells as the 
independent variable. Inducible virion production was found to be statistically significant in the exact logistic 
regression model (p=0.009), and for each log increase in the level of inducible virion production, the log odds of a 
positive QVOA increase by 9.0. 
 
The correlation between virion production and infectious viral outgrowth by QVOA in 
rCD4 cells was not as strong (rho=0.68, p=0.022) as the correlation that was found in tCD4 cells. 
However, in rCD4 cells, the exact logistic regression was very statistically strong, in that the p 
value for the levels of virion production as a predictor for positive viral outgrowth was very low 
(p=0.009). Once again, the level of virion production from rCD4 cells did not guarantee viral 
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outgrowth at any given point, but rather increased the odds of positive QVOA. It is worth noting 
that the odds of viral outgrowth are high when the levels of virions produced from activated 
rCD4 cells in culture as measures by PVR was greater than 1000 copies per milliliter of culture 
supernatant.  
 
8.4 DISCUSSION 
In this study, we primarily sought to evaluate whether there was a distinct latent and inducible 
reservoir in tCD4 cells that was distinct from the well-described reservoir in rCD4 cells131. By 
measuring virion production from unstimulated and PMA/ionomycin treated tCD4 and rCD4 
cells, we found that there is a latent and inducible reservoir present in tCD4 cells of a larger 
magnitude that rCD4 cells. While rCD4 cells are a component of the tCD4 cell population, it is 
logical that any HIV-1 infected and activated cells within tCD4 cells would be producing viral 
mRNA, proteins and virions, and should be short-lived due to viral cytopathic effects and the 
general apoptotic nature of the majority of activated T cells. However, instead we find that there 
is approximately 3-fold higher virion production when tCD4 cells are activated compared with 
rCD4 cells, and we can therefore infer that activated CD4+ T cells within the CD4+ T cell 
population harbor latent and inducible proviruses. These data also suggest that only evaluating 
rCD4 cells when investigating strategies aimed at reducing the size of the inducible reservoir 
likely misses a portion of the inducible reservoir in some patients.  
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We next sought to assess whether any variables were directly related to the level of 
inducible virion production from tCD4 and rCD4 cells. When looking at virologic measures of 
viral persistence in PBMC, tCD4 cells, and rCD4 cells, we found that the only factor that was 
statistically significantly related to the level of inducible virion production in this small group of 
study participants was the overall level of transcription per million PBMC. This finding is 
consistent when comparing it to other studies, including the previous chapter of this dissertation 
and the finding by Li et al. that the time to viral rebound is associated with the level of 
transcription in PBMC361. However, these results also differ from those of the previous chapter 
and other studies359 in that the levels of cellular HIV-1 DNA per million PBMC did not correlate 
with the size of the inducible reservoir. Upon inspection of putative 95% confidence intervals 
using Pearson’s correlation, we find that the value for the correlation coefficient observed in this 
study overlaps with the confidence interval for the correlation coefficient observed in the 
previous chapter. Therefore, it is likely that cellular HIV-1 DNA is related to the size of the 
inducible reservoir, and was just not observed in this small cohort of study participants. 
Although a relationship between levels of cellular HIV-1 DNA and cellular HIV-1 RNA 
was not observed in PBMC, there were significant relationships between levels of cellular HIV-1 
DNA and cellular HIV-1 RNA in both tCD4 cells and rCD4 cells, and between tCD4 cells and 
rCD4 cells. As rCD4 cells are a subset of tCD4 cells, it is not surprising that there was a strong 
correlation between levels of cellular HIV-1 DNA and cellular HIV-1 RNA in in tCD4 and rCD4 
cells. When looking at the relationships between levels of cellular HIV-1 DNA in tCD4 versus 
rCD4 cells, we found that the frequency of infection in tCD4 versus rCD4 cells was similar. 
When looking at cellular HIV-1 RNA in tCD4 versus rCD4 cells, we found that HIV-1 RNA was 
more prevalent per infected cell in rCD4 cells versus tCD4 cells, suggesting non-resting cells in 
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the tCD4 cell population may be subjected to an environment in which transcription of cellular 
HIV-1 RNA is selected against.  
Other studies have preliminarily sought to evaluate levels of HIV-1 DNA in activated 
versus resting CD4+ T cell populations. Chun et al. evaluated levels of HIV-1 DNA in activated 
CD4+ T cells as a means of comparison to levels of HIV-1 DNA in gut-associated CD4+ T cells 
(which are typically of a more activated phenotype369), and found that levels of HIV-1 DNA 
were somewhat higher in activated versus resting CD4+ T cells366. Murray et al. performed a 
longitudinal analysis of the decay rates of total and integrated HIV-1 DNA in resting and 
activated CD4+ T cell populations in those initiating ART, and found that by week 52 of ART, 
levels of total HIV-1 DNA and integrated HIV-1 DNA were similar between activated (defined 
as CD38+) and resting (defined as CD38-) CD4+ T cells367, which is consistent with our results 
between total and resting CD4+ T cells (although we defined resting CD4+ T cells differently). 
When looking for factors that explained the differences observed in virion production 
between tCD4 cells and rCD4 cells, we found that the percent of CD4+ T cells in the tCD4 cell 
population that express activation markers was positively correlated with the ratio of virion 
production from tCD4 cells versus rCD4 cells, meaning as there are more non-resting CD4+ T 
cells in the overall tCD4 population, the virion production from tCD4 relative to rCD4 increases.  
We also found that the frequency of infection per million tCD4 cells increases with an 
increase in the frequency of activated CD4+ T cells in tCD4 cells. Others have found a 
relationship between levels of immune activation/exhaustion and the size of the reservoir370,371, 
although results to date do not not allow for any inference about whether activation is driving 
reservoir size or reservoir size is driving activation.  
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Many studies to date have evaluated relationships between inflammation and HIV-1 
infection (reviewed by Klatt et al.372). A general consensus from these studies is that levels of 
activation are high in this with uncontrolled viral replication373-379, and that ART reduces 
measures of inflammation concomitantly with reductions in plasma viremia377,380-383, although 
measures of inflammation remain slightly elevated in those on ART. Many factors, including 
infection with herpes viruses384, contribute to these heightened levels of inflammation on 
ART385,386, but damage done to the gut mucosa during uncontrolled viral replication likely 
contributes substantially to chronic inflammation on ART387-390. Interestingly, although the 
frequency of CD4+ T cells in the gut is less than that in peripheral blood366,369, frequencies of 
infection are much higher366,369, but the ratio of transcription to infection seems to be much 
lower391. Finally, recent evidence has indicated that CD4+ T cells may not traffic efficiently to 
the gut in those with HIV-1 infection392, and that cells in the periphery expressing homing 
markers directing them to the gut are enriched for HIV-1 DNA393. Together, these lines of 
evidence may potentially link chronic inflammation derived from the gut to the persistence of 
infected cells within the tCD4 cell population in the periphery. This hypothesis is highly 
speculative, and will need to be evaluated in future studies.  
In addition to evaluating the size of inducible reservoir in tCD4 and rCD4 cells, we also 
investigated the size of the infectious reservoir in tCD4 versus rCD4 cells, and found that there 
was a trend towards a larger infectious reservoir in tCD4 cells compared with rCD4 cells. In the 
7 donors from whom infectious virus was recoverable from either tCD4 or rCD4 cells, we found 
that 5 of these donors produced more infectious virus from tCD4 cells compared with rCD4 
cells. Importantly, we also found that low level plasma viremia in participants on long-term 
suppressive ART was related to the size of the infectious reservoir in rCD4 cells, consistent with 
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previous findings358. Interestingly, all study participants that had a low-level viremia by mega-
iSCA that was greater than 0.3 copies per milliliter of plasma were found to have positive viral 
outgrowth from rCD4 cells. There was also an inverse relationship between the duration of 
suppression and the ratio of infectious viral outgrowth from tCD4 cells versus rCD4 cells, with a 
shorter duration of suppression being associated with a higher degree of viral outgrowth from 
tCD4 versus rCD4 cells. This result suggests that cells containing infectious proviruses in tCD4 
cells either transition into the rCD4 population over time, or decay more rapidly than cells 
containing infectious proviruses in rCD4 cells. 
Of critical importance, we found that the levels of virions produced following activation 
of tCD4 or rCD4 cells were correlated with levels of infectious units per million cells from tCD4 
or rCD4 cells, correspondingly. It also appears that there are two distinct points in the infectious 
viral lifecycle that depend on stochastic events for viral spread. The first stochastic barrier to 
overcome is sufficient production of virions, and the second stochastic barrier is the infection 
and spread of virus in susceptable cells. As such, the odds of viral outgrowth increase following 
with higher levels of virion production, but there does not seem to be a point where production of 
a certain number of virions guarantees viral outgrowth. Instead, increasing levels of virion 
production correspond to higher odds of viral outgrowth. This result is inconsistent with the 
results of Laird et al., who found that any well that contained properly poly-adenylated virion 
associated HIV-1 RNA was subsequently found to undergo viral outgrowth394, although we did 
not measure poly-adenylated transcripts and used activated cells from HIV-negative blood 
donors for viral outgrowth, while Laird et al. utilized Molt-4/CCR5 cells to propagate virus. 
Taken together, the results of this study begin to shed light on the nature of the viral 
reservoir in those on long-term suppressive ART. Consistent with the plethora of functions that 
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CD4+ T cells contribute to in vivo395,396, the persistence of HIV-1 within tCD4 cells is indeed 
complicated. In addition to the well-described viral reservoir in rCD4 cells that is thought to lead 
to life-long persistence of HIV-1, we find that there is a reservoir present in tCD4 cells, and that 
this reservoir leads to levels of virion production that are greater than those produced from rCD4 
cells alone. We have shown this reservoir to be latent and inducible, and to contain replication 
competent proviruses. In particular, to better understand the tCD4 cell reservoir, activated CD4+ 
T cells will need to be evaluated independently of rCD4 cells. Direct quantification of HIV-1 
RNA and DNA in activated versus tCD4 versus rCD4 cells will be an important component of 
future studies. The interplay between the latent reservoir in rCD4 cells and tCD4 cells harboring 
latent, inducible, infectious virions also needs to be further clarified. While levels of cellular 
HIV-1 DNA and RNA in tCD4 cells and rCD4 cells are correlated, it is not clear why levels of 
cellular HIV-1 RNA transcription in tCD4 cells are lower compared to rCD4 cells, and whether 
rCD4 cells exit from the latent reservoir and enter in the tCD4 cell compartment, or whether the 
tCD4 cells harbor a distinct reservoir. The existence of this reservoir in tCD4 cells further 
complicates curative strategies, and the biology of this novel reservoir needs to be thoroughly 
evaluated in future studies. 
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9.0  OVERALL CONCLUSIONS AND FUTURE DIRECTIONS 
The projects described in this dissertation began in 2012, at which time the only latency reversal 
agent that had entered clinical trials was vorinostat251, and the relative potency of vorinostat 
compared to other HDACi and whether HDACi had an effect on the inducible reservoir were 
unknown. The results from the trial of vorinostat suggested that it was an active latency reversal 
agent, and that the proof of principle of “kick and kill” had been demonstrated. This first clinical 
report of the activity of vorinistat was the impetus for the study of latency reversal agents at the 
level of individual proviruses, the development of an assay to assess fractional provirus 
expression, and the investigation of the potency of latency reversal agents targeting other known 
mechanisms of proviral latency. 
At the time when this dissertation began, the concept of total inducible virion production 
versus viral outgrowth had not yet been investigated, and the only way to measures the size of 
the reservoir ex vivo was to evaluate viral outgrowth302. Initial studies conducted in the AIDS 
Clinical Trials Group by Gandhi et al. suggested that the size of the infectious reservoir was 
correlated with the degree of low-level viremia in plasma358, and another study by Eriksson et al. 
demonstrated that integrated HIV-1 DNA in PBMC was associated with the magnitude of viral 
outgrowth359. These two studies served as a foundation for our investigation of the nature of viral 
persistence. The small amount of data in these initial studies was sufficient to spur us to answer 
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questions that were important to the field at the genesis of this dissertation project, and that they 
remain important at the completion of this dissertation. 
At the outset of this dissertation, the goals were : i.) to develop and implement an assay to 
assess the potency of latency reversal agents targeting known aspects of proviral latency at the 
single proviral level, and to determine whether LRA treatment reduces the size of the latent 
reservoir ex vivo; ii.) to quantify relationships between spontaneous and inducible virion 
production from resting CD4+ T cells, and to relate these measures to other molecular 
biomarkers of HIV-1 persistence in vivo; and iii.) to determine whether a reservoir of latent, 
inducible, and infectious HIV-1 was present in total CD4+ T cells, and to ascertain whether 
levels of total inducible virus were related to infectious virus outgrowth.  
9.1 FRACTIONAL PROVIRUS EXPRESSION REVEALS POOR POTENTCY OF 
PUTATIVE LATENCY REVERSING AGENTS 
9.1.1 Establishment of fractional provirus expression 
Our initial goal was to determine the most suitable assay format to assess the fraction of 
proviruses that spontaneously produced virions, and the fraction that could be induced to produce 
virions following maximum T cell activation. An assay that could determine the fraction of 
proviruses reactivated with any given treatment could answer the open question as to the potency 
of vorinostat at the level of individual proviruses. The best method to achieve this goal was 
found to be a limiting dilution culture assay, where replicate wells of rCD4 cells were serially 
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diluted and treated with medium control (negative control), anti-CD3/CD28 activation beads 
(positive control) or LRAs of interest. Following 7 days of culture, the supernatants were 
harvested from these wells, and the amount of virion associated HIV-1 RNA present in the 
supernatant was evaluated. By knowing the number of cells per well (and therefore the number 
of proviruses present per well), we were able to apply a parametric binomial maximum 
likelihood estimate to evaluate the proportion of proviruses that were responsible for virion 
production in any given treatment condition (Chapter 1). We then used this fractional proviral 
expression (fPVE) assay to evaluate the fraction of proviruses that were responsible for virion 
production from rCD4 cells following treatment with medium control, anti-CD3/CD28 or 
vorniostat, and found that only 1.5% of proviruses could be activated with anti-CD3/CD28, 
0.041% were spontaneously producing virions, and 0.12% were activated to produce virions 
following treatment with vorinostat (Chapter 1). We also found a significant relationship 
between unspliced cellular HIV-1 RNA expression and virion production following anti-
CD3/CD28 treatment, but not following vorinostat treatment, likely due to the inability of 
vorinostat to reverse all blocks associated with proviral latency. This study established the 
framework for the assessment of other LRAs described in Chapter 2 of this dissertation, and 
provided the first inkling that putative LRAs are weak activators of the reservoir in rCD4 cells at 
the level of individual proviruses.  
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9.1.2 Investigation of the potency of putative LRAs and the relevance of previously 
described mechanisms of proviral latency 
After establishing that fPVE was a robust way to assess the reversal of HIV-1 latency in rCD4 
cells at the level of individual proviruses, we next sought to evaluate whether targeting known 
mechanisms of proviral latency with putative LRAs was effective ex vivo. We selected a panel of 
latency reversal agents based on previously described mechanisms of proviral latency, and 
disqualified agents that were thought to cause T cell activation. The selected agents tested 
whether histone acetylation, availability of P-TEFb, activation of NF-κB, or combinations of 
these mechanisms of proviral latency could be specifically therapeutically targeted to permit 
virus production (Chapter 2).  
Investigating these agents led to the conclusion that, although some LRAs could activate 
virion production, no LRA or combination of LRAs led to activation of a significant proportion 
of latent proviruses compared with anti-CD3/CD28 treatment. Treatment of rCD4 cells with anti-
CD3/CD28 activated a median of 3.8% of proviruses, while treatment with romidepsin, JQ1, 
bryostatin, romidepsin + JQ1 and bryostatin + romidepsin each reactivated 0.062%, 0.017%, 
0.012%, 0.12% and 0.083% of proviruses (Chapter 2). Additionally, treatment of rCD4 cells 
with bryostatin, a known PKC agonist, led to activation of rCD4 cells in some donors as 
evidence by increased expression of CD69. This increase in expression of activation markers 
could be potentially dangerous in vivo, as non-specific immune activation can lead to cytokine 
related illness. These findings demonstrate that targeting one or a few known mechanisms of 
proviral latency ex vivo is not sufficient to adequately reverse proviral latency, and that targeting 
cellular pathways can lead to increased expression of activation markers and cellular activation. 
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This is the only in depth study of LRAs that has evaluated their relative activity compared to T 
cell activation at the level of individual proviruses, and provides important information about the 
relative inactivity of LRAs. The ability of LRAs to reactivate only a few proviruses is not 
currently appreciated. However, we did not assess the potency of latency reversal at the level of 
cellular HIV-1 mRNA in this study, and it is possible that expression of cellular HIV-1 RNA was 
increased, possibly leading to translation of viral proteins and death from viral-mediated cellular 
cytopathic effects or from immune clearance. 
9.2 EVALUATION OF CHANGES IN THE SIZE OF THE INDUCIBLE RESERVOIR 
IN RESTING CD4+ T CELLS FOLLOWING TREATMENT WITH LATENCY 
REVERSING AGENTS 
The experiments described in Chapter 2 indicated that there is no significant increase in virion 
production following the treatment of rCD4 cells with LRAs. This finding, though important, 
does not preclude the possibility that cellular transcription of HIV-1 mRNA may have been 
modulated, leading to the translation of viral proteins and death of reactivated cells through viral 
cytopathic effects. To evaluate this possibility, we performed a series of experiments in which 
rCD4 cells were first treated with LRAs and then maximally reactivated to assess whether there 
was a decrease in the size of the inducible reservoir. In this context, if the inducible reservoir had 
been depleted by LRAs, this would be clear by a reduction in virion production or fPVE from the 
treated cells compared to medium control cells. Importantly, we also assessed both viability and 
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activation marker expression following maximum reactivation to elucidate whether the rCD4 
cells had become less responsive to reactivation. 
  Using the experimental approach described above, we found that the median reductions 
in the size of the latent reservoir following treatment with romidepsin, bryostatin and bryostatin 
+ romidepsin compared to medium control was 1.5, 2.0, and 3.4 fold respectively (Chapter 3). 
Although it initially appeared that these LRAs may have an effect on the size of the inducible 
reservoir following maximum reactivation, this finding is confounded by the fact that the 
viability is substantially lower for romidepsin and bryostatin + romidepsin treated cells compared 
with medium control following full latency reversal. Thus, it appears that these cells become 
somewhat resistant to activation following treatment with romidepsin and bryostatin + 
romidepsin, complicating the conclusion that fewer proviruses are inducible due to the depletion 
of the latent reservoir rather than simply resistance to T cell activation stimuli. It is possible that 
bryostatin may reduce the size of the inducible reservoir, as it was not found to substantially 
reduce viability upon maximum stimulation. However, there was some variability in activation 
marker expression following treatment with bryostatin (Chapter 3). 
The results from Chapter 3 demonstrate once again the importance of assessing the 
fraction of proviruses that are inducible following treatment with LRAs. Although most of the 
treatment conditions led to reduced viability following subsequently maximum reactivation, it is 
interesting to note that bryostatin appears to cause a reduction in the median size of the inducible 
reservoir, albeit a modest 2 fold reduction. These results are the first to assess whether latency 
reversal agents cause reductions in the size of the inducible reservoir. 
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9.3 FREQUENCY OF INFECTED CELLS AND THEIR TRANSCRIPTIONAL 
ACTIVITY IN PBMC CORRELATE WITH THE SIZE OF THE INDUCIBLE 
RESERVOIR IN RESTING CD4+ T CELLS 
The goal of this study was to evaluate whether there were relationships between molecular 
measures of viral persistence and the size of the inducible reservoir in rCD4 cells in study 
participants on long-term suppressive antiretroviral therapy. In collaboration with Gilead 
Sciences, we evaluated levels of cellular HIV-1 DNA and RNA in PBMC, low-level viremia in 
plasma by large-volume single copy assay, and inducible and spontaneous virion production 
from cultured rCD4 cells in 21 study participants (Chapter 4). To date, this is the first study to 
examine relationships between measures of viral persistence in conjunction with their 
relationship to the amount of spontaneous virion production and the size of the inducible 
reservoir. 
Our led to the elucidation of a number of important relationships that were not previously 
appreciated. Principal among these was the finding that simple measures of cellular HIV-1 RNA 
and DNA in PBMC were strongly associated with the size of the inducible reservoir in rCD4 
cells. There has been much discussion recently regarding whether proviruses detectable by qPCR 
are intact, harbor large internal deletions, are hypermutated, or are otherwise unable to produce 
virions, and whether the magnitude of the reservoir is comparable to molecular measures of 
persistence151,359. This is a valid concern, but the reality is that the frequency of infected cells 
likely correlates with the frequency of cells that are capable of producing virions following 
reactivation, a proportionality that has likely not been appreciated elsewhere thus far. 
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In addition to the finding that cellular HIV-1 RNA and DNA in PBMC are related to the 
size of the inducible reservoir, we also found that the magnitude of low-level viremia present in 
plasma was correlated with the magnitude of spontaneous virion production from both PBMC 
and rCD4 cells. This is an important finding, in that it connects the in vivo measure of viral 
persistence to peripheral measures of the basal virion production, and implies that virion release 
in the periphery is the source of plasma viremia (Chapter 4).  
This study identified substantial and previously unknown relationships between 
molecular measures of HIV-1 persistence and the size of the inducible reservoir in rCD4 cells in 
study participants on long-term suppressive ART. These findings beg further study of the 
reservoir in rCD4 cells, specifically whether measures of inducible virion production are 
associated with the size of the infectious reservoir in rCD4 cells. In addition, this study had 
assumed that the reservoir of HIV-1 is primarily in rCD4 cells, and did not evaluate the presence 
of a viral reservoir within the activated CD4+ T cell population.  
9.4 PRESENCE OF AN INDUCIBLE INFECTIOUS RESERVOIR OF HIV-1 
WITHIN TOTAL CD4+ T CELLS, AND RELATIONSHIP BETWEEN INDUCIBLE 
AND INFECTIOUS VIRION PRODUCTION 
The final objective of this dissertation was to assess whether there is a cellular population within 
total CD4+ T cells, distinct from rCD4 cells, that harbors an inducible infectious viral reservoir. 
We also proposed to evaluate whether there is a relationship between the size of the inducible 
reservoir and the magnitude of viral outgrowth in total and resting CD4+ T cells. To evaluate 
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this, we quantified levels of inducible virus in tCD4 cells and rCD4 cells, and levels of infectious 
virus in tCD4 cells and rCD4 cells in parallel. If there is a reservoir in tCD4 cells that is distinct 
from rCD4 cells, we would expect to observe higher levels of virion production and infectious 
virion production from tCD4 cells, in the absence of high levels of spontaneous virion release 
from productively infected cells (Chapter 5).  
 In a small cohort of 11 study participants on long-term suppressive ART, we found that 
levels of inducible virion production were 2.5-fold higher from tCD4 cells compared with rCD4 
cells, and that this difference was statistically significant. Levels of infectious virion production 
from tCD4 cells also tended to be higher versus rCD4 cells, although this did not reach statistical 
significant in this cohort due to the small size, and the censoring of several donors who did not 
have detectable infectious virus in either tCD4 or rCD4 cells. In the 7 donors with quantifiable 
infectious virion production from either tCD4 cells or rCD4 cells, we found that 6 of 7 donors 
had higher levels of infectious virus outgrowth in tCD4 cells versus rCD4 cells, and that the 
mean fold-difference in viral outgrowth between tCD4 and rCD4 cells (2-9-fold difference) 
paralleled that observed in inducible virion production between tCD4 and rCD4 cells. 
In agreement with the observed fold-change in tCD4 versus rCD4 cells for virion 
production and infectious viral outgrowth, we also found important, statistically significant 
correlations between the levels of total inducible virion production and viral outgrowth in tCD4 
cells and rCD4 cells. This finding suggests that higher levels of virion production are associated 
with higher levels of infectious virion production, which is in partial agreement with the finding 
by Laird et al. that any wells in a modified viral outgrowth assay that were positive on Day 7 for 
virion production, subsequently became positive by p24 for viral outgrowth394. Our results differ 
from that of Laird et al. in that virion-associated HIV-1 RNA was detected following reactivation 
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of rCD4 and tCD4 cells from all study participants, and did not guarantee viral outgrowth after 
subsequent protracted co-culture. Finally, in agreement with a previous study within the AIDS 
Clinical Trials Group by Gandhi et al.358, we found that levels of low-level viremia measured by 
large-volume single copy assays were statistically significantly correlated with levels of 
infectious virus within rCD4 cells, though not tCD4 cells. 
The results presented in Chapters 4 and 5, when considered simultaneously, suggest that 
assessing the size of the latent reservoir in those on long term suppressive ART can be 
considerably simplified. The interrelated nature of the molecular markers of viral persistence 
also suggest that measuring only a few markers of persistence likely provides substantial 
information about this size and state of the reservoir. These findings should greatly accelerate the 
study of in vivo interventions aimed at reducing the size of the reservoir in those on suppressive 
ART.  
9.5 FUTURE DIRECTIONS 
9.5.1 Investigation of latency reversal agents specific for HIV-1 
The investigation of latency reversal agents to reactivate latently infected CD4+ T cells has 
generally been viewed as a promising strategy to perturb the latent reservoir, and to make it 
amenable to immune clearance. However, these studies suggest that, when measuring the 
potency of LRAs at the level of individual proviruses, that their activity is quite limited. 
Additionally, studies that evaluated whether LRAs have reduced the size of the latent reservoir 
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ex vivo were complicated by the reduced viability of rCD4 cells to reactivation after treatment 
with LRAs. While bryostatin treatment seemed to cause a reduction in the size of the reservoir, it 
did so at the cost of partial activation of rCD4 cells, which suggests that in vivo dosing may be 
associated with side effects that are ultimately too toxic for those who are otherwise relatively 
healthy on suppressive ART.    
The potential for current LRAs to reduce the size of the latent reservoir is therefore 
limited. One factor that is shared by the compounds that are currently being tested as LRAs is 
that they are all specific for host cell functions, and therefore are relatively non-specific for HIV-
1 activation. ART, on the other hand, is highly specific for the virus (rather than the host), and 
therefore is maximally efficacious at suppressing viral replication at favorable therapeutic 
indices. The use of LRA compounds targeting host cellular factors that have previously been 
identified to be associated with latency is therefore never going to be as efficacious as targeting a 
specific aspect of the virus itself, although at this point it is unclear how this could be achieved.  
The functions of CD4+ T cells in vivo are highly varied, and the immune system has a 
large degree of redundancy and plasticity, leading to a high degree of heterogeneity in the 
physiology of individual cells. While this complexity is appreciated in vivo, much of it is lost in 
cell lines by the vary nature of homogeneity they strive to achieve. This has been observed in 
comparison studies of different cell lines and primary cell models of HIV-1 infection, where no 
one model captures all aspects of proviral latency in vivo or ex vivo, leading to significant 
departures from physiological behavior and limited relevance of the established cell models258. 
The use of cell lines to identify and characterize factors associated with proviral latency has 
doubtlessly led to an oversimplification of the mechanisms that contribute to proviral latency in 
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vivo. This highlights an important shortcoming of homogenous cell lines that should be 
considered at early stages of development of LRAs. 
Targeting a specific aspect of the virus itself in a latent cell would be an admirable goal, 
given the problems discussed above with targeting cellular pathways. This is an apparent 
paradox though, as the latent provirus does little to favor transition to latency from active 
infection; the provirus is more passenger than driver in the trip to latency. There are a few 
options that would be worth considering, such as a mimic of Tat protein that would foster highly 
processive full-length transcription of HIV-1 RNA. In our initial study of vorinostat, we found 
that there was not a relationship between levels of unspliced cellular HIV-1 RNA transcription 
and virion production, suggesting a block between transcription and translation. These findings 
suggest that another option for a virus-specific latency reversing agents would be a drug that 
mimics the activity of Rev, bringing HIV-1 transcripts into the cytosol for efficient translation 
into HIV-1 proteins. Developing small molecules that are bioavailable and that can perform all 
the functions usually achieved by large proteins with multiple protein interaction sites in vivo 
would certainly be a challenge, but may ultimately be more successful that targeting cellular 
aspects of proviral latency. At this juncture, the path forward for latency reversal agents is 
uncertain at best.  
9.5.2 Investigation of the non-resting cells within tCD4 cells that harbor proviruses 
We have found, for the first time, that there is a latent and inducible population of cells within 
total CD4+ T cells that harbor latent, inducible and infectious proviruses. The latent infectious 
reservoir in resting CD4+ T cells has been well described, and is thought to lead to rebound 
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plasma viremia following cessation of ART. While the reservoir in rCD4 cells is certainly an 
important reservoir, it is likely only part of the picture. It seems that cells expressing one or more 
activation markers, representing various degrees of activation, also satisfy the conditions 
required to be a latent reservoir. 
One important question that arises from these data is which cells in the tCD4 pool that 
express CD25/CD69/HLA-DR are the most relevant reservoir in tCD4 cells. Characterizing the 
relative contribution of these cells to the total reservoir in tCD4 cells will be important to more 
fully understanding the biology of this reservoir. Comparing the frequency of infection, and the 
amount of HIV-1 RNA transcription in activated versus total versus resting CD4+ T cells will be 
an important next step, followed by characterization of the proviral and HIV-1 mRNA species 
that are present in each cell population. This will lead to insight as to whether the activated 
CD4+ T cells are transitioning out of the latent reservoir or represent a novel, stable species in 
those on long term ART. If the tCD4 cell compartment harbors a biologically distinct reservoir, 
evaluating whether this reservoir size is associated with viral rebound will be an important task. 
Finally, if this reservoir is truly distinct and biologically relevant, novel therapeutics should be 
investigated to eliminate these cells. These cells may be more amenable to therapeutic targeting, 
since they are likely to be more metabolically active than their rCD4 cell counterparts.  
9.5.3 Evaluation of biomarkers of time to viral rebound following cessation of ART 
Perhaps the most natural extension of the findings presented in this dissertation will be to 
prospectively evaluate the biomarkers pertaining to the size of the inducible reservoir as 
predictors of the time to virologic rebound. From the results presented here, the simplest markers 
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of the size of the latent reservoir would be molecular measures of plasma viremia, and cellular 
HIV-1 RNA and DNA in unfractionated PBMC. However, one could imagine scenarios wherein 
all the replication competent (~1 cell per million rCD4 cells) proviruses capable of producing 
virions following activation (2-4%) would be eliminated, with a minimal effect on the frequency 
of infected cells. As such, it seems that the most robust measure of the size of the inducible 
reservoir would be virion production by PVR from total CD4+ T cells. This measure of reservoir 
size would be the best for several reasons: i.) tCD4 PVR correlations with the size of the 
infectious reservoir in tCD4 cells, which is of a larger magnitude than the size of the reservoir in 
rCD4 cells; ii.) tCD4 PVR also correlations with the level of cellular transcription of HIV-1 in 
PBMC, demonstrating a connection to a molecular measure; iii.) virion production is a robust 
measure of the size of the inducible reservoir, as it has a large dynamic range, is a surrogate for 
the number of proviruses that have been reactivated, and is relatively easy to measure.  
Although prospective trials are expensive and time consuming, the type of interruption 
trial where participants are closely monitored for viral rebound should be relatively safe for study 
participants, as long as rebound is identified without delay and ART is reinitiated in a timely 
manner. It will also be an important step forward for the prospective assessment of biomarkers of 
the inducible reservoir. Simplification of measures of the inducible reservoir will greatly 
expedite progress towards therapies that reduce the size of the reservoir by eliminating the need 
for expensive and time-consuming treatment interruptions studies in small scale proof of 
principle trials, the type of which have been advocated for in HIV-1 curative research397. Large-
scale treatment interruption trials could then be used as the final validation tool for very 
promising strategies that have been advanced to later-stage clinical development. 
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